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ABSTRACT 
This thesis aims to present the case for establishing a routine service for testing and 
treatment of hepatitis C (HCV) for people prescribed opioid substitution therapy (OST) 
and attending community pharmacies.  In order to support its contention, it reports on the 
methodological strategies, knowledge translation and evidence outcomes from the 
contributions of a series of published research studies.  The studies were the outputs from 
a research fellowship provided by Gilead and from two research grants obtained from 
Gilead, the Scottish Government and Bristol Myers Squibb during the period 2013-2018.  
The studies were conceptualised, developed and interpreted through participatory and 
iterative research planning processes.  The research drew on theories and constructs from 
many sources, but was especially reliant on the Medical Research Council’s Framework 
for the development and evaluation of complex interventions to improve public health.  
Its key generalisable findings are summarised as follows: 
-The identification of a large, but fragmented pool of knowledge indicating that the 
technology provided through innovation in medicines design and marketing can lead to a 
simplification of healthcare processes and therefore increase access for vulnerable and 
stigmatised populations 
-That the way healthcare is organised may be determined by inertia and the needs of 
health services, rather than by the effective deployment of resources to maximally impact 
on health gain 
-The implementation of innovative services in healthcare requires additional skil ls to 
those established and recognised as central to development of evidence-based healthcare.  
These include practical approaches to stakeholder management, resource deployment and 
contracting.  The political context and business objectives of stakeholders may have 
greater weight in determining uptake of a service than evidence of population health gain.  
-That the real life healthcare environment can provide the context for healthcare research 
and evaluation and that the participation in research by stakeholders, service providers 
and patients can be part of the process of modernisation of heath care services.  
This thesis aims to establish the case that the programme of research presented has made 
an original and useful contribution to knowledge on design, implementation and 
evaluation of a community pharmacy service.  It further aims to build the case that 
evidence generated in this  
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way can inform and support policy development in the wider context, with a reappraisal 
of capability and capacity. 
Its most significant contributions have been: 
-Support for the delivery of the WHO strategic aim for the Elimination for Hepatitis C as 
a public health concern by 2034.  
-Providing supporting evidence and guiding the development of recommendations  
-Informing and supporting the development of Governments’ policy on elimination of 
hepatitis C as a public health concern 
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CHAPTER 1 
INTRODUCTION: THE CASE FOR MODELLING, ESTABLISHING 
AND EVALUATING TESTING AND TREATING HEPATITIS C IN 
COMMUNITY PHARMACY 
In May 2016, The World Health Assembly adopted the first “Global Health Sector 
Strategy on Viral Hepatitis, 2016-2021”. The strategy highlights the critical role of 
Universal Health Coverage and the targets of the strategy are aligned with those of the 
Sustainable Development Goals. The strategy has a vision of eliminating viral hepatitis as 
a public health concern and this is encapsulated in the global targets of reducing new viral 
hepatitis infections by 90% and reducing deaths due to viral hepatitis by 65% by 2030. 
(WHO 2016) 
“Viral hepatitis is an international public health challenge, comparable to other major 
communicable diseases, including HIV, tuberculosis and malaria. Despite the significant 
burden it places on communities across all global regions, hepatitis has been largely 
ignored as a health and development priority until recently. It will no longer remain 
hidden, however, with the adoption of the resolution on the 2030 Agenda for Sustainable 
Development”. 
 
 
 
Content 
This chapter is an introduction to thesis contents. It provides an overview of the 
knowledge and evidence that guided and shaped the aims and rationale for the research 
presented in this theses, culminating in delivery of the SuperDOT-C cluster randomised 
trial. 
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1.1 Thesis aims and objectives 
This thesis aims to make a useful and original contribution to the evidence base guiding 
the global response to the elimination of hepatitis C (HCV) as a public health concern.  It 
also aims to demonstrate the knowledge translation contributions of its research outcomes 
to policy development processes. 
The primary purpose of all research presented in this thesis has been to support the 
development of more effective care pathways that enable greater access to testing and 
treatment of hepatitis, by the disadvantaged and vulnerable populations who are 
prescribed opioid substitution therapy (OST) to treat their injecting drug use.  In the 
United Kingdom, the practical delivery of OST is mainly undertaken by community 
pharmacists.  
The “Global Health Sector Strategy on Viral Hepatitis, 2016-2021” (WHO 2016a) sets 
out five strategic directions that it suggests are vital to the elimination of viral hepatitis as 
a public health threat: 
Strategic Direction 1 
Information for focused 
action: 
Developing a strong strategic information system to 
understand viral hepatitis epidemics and focus the 
response; 
Strategic Direction 2 
Interventions for impact: 
Defining essential, high-impact interventions on the 
continuum of hepatitis services that should be included in 
health benefit packages; 
Strategic Direction 3 
Delivering for equity: 
Strengthening health and community systems to deliver 
high-quality services to achieve equitable coverage and 
maximum impact; 
Strategic Direction 4 
Financing for sustainability: 
Proposing strategies to reduce costs, improve efficiencies 
and minimise the risk of financial hardship for those 
requiring the services; 
Strategic Direction 5 
Innovation for acceleration: 
Promoting and embracing innovation to drive rapid 
progress. 
 
Within the context of these broad strategic goals, the specific aim of this thesis is to 
present evidence on how the community pharmacy health-promotion resource can be 
wielded to deliver an innovative and effective contribution to the health sector response to 
the Strategy. 
12 
 
Objectives and Goals 
The purpose of this research is to explore a range of patient outcomes associated with a 
change in delivery model from a current hospital-based pathway to a primary care-based 
pathway delivered through community pharmacy. 
Although the clinical trials used to enable licensing of the medicines to treat HCV 
infection demonstrate safety, quality and efficacy of direct acting antiviral medicines 
(DAAs), the effective delivery of a new care pathway in a real-world environment and 
within the context of the day-to-day life of a vulnerable population is not described for a 
community pharmacist-led intervention. 
The way that the National Health Service operationalises clinical trials evidence is of 
general concern (Glasziou and Haynes 2005).  Standard evidence used to satisfy 
regulatory bodies does not address the interactions between people who use a service, the 
staff that provide the services and influence of the environment within the community at 
large.  These interactions may produce different results to those described within a 
clinical trial. 
Programme Research Questions 
Can a pharmacist-led care pathway designed to test and treat HCV infection in people 
prescribed OST, increase the numbers of this population who access treatment and cure 
for hepatitis C? 
Secondary Questions 
What are the views and experiences of people who access pharmacy services to receive 
OST? 
What are the important factors to be considered in the design of a pharmacist -led care 
pathway, from the perspective of the service-user population? 
Can a pharmacy-based testing service for HCV infection encourage the target population 
of OST service users to take a test for blood borne viruses (BBVs)? 
Is the delivery of a pharmacist-led pathway to deliver testing and treatment for HCV 
feasible? How do service providers describe the provision of this service? 
What are the barriers and facilitators identified that impinge on the access and delivery of 
effective care? 
What are the potential causal mechanisms which may be identified that impinge on access 
and delivery of effective HCV care? 
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1.2 Rationale for research aims and objectives 
The thesis title describes the desire to establish a care pathway for delivery of testing and 
treatment of HCV and then to evaluate the effects of this change to health service 
delivery.  The rationale for doing so is to enable a greater number of the people who 
inject drugs (PWIDs) and are prescribed OST to access the health technologies that will 
cure them of HCV.  The PWID population are a vulnerable group at significant risk of 
adverse health outcomes and health inequalities. 
Randomised controlled trials (RCTs) may be the gold standard in evaluating the effects of 
treatments.  For the evidence presented in an RCT to be clinically relevant, the 
intervention evaluated must be deliverable to the specific patient population it is intended 
to be applied to, and the setting must have similarities to the setting where patients are 
actually located.  Trials conducted in ideal settings with strictly limited criteria for study 
conduct may trade external validity for internal validity and so be less generalisable.  
Pragmatic trials, designed to evaluate treatments and care delivery in real world 
situations, may be more applicable to clinical practice, but may be unable to emulate high 
levels of internal validity due to practical constraints (Loudon, Treweek et al, 2015). 
Multiple factors can determine generalisability and applicability of RCTs including 
baseline patient population characteristics; geographical spread; the way a condition is 
diagnosed and classified; the presence of a range of long-term conditions in an ageing 
population and the co-prescribed items used to treat these; the availability and licensing 
of medicine regimens; health care costs; patient adherence and attitudes; staff availability, 
practice norms and attitudes.  
Exploratory trials are designed to determine the presence or size of an effect under ideal 
circumstances. They therefore may not draw sufficiently on routine clinical practice to 
enable the recommendations arising from these studies to be integrated directly into a 
patient-focussed decision-making process.  Random allocation to study intervention or 
control, allocation concealment and blinding strengthen internal but may compromise 
external validity (Gartlehner, Hansen et al, 2006). 
This thesis and the research it presents therefore aims to provide pragmatic answers to 
guide the implementation of an HCV testing and treatment pathway in community 
pharmacies providing OST for PWIDs.  It aims to do this by exploring the practicalities 
of delivering HCV care from a community pharmacy, taking into account the views and 
experiences of the patient cohort and staff , the interaction of the health system with the 
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people using it, within the broader policy context within the United Kingdom and 
internationally.  It attempts to do this through the processes and procedures suggested by 
the Medical Research Council’s Guidance on “Developing and Evaluating Complex 
Interventions”, with development, feasibility and modelling stages, alongside 
implementation and evaluation activities (Craig, Dieppe et al 2008) 
As a conceptual framework to understand the way that people, places and technology 
interact and to draw together the interactions of agency, power and culture, cognisance of 
Actor Network Theory (ANT) has been taken (Munro 2009).  The consideration 
surrounding ANT: that it is the interactions of people with buildings and service 
configurations that determine behaviour and its consequences for health, has been most 
helpful in exploring practical ways to devise an effective care pathway within the 
complexities of a modern NHS. 
1.3 Thesis Structure and Content 
Chapter 1: Introduction: the case for modelling, establishing and evaluating testing and 
treating Hepatitis C in Community Pharmacy, is intended to set out the context for 
Chapters 2-7.  It has outlined the aims and objectives, structure and content as well as the 
underpinning constructs for its specific research focus. The next section of this  chapter 
briefly presents the background that underpins the research that has been undertaken, so 
that the hepatology practice and chain of events leading up to the development of this 
thesis are highlighted. 
Evidence presented in the thesis has been generated from a series of research projects 
undertaken to fulfil the objectives of a research fellowship provided by Gilead Sciences, 
and two research grants provided by Gilead Science, the Scottish Government and Bristol 
Myers Squibb.  They were conducted and/or led during the period 2013-2018 by the 
author of this thesis.  The results of this programme of research have been published as a 
series of papers and also conference abstracts.  The author of this thesis is the principal 
author for all of these.  The role of the principal author and all co-authors, is provided as 
part of the published manuscripts and in the supplementary information for chapters 2-7.  
As described in Figure 1: Schematic outline of thesis structure and content, the purpose of 
the peer reviewed papers is to present generalisable evidence contributions of the 
programme of research to real-world policy development processes. A schematic for 
thesis structure and content is presented in Figure 1 below: 
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Figure 1: Schematic Outline for Thesis Structure and Content
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*
adapted from MRC 2000 
1.4 Background and Underpinning Practice for the Testing and 
Treatment of Hepatitis C 
Hepatitis C (HCV) is a blood-borne viral infection (BBV) causing liver disease (WHO, 
2016).  It is most commonly transmitted through: 
-Injecting drug use through the sharing of injection equipment; 
-The reuse or inadequate sterilization of medical equipment, especially syringes and 
needles in healthcare settings; and 
-The transfusion of unscreened blood and blood products. 
HCV can also be transmitted sexually and can be passed vertically from an infected 
mother to her baby; however these modes of transmission are much less common. 
Hepatitis C is not spread through breast milk, food, water or by casual contact such as 
hugging, kissing and sharing food or drinks with an infected person. 
The hepatitis C virus is an RNA virus that occurs as distinct geographical genotypes. 
There are eight confirmed HCV genotypes and 86 subtypes have been reported.  44% of 
infections with HCV worldwide and 60% of HCV infections in high-income and middle-
income countries are of genotype 1. Around a third of genotype 1 infections occur in east 
Asia. Genotype 3 infections are more common in lower-middle-income countries 
(LMICs) than in high-income, upper-middle-income, and low-income countries, and they 
account for 25% of all HCV infections; around 75% of infections with HCV genotype 3 
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occur in south Asia. Genotype 4 infections constitute 15% of all HCV infections and they 
are most common in North Africa and the Middle East. Genotype 2 and 6 infections occur 
largely in east Asia. Genotypes 5, 7, and 8 comprise less than 1% of global HCV 
infections, with most cases originating in southern and central sub-Saharan Africa. HCV 
genotypes and subtypes respond differently to available therapies (Spearman, Dusheiko et 
al 2019) 
Around 0.8% of the Scottish population are chronically infected with HCV (Scottish 
Intercollegiate Guidelines Network, 2013).  The world-wide burden of HCV infection has 
been estimated as 71.1 million infections (62.5—79.4), with the largest group being 
genotype1 (Polaris Observatory HCV Collaborators 2017).  The increased morbidity, 
mortality and economic impact of the infection are of concern to both industrialised and 
developing countries (Lavanchy, 2009). 
The incubation period for hepatitis C is 2 weeks to 6 months. Following initial infection, 
approximately 80% of people do not exhibit any symptoms. Those who are acutely 
symptomatic may exhibit fever, fatigue, decreased appetite, nausea, vomiting, abdominal 
pain, dark urine, grey-coloured faeces, joint pain and jaundice (yellowing of skin and the 
whites of the eyes). 
Due to the fact that acute HCV infection is often asymptomatic, few people are diagnosed 
during the acute infection phase. In those people who go on to develop chronic HCV 
infection, the infection is also often undiagnosed because the infection remains 
asymptomatic until decades after infection when symptoms develop secondary to serious 
liver damage. 
HCV infection is diagnosed in 2 steps: 
-Screening for anti-HCV antibodies with a serological test identifies people who have 
been infected with the virus. 
-If the test is positive for anti-HCV antibodies, a nucleic acid test (polymerase chain 
reaction) for HCV ribonucleic acid (RNA) is needed to confirm chronic infection because 
about 30% of people infected with HCV spontaneously clear the infection by a strong 
immune response without the need for treatment.  
After a person has been diagnosed with chronic HCV infection, they should have an 
assessment of the degree of liver damage (fibrosis and cirrhosis). This can be done by 
liver biopsy or through a variety of non-invasive tests including liver ultrasound 
(fibroscan) and assessment of liver biochemistry (Fib 4 / APRI). (Yen, Kuo et al, 2018) 
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People diagnosed as having an HCV infection should have the genotype of the HCV 
strain established by laboratory testing. There are 6 genotypes of the HCV.  The 
genotypes have a specific geographical spread and may respond differently to the range of 
treatments that are available. Through transmission from different sources, it is possible 
for a person to be infected with more than 1 genotype. The degree of liver damage and 
virus genotype are used to individualise treatment decisions and guide the management of 
the disease. 
Populations at increased risk of HCV infection include: 
-people who inject drugs (PWIDs); 
-people using intranasal drugs; 
-recipients of infected blood products; recipients of invasive procedures in health-care 
facilities with inadequate standards of infection control; 
-vertical transmission to children born to mothers infected with HCV ; 
-Rarely, people with sexual partners who are HCV-infected; 
-people with HIV co-infection; 
-prisoners or people who have been previously incarcerated. 
-people who have had tattoos or piercings from unsterilized equipment. 
Hepatitis C infection may be cleared by the immune system of the person infected and 
some people with chronic infection may not develop liver damage or hepatocellular 
carcinoma. When treatment is necessary, the goal of hepatitis C treatment is cure. The 
cure rate depends on several factors including the strain of the virus and the type of 
treatment given.  It is accepted that a cure is a Sustained Viral Response to antiviral 
therapy at twelve weeks after the course of antiviral treatment has been completed 
(SVR12) (Kozbial, Moser, and Al-Zoairy 2018) 
The standard of care for hepatitis C is changing rapidly. Sofosbuvir, Daclatasvir and the 
Sofosbuvir/Ledipasvir combination are part of the preferred regimens in the WHO 
guidelines, and can achieve cure rates above 95%. These medicines are much more 
effective, safer and better-tolerated than the older therapies, which included pegylated 
interferon and ribavirin. Therapy with DAAs can cure most persons with HCV infection 
and treatment is shorter (usually 12 weeks).  Newer DAAs currently being introduced can 
effect a cure across HCV genotypes and are less affected by the presence of liver disease 
than previous medicines. 
A recent Public Health England report highlighted that less than 3% of those known to be 
infected with HCV are being treated and less than half of those infected are known 
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(Public Health England, 2018).  The largest single infected group in the United Kingdom 
are those prescribed OST (Arain and  Robaeys, 2014). Research suggests around 40% of 
people receiving OST in the United Kingdom have HCV (Aspinall, Doyle et al, 2015; 
Edlin, Kresina et al, 2005). 
The paradigm shift resulting from the introduction of Direct-Acting Antiviral drugs 
(DAAs) has changed the narrative around HCV, with a realisation that HCV could be 
eliminated in people who inject drugs (Lima, Rozada et al, 2015).  There is optimism that 
the use of DAAs offers a high chance of clearance of HCV infection from the population 
(Grebely and Dore, 2014).  Treating all groups with HCV would yield substantial benefits 
(Van Nuys, Brookmeyer et al, 2014) but there are concerns that the infrastructure and 
treatment capacity to deliver the required health outcomes are not generally available or 
of insufficient scale (Leask and Dillon, 2016). 
Treatment uptake for HCV amongst people who inject drugs is currently low (Wiessing, 
Ferri et al, 2014) and prospective patients may have a number of barriers to overcome in 
order to access care (Fernandez-Montero, Vispo et al, 2013).  There are identified 
deficiencies in the extent of screening and diagnosis of at-risk populations, as well as 
improvements required in access to treatment initiation and clinical monitoring (Artenie, 
Jutras-Aswad et al, 2015): People who inject drugs may find it difficult to consistently 
attend medical clinics (Papatheodoridis, Tsochatzis et al, 2014).  However, the delivery of 
HCV testing and treatment through community-based care pathways has been shown to 
be feasible (Wade, Doyle et al, 2016) and Dried Blood Spot Testing (DBST) has been 
demonstrated to increase the uptake of testing from high-risk populations (Coats and 
Dillon, 2015). 
Creating the complex interventions necessary to eliminate HCV requires that well-
designed cross-disciplinary programmes are put in place (Suther and Harries, 2015) using 
different strategies to increase screening, testing and diagnosis (Brouard, Le Strat et al, 
2014).  The potential of community pharmacy practices to make a greater contribution to 
the health of their local populations has been recognised for some time (Anderson, 
Blenkinsop and, Armstrong, 2009).  Pharmacists have long had a major role in delivering 
OST to this group with a high prevalence of HCV (Anderson, 2007) and pharmacist 
involvement in delivering HCV treatment through multi-disciplinary clinics has been 
described for some time (Kolor 2005; Arora, Thornton et al 2011). People prescribed 
OST may see a pharmacist every day (Mathieson 1998).  The relationships that are built 
through this daily interaction may have the potential to be utilised for wider therapeutic 
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purposes. With the availability of highly effective medicines with a low treatment burden 
to cure HCV and the daily interaction with a healthcare professional trained to deliver 
drug therapy, it is likely that current issues with access to and delivery of HCV treatment, 
could be addressed through use of a pharmacy-based pathway. 
The Tayside region of Scotland has sequentially developed integrated HCV treatment 
services over the last two decades, moving from standard secondary care-based hospital 
outpatients, onto nurse-supported treatment services, then to a HCV managed care 
network (MCN) including a widespread dry blood spot testing programme in drug 
services and development in our outreach services across the region. This most recent 
development includes providing treatment within drug services and prisons (Tait, Wang 
et al 2017).  The network aims for wide involvement in BBV testing and follow-up, with 
healthcare professionals such as drug workers, GPs, prison nurses and social workers 
taking the opportunity to discuss referral and treatment with patients. 
Currently Pharmacists can signpost to testing and referral and some can offer HCV 
testing on site (Taheri 2010).  Key barriers in the current NHS pathway are (i) low testing 
rates, (ii) poor linkage of those tested positively to treatment sites (a key factor being the 
limited number of treatment centres), (iii) staff perceptions of this group’s ability to 
adhere to therapy attitudes and (iv) suboptimal adherence and persistence to the 
treatment. Cure of hepatitis C is defined by a sustained viral response (SVR) – no HCV 
RNA in the blood 12 weeks post treatment. The new all oral anti-HCV therapy (DAAs) 
are now available with cure rates greater than 95%, minimal side effects and no need for 
complex monitoring. These could be delivered in new environments via novel pathways. 
These regimens could be safely delivered by community pharmacists.  
The World Health Organisation has provided an Advocacy Brief that sets out the actions 
required by Governments to achieve the Elimination Target of 2030 (WHO, 2016a). The 
brief notes that new medicines make the elimination of HCV possible.  HCV is a leading 
cause of death through cirrhosis and hepatocellular carcinoma with mortality rising due to 
poor access to care.  The WHO advocate that care pathways should be scaled up to meet 
assessed need and that innovation should be embraced to deliver wider access to care. 
1.5 Factors Affecting the Habitus of Individuals Infected with the 
Hepatitis C Virus through Injecting Drug Use 
The World Health Organisation has included the elimination of HCV as a public health 
concern by 2030 and governments are urged to invest in the health technologies available 
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to deliver this aim (WHO 2016b).  However the numbers of people engaging with testing 
and treatment for HCV are low, despite the availability of effective cures with small 
treatment burdens and minimal monitoring requirements (EMCDDA 2016).  The 
perception of a cure for HCV, as solely a clinical outcome, may in part explain the 
reticence of patients and payers to enthusiastically accept the advance in treatment 
provided by Direct-Acting Antiviral (DAA) medicines.  The additional perspective of a 
cure, viewed from a social viewpoint may provide further compelling reasons to engage 
in HCV elimination (Rhodes, Harris et al,  2013) 
The literature describes the many psychological, physical and social aspects of living with 
hepatitis C (Treolar and Rhodes 2009, Dowsett, Coward et al 2017).  Experiences of 
stigma and discrimination are common for people who inject drugs, creating strong 
barriers to accessing HCV care and treatment (Fraser and Treolar 2007; Treolar, Rance 
and Backmund 2013).  Physical and mental fatigue arising from HCV infection 
discourages a normal life and frames a person’s social interactions (Groessl, Weingart et 
al 2008). Changes to employment status and social roles have implications for finances 
and morale, while relationships can be affected detrimentally, increasing feelings of 
isolation (Dunne & Quayle 2001). Many individuals reported negative experiences with 
the healthcare system; themes of feeling unsupported, not having adequate information, 
and not feeling involved in decisions are reported. (Harris, Van Essen and Litwin 2009). 
Participants may experience a reduced quality of life due to physical symptoms and all 
these factors contribute to people with HCV undertaking part-time work or not working 
(Hill, Pfeil et al, 2014). 
Many authors have described the transformative experience of HCV cure and how people 
undergoing treatment are encouraged to take steps towards “a normal life” (Batchelder, 
Peyser et al, 2015).  Interferon-based regimes require significant stoicism and resilience 
on the part of both patient and physician because of the burden of treatment.  Undertaking 
a course of treatment with interferon-based regimes has a flavour of personal trial and 
rehabilitation (Clark and Gifford 2015) and many authors have discussed how the 
experiences have contributed to a change in personal perspective (Newman, Beckstead et 
al 2013; Rance, Treolar et al 2013; Rhodes, Harris and Martin 2013; Jones, Atkinson et al 
2014, Maticic, Katelic et al 2014, Clark and Gifford 2015).  
However, a narrative describing this transformation in the post-interferon era is difficult 
to identify in current literature, mainly because of the recent transition to the use of 
regimes containing solely DAA medicines.  There is a potential paradox, in that the 
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DAA-based regimes provide a reliable cure, for a large majority of patients, with a 
relatively small treatment burden, but may not be a “personal trial” and may have a lesser 
impact on rehabilitation and recovery. Currently re-Infection rates may be only available 
marker of continuing drug-use post treatment (Grebely, Conway et al 2006) or failure of 
rehabilitation, but this indicator does not provide insights into the behaviours of recipients 
and of how treatment has changed their perspectives on their place in society.  The 
success of attempts by the group cured of HCV, to progress down a recovery pathway and 
to resume activities thought of as being part of normal citizenship, are therefore unclear.  
1.6 Funding of Studies Presented in This Thesis 
The programme of research presented in this thesis has been undertaken with the benefit 
of funding gained through a series of fellowships and grants gained by the author. The 
details of these are presented below: 
-Gilead Research Fellowships 2013-2015. Principal Investigator - Design and 
implementation of focus group series, discreet choice experiment, quasi-experimental 
study as preparation for pilot cluster RCT of directly observed therapy for treatment of 
HCV infection in community pharmacies. Andrew Radley and John Dillon. (£36k) 
-Gilead Research Grant 2015-2016. Principal Investigator – Design and delivery of DOT-
C: A cluster feasibility randomised controlled trial. Andrew Radley and John Dillon. 
(£247k).  
-Scottish Government/ Gilead/ BMS 2015-2018. Principal Investigator - Super Dot-C. 
Phase 3 RCT of Community Pharmacy Pathway for Hepatitis C Treatment. Andrew 
Radley and John Dillon. (£16M) 
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Table 1: Schematic Outline of Thesis Structure 
Chapter 1: 
Introduction: the case for modelling, establishing and evaluating testing and 
treatment of hepatitis C in community pharmacy 
Overview of content and rationale for inclusion: 
This chapter sets out the aims and objectives of this research and the rationale for the 
approach taken in delivering the outcomes.  The structure of the thesis is set out and an 
overview of the content described. 
In defining the context for the research, the challenge of hepatitis C elimination is 
established, as defined by the World Health Organisation (WHO 2016a, WHO 2016b).  
Important factors influencing current health care practice for the treatment of people with 
HCV are briefly described, together with identified factors known to influence the uptake 
of the offer of treatment.   
Research Objective 
Can a pharmacist-led care pathway designed to test and treat HCV infection in people 
prescribed OST, increase the numbers of this population who access treatment and cure 
for hepatitis C? 
Secondary Questions 
What are the views and experiences of people who access pharmacy services to receive 
OST? 
What are the important factors to be considered in the design of a pharmacist -led care 
pathway, from the perspective of the service-user population? 
Can a pharmacy-based testing service for HCV infection encourage the target population 
of OST service users to take a test for blood borne viruses (BBVs)? 
Is the delivery of a pharmacist-led pathway to deliver testing and treatment for HCV 
feasible? 
How do service providers describe the provision of this service? 
What causal mechanisms may be identified that impinge on the access to and delivery of 
effective care? 
Chapter 2: 
Developing and evaluating complex interventions 
Overview of content and rationale for inclusion: 
This chapter reviews the rationale for a systematic approach to the design, 
implementation and evaluation of complex interventions.  Understanding of effective and 
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efficient design requires taking into account of the complexity of systems and their 
tendency to adjust to forces that impinge on them (Campbell M, Fitzpatrick R 2000).  The 
Medical Research Council’s Guidance on complex public health interventions 
acknowledges that an iterative approach to the design of an intervention is necessary, 
with planned stages of development to ensure that a subsequent experimental evaluation 
is robust and worthwhile (Craig P, Dieppe P et al 2006).  Development of complex 
interventions should be informed by theory and their evaluation should take account of 
the context for delivery and the processes and human factors that may influence their 
implementation (Moore G, Audrey S et al 2008).  It is included because it describes best 
practice in intervention design and sets the pattern for future work.  The chapter outlines 
the methodological approach used, as well as the strengths and weaknesses of the 
research methods selected. 
Chapter 3: 
Delivering hepatitis C testing and treatment in community and primary care settings  
Sources of Content: 
Radley A, Robinson E, Aspinall EJ, Angus K, Tan L, Dillon JF.  A systematic review and 
meta-analysis of community and primary-care-based hepatitis C testing and treatment 
services that employ direct acting antiviral drug treatments –BMC Health Services 
Research 2019 (19) 765. https://doi.org/10.1186/s12913-019-4635-7  
Overview of content and rationale for inclusion: 
The paper provides an overview of the evidence base describing the evaluations of care 
pathways that offer the newly introduced Direct Acting Antiviral (DAA) medicines into 
community and primary care environments. It reports the results of an updated systematic 
literature and meta-analysis of the first studies to be published after the marketing of 
these medicines in 2013.  The World Health Organisation Guidelines for the care and 
treatment of persons diagnosed with chronic hepatitis C virus infection, promote 
simplified service delivery models; integration with other services; decentralised services 
supported by task-sharing and community engagement to address stigma and increase 
reach. task-shifting to non-specialist clinicians.  It is included because it demonstrates the 
current status of implementation of the changes required to achieve the WHO goals, from 
published evidence 
It is included because it demonstrates that initial steps have been taken to implement 
these guidelines, but that strong evidence based on experimental study designs is 
currently lacking 
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A critical reflective section is included with a critique of methods and of analysis, 
building on the discussion in Chapter 2. 
Chapter 4:  
Development and modelling of an intervention in community pharmacy  
Sources of content: 
Radley AS, Melville K, Easton P, Williams B, Dillon JF. “Standing Outside the Junkie 
Door” – Services users experiences of using community pharmacies to access treatment 
for opioid dependency. J. Public Health 2016 doi:10.1093/pubmed/fdw138 
Radley A, van de Pol M, Dillon JF. Designing a hepatitis C testing service in primary 
care:  a discrete choice experiment. International Journal Of Drug Policy 2019; 65:1-7. 
https://doi.org/10.1016/j.drugpo.2018.12.008  
Radley AS, Melville K, Tait J, Stephens B, Evans JEE, Dillon JF.  A quasi-experimental 
evaluation of dried blood spot testing through community pharmacies in the Tayside 
region of Scotland. Frontline Gastroenterology 2017 doi: 10.1136/flgastro-2016-100776 
Overview of content and rationale for inclusion: 
These papers outline pilot and feasibility work undertaken to develop and describe the 
pharmacist-led intervention, as part of the process of acquiring increasing evidence to 
inform the design of a definitive experimental study.   
The paper describing a focus group series illustrates the lived experience of people 
prescribed opioid substitution therapy and identifies a variety of themes that form a basis 
for a grounded approach to co-design of the intervention. 
The paper describing a discrete choice experiment utilises themes identified from the 
focus group series plus several structural themes and evaluates the preferences of a cohort 
of people prescribed opioid substitution therapy for the design of a pharmacist -led 
intervention.  The method provides an estimate of the additional uptake predicted by the 
preferred model. 
The paper describing a quasi-experimental approach to blood-borne virus testing in 
pharmacies demonstrates the implementation of the first part of the intervention and 
explores initial participant and provider views about delivery.  
These papers are included here to record how the pilot and feasibility work have shaped 
and informed the subsequent development of the SuperDOT-C intervention. 
A critical reflective section is included with a critique of methods and of analysis, 
building on the discussion in Chapter 2 
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Chapter 5:  
Feasibility assessment and evaluation of a care pathway for testing and treatment of 
hepatitis C infection in community pharmacies. 
Sources of content: 
Radley A, Tait J, Dillon JF. DOT-C: A Cluster Randomised Feasibility Trial Evaluating 
Directly Observed Anti-HCV Therapy in a population receiving opioid substitute therapy 
from community pharmacy. International Journal of Drug Policy 2017; 47: 126-136. doi: 
10.1016/j.drugpo.2017.05.042. 
Radley A, de Bruin M, Inglis S, Donnan PT, Dillon JF.  Clinical effectiveness of 
pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in 
patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster 
randomised trial. BMJ Open 2018; 8:e021443. doi: 10.1136/bmjopen-2017-021443 
Radley A, de Bruin M, Inglis S, Donnan PT, Hapca A, Barclay ST, Fraser A, Dillon JF.  
Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment 
for hepatitis C in patients receiving opioid substitution therapy: a pragmatic cluster 
randomised trial (Submitted Lancet Gastroenterology and Hepatology 2020). 
Overview of content and rationale for inclusion: 
These papers outline the feasibility assessment and evaluation of the designed care 
pathway using a cluster randomised controlled trial methodology to evaluate causation. 
Causal inferences indentified through the course of the programme of research are 
defined and supported with evidence gained through the qualitative research elements that 
have been undertaken.  
The paper describing the feasibility trial evaluates the implementation of the care 
pathway as a whole process. The process evaluation describes the views and perceptions 
recorded by participants and staff members through their experiences receiving and 
providing care. 
The study protocol sets out the intentions and experimental procedures undertaken to 
deliver a multi-centre cluster randomised controlled trial, documenting the plans for 
analysis and governance provisions for safe and ethical research. 
The outcomes of the definitive cluster randomised controlled trial, as an endpoint of the 
programme of research are set out in the penultimate paper, together with details of the 
process analysis and an economic analysis 
A critical reflective section is included with a critique of methods and of analysis, 
building on the discussion in Chapter 2 
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Chapter 6  
Mapping of Causal Inferences Identified During the Development and Evaluation of 
a Complex Public Health Intervention 
Sources of content 
Radley A, Inglis Sk, Dillon JF. Using a systems-thinking approach to elucidate 
programme theory underpinning the effectiveness of the SuperDOt-C Intervention: a 
pharmacy-led test and treat pathway for PWIDs with hepatitis c infection prescribed 
opioid substitution therapy. 
Overview of content and rationale for inclusion 
This paper brings together the insights and learning developed from the evaluative and 
experimental work carried out through this programme of research. The elements 
identified from the published studies are conceptualised visually as a causal loop diagram. 
A critical reflective section is included with a critique of methods and of analysis, 
building on the discussion in Chapter 2 
Chapter7 
Discussion and Conclusion 
Overview of content 
This chapter provides a summary and reflection on the programme of study with a 
discussion of strengths and weaknesses. A summary of the unique contribution to 
knowledge in this area is set out. A summary of knowledge and evidence contributions of 
the thesis to policy development and scholarship is given as well as a narrative about the 
development, processes and decisions made in delivering this programme of study. An 
account of future plans is provided. 
Chapter 8  
Bibliography 
A full list of sources used in this thesis is provided 
Chapter 9 
Appendices 
Copies of published papers are provided 
 
  
27 
 
CHAPTER 2 
DEVELOPING AND EVALUATING A COMPLEX HEALTH CARE 
INTERVENTION 
Complexity in a system is determined by such factors as the number of components and 
the intricacy of the interfaces between them, the number and intricacy of conditional 
branches, the degree of nesting, and the types of data structures. A complex system is one 
in which there are multiple interactions between many different components.  Complex 
systems are observed to have a number of consistent properties including non-linearity, 
where the interaction of two components are not the sum or product of its parts; where 
feedback from interaction of its components changes its state; where spontaneous order 
arises from the random aggregation of a large number of uncoordinated interactions; 
where the complex system is stable and robust in the presence of forces exerted on it; and 
its has many levels of hierarchy and a tendency to increase in complexity.(Ladyman and 
Wiesner 2013)  Within complex systems, the term “feedback” describes the situation in 
which a change reinforces or balances further change. Also, the term “adaptation” refers 
to adjustments in behaviour in response to interventions.  This includes the operations, 
structures and relations that exist in each setting. 
A complex systems model of public health conceptualises poor health and health 
inequalities as the outcomes of a multitude of interdependent elements within a connected 
whole.  These elements affect each other in sometimes subtle ways, with changes that 
have consequences for the whole system (Petticrew 2011). 
Therefore for areas of interest to public health, complexity is a property of the system or 
environment in which an intervention operates, rather than for the intervention itself.  
Such a system is adaptive to changes in its local environment, is composed of other 
complex systems, and behaves in a non-linear fashion.  Interventions in complex systems 
may be simple or complicated, but there will be an interaction between the intervention 
and the context in which it is implemented.  The properties of a complex system cannot 
be entirely predicted from the elements within it and are more than a sum of its parts.   
Complex interventions are widely used in health services, in public health practice and in 
areas of social policy.  Complex interventions are built up from a number of components 
which may act both independently and interdependently.  Randomised trials of complex 
interventions have a number of interacting components within the experimental and 
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comparator interventions; they require performance of a number of behaviours of 
differing complexity; different groups or organisational levels are targeted; there are a 
number of outcomes; the intervention may require to be flexed or tailored to individual 
contexts. 
Acceptance of a complex system approach necessitates use of a broad spectrum of 
methods to design, implement and evaluate interventions that aim to change these systems 
and improve public health. The properties of a complex system mean that it is stable and 
robust when external forces are applied to it, however, it can adapt and change through 
feedback provided through the interaction of its components.   Instead of evaluating 
whether an intervention works to fix a problem, researchers should aim to identify how it 
contributes to reshaping a system in a favourable way. Evaluations should take account of 
the complexity of systems (Rutter, Savona et al 2017).  The context for implementation 
has implications for the design and evaluation of an intervention (Shiell, Hawe and Gold 
2008).  Consideration of complexity changes focus away from simple, linear causal 
models to concern about the ways in which processes and outcomes at all points within a 
system drive change 
2.1 Developing Complex Interventions 
The Medical Research Council (MRC) published its first Framework for design and 
evaluation of complex interventions to improve health in 2000 (MRC 2000; Campbell, 
Fitzpatrick et al, 2000).  These guidelines recognised that a complex system approach 
required the use of a broad spectrum of methods to design, implement and evaluate 
interventions.   They identified that evaluation of complex interventions is difficult 
because of problems of developing, identifying, documenting, and reproducing the 
intervention; a phased approach to the development and evaluation of complex 
interventions is required to help researchers define clearly where they are in the research 
process and also that evaluation of complex interventions requires use of qualitative and 
quantitative evidence 
It is established that complex interventions are those that consist of a number of 
components that may act both independently and interdependently.  In taking account of 
this conceptualisation, the Medical Research Council emphasizes the importance of early 
phases of developing the intervention, measures and trial design. Developing phase one 
(review of theory) and phase 2 (modelling the intervention) (Craig, Dieppe, et al, 2008) 
are key steps. 
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2.1.1 Causal modelling 
In understanding the operation of an intervention, causal modelling can be used to guide 
the design of a programme to support behaviour change for trial evaluation. Causal 
assumptions may be drawn from social science theory, but should also be informed by 
other factors such as experience and common sense (Suzuki and Vanderweele 2018).  
Explicitly stating casual assumptions about how the intervention will work can allow 
external scrutiny of its plausibility and help evaluators decide which aspects of the 
intervention or its context to prioritise for investigation.  The relationships between 
implementation, mechanism and context may be interdependent as a complex system 
(Rutter, Savona, et al, 2017).  
Causal models should span behavioural determinants, health outcomes and their 
correlates: behaviour; physiological and biochemical variables; and health outcomes  
(Bonell, Melendez-et al 2018). Evidence about causal mechanisms can be described in a 
causal loop diagram that sets out the different influences that affect the performance of an 
intervention. (Yourkavitch, Hassmiller, et al 2018; Renmans, Holvoet and Criel 2017) 
Mechanisms are particularly important in understanding the explanation of causal 
processes.  Causation is a multifactorial phenomenon.  It is the combination of numerous 
conditions that give rise to health and social care outcomes (Suzuki and Vanderweele 
2018). 
A generic causal model can be derived from an epidemiological perspective to describe a 
causal pathway from behaviour to outcome (Hardeman, Sutton et al, 2005).  Examples 
can be drawn from the treatment of hepatitis C (Table 2). 
Table 2: Generic causal model *
 
Level Methods 
1. Behavioural 
determinants 
Defining the health outcome, its importance and predictors 
e.g. injecting drug use; receipt of opioid substitution therapy 
(OST) 
2. Behaviour Defining the target group 
e.g. people who use drugs; people who receive OST 
3. Physiological and 
biochemical variables 
Identification of the target behaviour and the likely impact of 
achievable behaviour change on physiological and biochemical 
variables  
e.g. attendance to receive OST; recovery from addiction; 
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adherence to anti-viral drug treatment (Direct Acting Antivirals, 
DAA) 
4. Health Outcome Development and validation of precise objective measures of the 
target behaviour 
e.g. Achievement of a sustained viral response to DAAs 
* 
Adapted from
 
Hardeman, Sutton et al, 2005
 
Causal models extend the MRC Framework in several ways (Hardeman, Sutton, et al, 
2005): 
-They guide the choice of intervention points and measures  
-They assist in the choice of behaviour change techniques 
-They inform the assessment of fidelity to theories 
-They enable statistical modelling of relationships between measured behaviours and 
health outcomes. 
The methods that can be used in the development of a causal model are show in Table 3 
Table 3: Methods used in the development of the causal model  
General Methods Specific methods 
1. Defining the health 
outcome and importance 
Review of the epidemiological evidence about the 
importance of the health outcome 
2. Specifying the 
physiological and 
biochemical variables 
Review the evidence about the physiological and 
biochemical risk factors 
3. Defining the target 
population 
Review of epidemiological evidence of determinants of 
the disease. 
Development of a feasible and acceptable strategy to 
identify individuals in the target group from the 
population. Engage with stakeholders and partners to co-
produce approach 
4. Developing objective 
measures of the target 
behaviour 
Identification of objective measures of desired outcome. 
Review of known behavioural determinants. 
Consultation with target group about the acceptability of 
the intervention. 
5. Specifying theory based 
behavioural 
Development of criteria for selection of theory. 
Assessment of systematic reviews 
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determinants 
6. Specifying the 
intervention points 
Development of matrices for objectives, intervention 
methods and strategies 
7. Specifying the 
behaviour change 
techniques 
Use of published evidence and expert opinion 
8. Developing measures to 
assess change in 
behavioural 
determinants 
Review of salient beliefs form the target group for 
engagement with the intervention. Development of a 
process evaluation approach to assess presumed 
intervention components 
* 
Adapted from
 
Hardeman, Sutton et al, 2005
 
2.2 Phased development of a complex intervention 
Different approaches can be used for intervention development and evaluation and 
include mapping techniques of various kinds including logic models (Conrad, Randolph, 
et al, 1999) and different matrices for objectives, intervention methods and strategies.  
Operationalisation may occur within a pilot randomised trial or feasibility study of the 
intervention. 
The phased development of a complex intervention may be iterative or cyclical  (Levin, 
Xepapadeas et al, 2013).  Existing evidence should identify what is already known about 
similar interventions and the use of similar methods in the area of interest. High quality 
systematic reviews can be utilised to summarise evidence or undertaken to provide an 
assessment of evidence. 
As part of the process for developing a complex intervention, the rationale for developing 
a complex intervention, the change that is expected to be delivered and the route by which 
that change is to be achieved should be explored using existing evidence and theory. New 
primary research can be used to inform gaps in existing knowledge.  
A number of limitations have been identified in the original MRC guidance and led to a 
revised document being published in 2008 (Craig, Dieppe, et al, 2008).  The key change 
in focus lies around the recommendations: for greater attention to be paid to early phase 
piloting and development activities; a less linear model of evaluation and integration of 
process and outcome evaluations.  There is an acknowledgement that complex 
interventions need to be adapted to local contexts rather than be completely standardised 
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and also that the theory of complex adaptive systems could provide some insight  (Levin, 
Xepapadeas et al, 2013). 
Randomisation is a powerful tool that can facilitate estimation of average causal effects 
even in the face of complexity and uncertainty. Randomised controlled trials (RCTs) 
allocate individuals or clusters of individuals to different groups, exposing them to new, 
existing or no interventions.  Randomisation prevents systematic bias in allocation and 
aims to minimise chance imbalances (Bonell, Melendez-Torres and Quilley 2018).  
However RCTs alone may be insufficient to understand how the efficacy of an 
intervention in a trial situation can be translated into an effective intervention in a real 
world context.  Effective deployment of trial evidence also requires that there is an 
understanding mechanisms of action and the performance of the intervention in different 
contexts. 
A series of studies may be required to progressively gain an understanding of the way an 
intervention is designed and to optimise the way it performs.  An economic analysis that 
indicates that an intervention is unlikely to be cost-effective would provide evidence that 
it should not be developed further in the same way. 
2.3 Process evaluation  
Process evaluations which explore the way in which a study is implemented will provide 
insights and possible explanations into the way an intervention performs and why factors  
involving acceptability, compliance, delivery, recruitment and retention have occurred.  A 
process evaluation undertaken within a trial can be used to assess the fidelity and quality 
of implementation, inform the understanding of causal mechanisms and the contextual 
factors associated with site-by-site variation in outcome (Craig, Dieppe et al 2008). 
RCTs may be regarded as the gold standard for establishing the effectiveness of 
interventions, where randomisation is possible. However effect sizes do not provide 
policy makers with information on how an intervention might perform in their specific 
context and whether trial outcomes will be reproduced.  
The updated Medical Research Council Guidance recognises the value of process 
evaluation within trials to assess the fidelity and quality of implementation, clarify causal 
mechanisms and identify contextual factors associated with variation in outcomes (Craig, 
Dieppe et al 2008). 
Process evaluations can usefully investigate how the intervention was delivered and 
provide policy makers with information about how the outcomes may be replicated in 
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their particular context. Context is anything external to the intervention that may act as a 
barrier or facilitator to its implementation and effects.  Understanding context is critical 
in interpreting the findings of a specific evaluation and generalising beyond it.  Issues to 
be considered include training and support, communication and management structures 
and the interaction with implementer’s attitudes and circumstances. 
During a process evaluation, evaluators need to be close enough to the intervention to 
record problems, but sufficiently independent to report these to intervention stakeholders.   
Initial analysis of the process data should be conducted before the outcomes analysis to 
avoid biased interpretation of process data. 
Process evaluations also commonly investigate the reach of interventions, that is, whether 
the intended audience comes into contact with the intervention and how.  Process 
evaluations may test hypothesised causal pathways using quantitative and qualitative data 
to understand complex pathways and identify unexpected mechanisms (Moore, Audrey et 
al 2015) 
The MRC Framework has a strong focus on clinical trials and conceptualises five phases 
representing a continuum of increasing evidence when developing an intervention. The 
MRC Framework recommends a feasibility and piloting phase to test the proposed 
intervention. During this phase, a process evaluation has a role in understanding the 
feasibility of the intervention and optimising its design and evaluation.  However the next 
stage shifts the focus of a process evaluation onto providing greater confidence in 
conclusions about effectiveness by assessing the quantity and quality of what was 
delivered and assessing the generalisability of its effectiveness by understanding the role 
of context. A process evaluation will be needed to accompany a full trial, since new 
problems are likely to emerge. 
Process models are used to describe or guide the translation of research into practice. 
Early process models tend to depict implementation as a rational liner process.  A more 
sophisticated approach to process modelling identifies that facilitation is required, with 
emphasis placed on the context in which research is implemented and used. 
It is useful to report assumptions about how the intervention works, ideally in a logic 
model and how these informed the selection of research questions and methods (Moore, 
Audrey et al 2015). 
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2.4 Phases of intervention development (MRC Guidance) 
The MRC Guidance is presented as a number of phases in which researchers gain a 
progressively greater understanding of how the proposed intervention will perform: 
Preclinical / theoretical phase – The first step is to identify the evidence that the 
intervention might have the intended effect.  Review of the theoretical basis for an 
intervention and development of the hypothesis with more detailed specification of the 
potential active ingredients.  Previous studies may provide empirical evidence.   
From an evaluation perspective, a theory is a set of analytical principles or statements 
designed to structure an observation, understanding and explanation of the world. A 
theory usually describes some kind of predictive capacity (Nilson 2015).  Theories can 
inform a hypothesis about causal processes and therefore allow researchers to explicitly 
test whether they hold or not. Theories can also offer insights into contextual conditions 
in which the intervention is likely to work.  Overarching unified theories might explain all 
observed uniformities of social behaviour, social organisation and change.  Theories that 
could be described in this way might include functionalism, symbolic interactionalism 
and social exchange theory.  Theories regarding collective and aggregate levels are 
relevant in implementation. Examples may include social network theory and social 
capital theory (Holman and Borgstom 2016). 
Middle range theories include Realist Evaluation (Pawson and Tilley 1991), which is 
framed as a theoretical approach to practical realism: what works for whom and in what 
context.  Realist research demonstrates the interplay between policy, programme or 
intervention, context, actors, causal mechanisms and outcomes (Van Belle, van de Pas 
and Machal. 2017) 
A realist approach seeks to identify what works, for whom and in what circumstances as a 
causal explanation of the relationship between context, mechanism and outcomes, rather 
than to seek causal relationships between intervention and effect (Harvey, Kitson et al 
2015; Carlile 2002) 
Critical realist sociologists view mechanisms as causal processes that can trigger events; 
contingently dependent on interactions with other mechanisms operating in a context.  
Interventions can be theorised to operate in terms of how the mechanisms that an 
intervention aims to trigger will interact with context to generate outcomes.  Realist 
evaluators suggest that evaluations should test hypotheses about context-mechanism-
outcome configurations to assess what works for whom and under what circumstances. 
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Economists theorise that behaviour is enabled or constrained by money.  Sociologists 
would broaden this to a theorising agency in which formal and informal rules and rituals 
shape social interactions. Evaluators should be aware of the contingency of mechanisms, 
dependent not only on context but also the agency of those providing and receiving 
interventions. Mechanisms are concepts that form an integral part of causal explanations  
(Bonell, Melendez-Torres and Quilley 2018)  
Poor theoretical underpinning makes it difficult to understand and explain how and why 
implementation succeeds or fails, thus restraining opportunities to predict the likelihood 
of implementation success and develop better strategies to achieve more successful 
implementation.  Implementation is part of a diffusion-dissemination-implementation 
continuum, where diffusion is passive, untargeted and unplanned (Nilson 2015). 
Phase 1 – defining components of the intervention. Modelling and simulation techniques 
can improve understanding of the components of an intervention and how they may 
interact. Qualitative approaches such as focus groups, surveys and interviews may help 
define components. Qualitative research may also be useful in defining how the 
intervention may work and what the associated barriers and facilitators may be. 
Phase 2 – Defining trial and intervention design – Information about acceptability of the 
intervention to potential providers and participants and feasibility of the components of 
the intervention being delivered. This is particularly important where health services may 
deliver a number of care pathways and patient treatments.  Feasibility studies are used to 
develop optimum intervention and evaluation design.  Research sites should develop an 
understanding of the intervention and how it is delivered.  Exploratory trials can also be 
used to determine the consistency with which the intervention is enacted.  The learning 
from these activities is used to ensure that the intervention is provided effectively 
(Campbell, Fitzpatrick, Haines, Kinmonth, Sandercock, Spiegelhalter, Tyrer 2000. 
It is important to demonstrate the effectiveness of the intervention and to understand the 
implementation process, the causal processes that underlie the intervention and the deeper 
societal change they envisage. 
A range of models and frameworks have been proposed in order to support effective 
intervention.  A model is a deliberate simplification of a phenomenon that describes 
rather than explains behaviours. A Framework usually denotes a structure, overview, 
outline, system or plan consisting of descriptive variables that are presumed to account 
for a phenomenon (Nilson 2015) 
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Determinant frameworks describe the general types of determinants that are hypothesised 
to influence implementation outcomes.  For example, the Theoretical Domains 
Framework was constructed on the basis of a synthesis ofm128 constructs related to 
behaviour change. The constructs are sorted into 14 theoretical domains. The Theoretical 
Domains Framework does not specify the causal mechanisms of an intervention. 
Determinant Frameworks indicate that multiple levels of influence across relationships, 
systems and organisations.( Michie, van Stralen, West et al 2016) 
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Table 4: Framework for the development and evaluation of complex interventions*  
Phases Methods 
1. Pre-clinical/theoretical Review relevant theory and evidence to ensure best choice of 
intervention and predict major confounders and strategic design 
issues 
2. Modelling Identify intervention components and inter-relationships and 
link to potential outcome measures 
3a. 
3b. 
Operationalisation 
Piloting exploratory 
trials  
Describe components of a replicable intervention 
Describe a feasible trial protocol for comparing the intervention 
to an appropriate alternative 
4. Definitive RCT Compare a fully-defined theory-based intervention to an 
appropriate alternative using a protocol that is reproducible, 
adequately controlled and statistically powered 
5. Long-term 
implementation 
Determine whether the intervention and results can be reliably 
replicated in uncontrolled settings over the long-term. 
*
adapted from Campbell, Fitzpatrick et al 2000).
 
The PRECIS-2 tool is also used to provide guidance to evaluators when designing trials, 
to help ensure that they are translatable into practice. (Loudon, Treweek et al, 2015) The 
PRECIS-2 model is intended to support researchers make design decisions consistent with 
the intended purpose of their trial. It uses a wheel format, with nine domains—eligibility 
criteria, recruitment, setting, organisation, flexibility (delivery), flexibility (adherence), 
follow-up, primary outcome, and primary analysis—scored from 1 (very explanatory) to 5 
(very pragmatic) to facilitate domain discussion and consensus (see figure). The tool 
therefore takes researchers through the process of explicitly matching of design decisions 
to how the trial results are intended to be used (www.precis-2.org)   
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Figure 2: the PRECIS Wheel 
 
 
2.5 Evaluating success in implementation 
Evaluation frameworks provide a structure for evaluating implementation e.g. RE-AIM.  
They specify implementation aspects that should be evaluated as part of intervention 
studies (Nilson 2015). 
The RE-AIM evaluation model focuses on the public health impact of interventions and 
its parameters are considered in MRC phases three to five.  The Reach, Effectiveness, 
Adoption, Implementation and Maintenance (RE-AIM) framework was designed to 
improve reporting on key issues involving implementation and external validity. 
Reach refers to the participation rate within the target population and the characteristics 
of participants as opposed to non-participants. Factors determining reach may include 
cost, referrals, scheduling, transportation and inconvenience. Efficacy is the impact of an 
intervention on specified outcome criteria.  Adoption is a systems level measure 
concerning the number and representativeness of organisations taking up the intervention.  
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Factors determining adoption include cost, level of resource and expertise required and 
similarity of services to current provision. Implementation refers to intervention integrity: 
the quality and consistency of delivery. Maintenance reflects how well behaviour change 
efforts are sustained in the long-term. 
Programme planners should make decisions regarding implementing and funding health 
services based on multiple dimensions, rather than only considering efficacy in 
randomised controlled trials (Glasgow, McKay et al 2001). 
A range of other models are also advocated:  Precede-Proceed specifies a needs 
assessment that maps across to MRC Framework phase 1. Logic models link inputs and 
activities to programme outputs and outcomes, whilst communicating the theory behind 
the programme; these are activities in the MRC Framework phases one to four 
(Hardeman, Sutton et al 2005). 
Evidence translation into practice is rarely straightforward and linear: the contestable 
nature of evidence; the multiple influences on decision making; the effect of contextual 
variables at a micro, meso and macro level. Translation strategies therefore often favour 
multi-faceted approaches. 
The PARIHS framework – Promoting Action on Research Implementation in Health 
Services – proposes that successful translation occurs when a combination of factors 
come into play (Rycroft-Malone, Seers et al 2013).  These include how robust the 
research evidence is and how it reflects clinical, patient and local evidence, the 
receptivity to new ideas, the prevailing culture, leadership, orientation to evaluation and 
learning and then how the adoption of new evidence is facilitated and by whom.  Where 
the environment for evidence adoption is challenging, then sophisticated skills in 
consensus building, negotiation and conflict management may be required. Translation is 
fundamentally about enabling others to act. 
The characteristics of knowledge that drive innovation within a function actually hinder 
problem solving and knowledge creation across function (Carlile 2002).  Syntactic 
boundaries are where differences in language and terminology create boundaries and are 
addressed when a common syntax is found. Semantic boundaries occur when there are 
differences in interpretation. Successful address may require attempts to identify a 
common meaning.  Pragmatic boundaries occur when there is a high degree of novelty 
involved.  Take-up of new knowledge is seen to involve acquisition of new costs by some 
stakeholders.  Teams may have to adapt their existing domain-specific knowledge, 
leading to processes of contestation and negotiation, involving issues such as power, 
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vested interests, roles and relationships: new knowledge challenges assumptions and 
understanding. 
Many interventions found to be effective in prevention and disease management research 
fail to be widely adopted or translated into meaningful outcomes.  Barriers to wide-scale 
implementation arise at multiple levels: citizens and patients; the practitioner and staff; 
organisational and community; and policy levels(Treweek and Zwarenstein 2009). 
Normalisation Process Theory (NPT) has been used to explain the success or failure of 
implementation projects, and is most often used retrospectively as an organising 
framework for analysis and reporting of findings (De Brun, O’Reilly et al 2016)  can be 
used as a learning device to critically interrogate experience and data.  The theory uses 
four overarching constructs: coherence (sense-making), cognitive participation 
(engagement), collective action (enactment) and reflexive monitoring (appraisal).  Best 
practice use of Normalisation Process Theory in intervention design is to engage with 
multiple stakeholders and to co-produce implementation processes from a range of 
perspectives.  The use of NPT has been linked to participatory learning methods in this 
context, to facilitate the commitment of the range of contributors to the research.  
2.6 Actor Network Theory 
Actor–network theory (ANT) is a theoretical and methodological approach to social 
theory which asserts that everything in the social and natural worlds exists in constantly 
shifting networks of relationships (Holman, Borgstom et al 2016).  It takes a position that 
nothing exists outside those relationships. All the factors involved in a social situation 
(human and non-human) are on the same level (they have symmetry), and there are no 
external social forces beyond what and how the network participants interact at present. 
Thus, objects, ideas, processes, and any other relevant factors are seen as just as 
important in creating social situations as humans. ANT holds that social forces do not 
exist in themselves, and therefore cannot be used to explain social phenomena (Latour 
2005).  
ANT envisages that social, psychological and physiological process can shape a situation.  
But also elements as diverse as the workplace, a life event, or political change can shape 
the form and content of relationships (Torronen, Tigersted et al, 2018).  These 
contributing elements, both human and non-human, are called actors.  In ANT, the 
assemblage of actors form a network that can direct, influence and transform action.  
ANT examines relational linkages as situational network-related dependencies between 
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actors. In real life, events are moved forward by heterogeneous and unpredictable 
interactions between human and non-human assemblages.  Action is therefore understood 
as “a conglomerate of many surprising sets of agencies that have to be slowly 
disentangled”(Latour 2005). The actors that actively combine are termed mediators. By 
connecting two or more mediators, ANT brings forward a modification or translation to a 
system.  Entities achieve their form and meaning only in relation to other entities  (Law 
1999).  ANT explores the multiple networks between human and non-human actors; how 
they are established, evolve, interrelate and move.  The goal of ANT is therefore to 
expose the actions, relations and processes that enable subjectivities, objects, effects, 
technological innovations and states of affairs to emerge and stabilise in networks.  ANT 
requires that every observable phenomenon exists thanks to its relations: actors only have 
an ability to act from what is around them (Duff 2013). 
ANT has been used to conceptualise the use of alcohol from the standpoint of a focus on 
relationships.  Existing perspectives often reduce alcohol dependence to a series of 
influencing factors including genes; physical dependence; a psychological disorder; will 
power family or social problems.  An analysis from an ANT perspective might mobilise 
human relationships as well as actors from community and government levels e.g. 
education; transportation; workplace; urban planning; welfare.  Entities such as 
knowledge; resources and communications technology might also be considered 
(Torronen, Tigersted et al 2018). ANT therefore provides scope for material and 
biological factors, as well as the human ingredients, to be considered in gaining an 
understanding of alcohol addiction.  The broader contexts of drug use have also been 
considered using ANT which can be used to describe how subjects, activities, agencies, 
networks and spaces are produced in and through the activity of drug consumption (Duff 
2013).  An ANT analysis examining the adherence of people with AIDS to their treatment 
concluded that taking the medicine was the least of the problems facing this patient group 
(Rossi and Pereira 2014)  
The way that health services form relational linkages with human and non-human actors 
can also be considered from an ANT perspective.  Services comprise of socio-technical 
(human and technological) factors which exchange various resources and competencies. 
Service networks mediate transfer resources and competencies, and cause translations in 
networks with positive or negative outcomes. Service networks become increasingly 
complex when technology is implemented to execute specific processes to deliver a 
service (Carroll, Richardson and Whelan 2013). ANT has been applied to care pathways 
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for asthmatic patients, considering the use of a metered dose inhaler (Prout 1996).  This 
analysis describes how the networks of actors (pharmaceutical scientists, doctors, 
pharmacists, nurses, manufacturing plant, distribution lorries, treatment guidelines) 
leading to the provision of the inhaler, are effaced in order that the flow of life can 
continue (punctualisation).  The teaching of the patient to effectively us the inhaler is 
described as “configuring the user”.  The successful endpoint of the relational interactions 
with the indefinite number of networks and the patient is successful delivery of an asthma 
medication. 
ANT is a useful tool for appraising complexity and analysing the production of change in 
health care, since it deals with systems made of human and non-human entities and 
proposes a relational view of action; it provides an understanding of the intervention-
context interaction; and understanding how interventions produce their effects  (Bilodeau 
and Potvin 2018).  ANT promotes the conceptualisation of context in relation to networks 
of actors and their actions. .  It is not the actors themselves that are the focal poin t, but the 
connections between them, through which they act.  Understanding the processes 
involved in producing effects assists the understanding of complexity.  
ANT has been used as a quality improvement tool in healthcare systems, where an 
understanding of the way that human and non-human actors interact enables a more 
comprehensive picture of the requirements for successful implementation to be built  
(Booth, Andrusyszyn et al 2016).  One of the main benefits is how the theory helps 
understanding of social effects are generated through the interactions of different actors in 
a network: that the interactions of human and non-human entities produces an outcome 
that would not be explained through consideration of either actor separately.  
In the context of complex public health interventions, ANT concentrates on the processes 
responsible for producing the effects of interventions, based on the premise that the 
observable changes are the end results of the interactions of human and non-human 
actors. Bilodeau and Potvin 2018)  Since of human and non-human actors are capable of 
agency, depending on how they are associated within a network, ANT allows the 
scientific evidence, expert opinion, financial resources and regulation to be considered a s 
shaping a public health intervention.  The premise of symmetry in ANT means that the 
interactions of human and non-human actors are intertwined. 
ANT refers to the linkage that connects disparate entities (e.g. humans, objects, ideas, 
interest, values) as translations.  Translation is the process by which networks are created, 
expand and act (Latour 2005).   The translation process is said to consist of four non-
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linear processes: problematization (identifying the relevant entities to a situation); 
Interessement (rallying the actors ); Enrolment (successful engagement of actors); 
Mobilisation (achieving a critical mass for action) (Craine, Parry et al 2009). 
ANT provides the understanding that an effective public health intervention requires 
transformative processes in complex systems.  A range of actors are required to come 
together to co-produce the knowledge and actions to deliver change.  The human and non-
human actors must be considered in planning and understanding the mechanism for the 
intervention and mediation of the change is delivered by the interaction of these elements 
in the complex system (Bilodeau and Potvin 2018).  Studies that evaluate complex 
interventions should consider ANT as part of the underpinning theory that guides the 
intervention design and accompanying process evaluation.  
 
2.7 Methods Employed 
The publications in this thesis have used a series of qualitative, quantitative and mixed 
methods approaches to addressing the defined research questions.  Qualitative and 
quantitative research approaches have differing fundamental assumptions about the way 
we know things and about what things are.  Quantitative research requires a systematic 
way to approach the classification of size and number and draws on a positivist view of 
knowledge.  Positivism is centred around a view that only things that are measurable 
actually exist and that an objective view of the world can be constructed.  Qualitative 
research uses a range of approaches to gain insights into the meanings, concepts 
definitions, characteristics, metaphors, symbols, and description of things (Pope and 
Mays 2006).  Triangulation of data provided by using different qualitative and 
quantitative methods supports the development of different insights and knowledge. Most 
importantly, a triangulation approach may help to generate further understanding from the 
data produced by research (O’Cathain, Murphy and Nicholl 2010) and provides the 
motivation for the qualitative process evaluations undertaken in the research approach.  
The methods chosen in this thesis were selected for their appropriateness in answering the 
research questions developed by each research study.  Publication One utilised a 
systematic review and meta-analysis method to assess current published literature 
describing the establishment of care pathways in primary care settings.  In publication 
Two, a focus group series was undertaken to gain views and perspectives of a target 
population, utilising Actor Network Theory as a way of providing a theoretical 
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perspective for the analysis.  Publication Three utilised a stated preference method and 
enhance participant involvement in care pathway design.  Publication Three employed the 
econometric method, a discrete choice experiment, which utilises a standard questionnaire 
describing different choices and asks participant to choose which option they prefer. 
Publication Four utilised a quasi-experimental approach to managing quantitative data 
generated from a testing pilot for blood borne viruses.  This study evaluated the ability of 
pharmacies to offer blood borne virus testing and utilised a logic model to guide a process 
evaluation based around normalisation process theory. Publication Five utilised a cluster 
randomised controlled trial to test the feasibility of the care pathway that had been 
developed; an extension to the process evaluation was undertaken and a comparison of 
pathway costs was mapped for both the intervention and conventional pathways.  
Publication Six is a protocol for a definitive multi-centre cluster randomised controlled 
trial and Publication Seven is the full enactment of this protocol after implementation and 
delivery. The multi-centre cluster randomised controlled trial also contains an economic 
analysis and post implementation process evaluation of staff views and perspectives .  
Publication Eight is a qualitative synthesis of the results gained from the previous process 
evaluation work undertaken in the programme, using a complexity approach to suggest 
causal relationships underlying the operation of the care pathway.  The use of these  
different techniques to triangulate knowledge is consistent with the iterative approach to 
the development of understanding in how an intervention performs in the real world, as 
suggested by the MRC guidance (Craig, Dieppe et al 2008) 
2.7.1 Systematic Reviews and Meta-analysis 
A systematic review is a method for identifying and assessing all relevant research on a 
specific topic, using all available sources and employing a pre-determined method.  
Systematic reviews may be conceptualised as following five stages: Framing the question; 
identifying relevant publications; assessing study quality; summarising the evidence; 
interpreting the findings (Khan, Kunz et al 2003).  The data collected in a systematic 
review can be observational or experimental and be synthesized by narrative synthesis 
and by meta-analysis.  Systematic reviews can be used to help resolve inconsistencies and 
controversies in the evidence base. Meta-analysis is a statistical technique for combining 
data from separate studies to provide a pooled estimate of the outcome of interest.  The 
pooled analysis can provide an indication of the size of effect associated with an 
intervention (Popay, Roberts et al 2006). 
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Limitations of systematic reviews include the difficulty of identifying all relevant 
publications.   There are numerous ways in which bias can be introduced into reviews and 
meta-analyses.  Inferior methodological quality of included trials may result in the 
findings of reviews of study outcomes being compromised.  Publication bias can distort 
findings since trials with positive results are more likely to get published, than trials that 
do not deliver a significant outcome.   Among published studies, those with significant 
results are more likely to get published in English and are more likely to be cited and so 
be more readily identified.  Positive findings are more likely to be published more than 
once which means that they will also be more likely to be identified and included in  a 
systematic literature search.   Studies tend to report the most favourable findings, which 
can result in bias.  Criteria for inclusion of studies (PICOS) into a review may be 
influenced by knowledge of the literature by the researchers (Eggar, Davey-Smith and 
Altman 2007).  
However, since systematic reviews are more likely to avoid bias than traditional, 
narrative reviews, this method was employed in this research programme.  The emergent 
nature of studies of care pathways using direct-acting antiviral medication in community 
and primary Several of the studies were also only available as conference abstracts. The 
opportunity to use assessment of bias and strength of evidence techniques within the 
study provided some assurance that the analysis of the evidence base was rigorous and 
trustworthy. 
2.7.2 Focus Groups 
Focus groups are a qualitative method of gathering data on what people think or feel 
about an issue, a product or a service. Participants are selected because they have certain 
characteristics in common that are important in delivering the topic of interest  being 
discussed in the focus group. Focus groups have a number of strengths and weaknesses 
that distinguishes them from other qualitative methodologies. The use of this method has 
its origins within the fields of social science and market research. In a good quality focus 
group, the researcher takes on a less dominant and directing role than in an interview 
approach and respondents can comment on areas considered by them to be most 
important.  Group reactions can be gauged to new ideas and group brainstorming can be 
prompted. 
Focus groups explicitly use group interactions as part of a controlled group discussion to 
generate data.  Focus groups can be viewed as performances in which participants jointly 
produce accounts about a proposed topic in a socially organised situation and in which 
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both the facilitator and the participants share an assumption about the purpose of the 
discussion (Smithson 2000).  The quality of the outcomes produced is dependent on the 
use of systematic procedures for data collection, data handling and data analysis and also 
on researcher neutrality.  Questions should be piloted to ensure that they are understood 
and the conditions that the group discussion is undertaken in need to facilitate open 
sharing. 
The findings of focus groups may be distorted by the presence of dominant voices and 
opinions.  Such influences can be ameliorated through purposefully making the structure 
of the groups homogeneous for sex, age, education and current occupational position.  
However, such plans may be limited by the lack of influence on which participants attend 
the sessions.  The facilitator can also contribute to the management of this effect, through 
attempting to balance contributions to the discussion and by encouraging quieter members 
of the focus group participants to express a viewpoint.  Since the unit of analysis of a 
focus group is said to be the collective voice, analysis recognises the existence of already-
held opinions within the group, plus the formation of a collective consensus through the 
process of group discussion: a normative discourse (Smithson 2000).  The effect of the 
facilitator may influence the outputs from the group discussion. It may be considered that 
a facilitator from the same cultural background as the participants may improve the 
quality of facilitation and interpretation of the discourse.  Considerations of this effect 
may be countered both by promoting the independence of the facilitator and also 
acknowledging reflexivity and self-awareness (Raheim, Magnussen et al 2016). 
2.2.3 Semi-Structured Interviews 
Semi-structured interviews are a qualitative method of eliciting views and perceptions on 
a topic and are conducted conventionally with a single participant who is asked a series of 
closed and open-ended questions, often accompanied by supplementary more probing 
questions looking to elicit further explanations (Newcomer, Hatry and Wholey 2015).  
The interviews may be conducted with the support of a topic guide which acts as a tool to 
aid the progress and scope of the interview.  Such topic guides support a systematic 
approach to data collection, data handling and analysis and enable a justification to be 
incorporated into the documentation for each question that is asked of the participant.  
Interviews are an intrusion into the participants’ private life, both in terms of time spent 
and the disturbance of questioning. 
Semi-structured interviews have a number of advantages and disadvantages over other 
qualitative methods. They enable independent contributions from an individual that are 
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distinct from those of group.  Probing open-ended questions can elicit a range of candid 
responses that may not be offered in the company of a focus group.  Such interviews can 
reduce incomplete answers, can approach a topic systematically and yet can be flexible 
enough to accommodate unexpected responses.    
However, the interviewer may have pre-conceived ideas and expectations about the topic 
which may introduce bias into the data collection, even if this is an unconscious effect. 
Such interviews are useful in a process evaluation where formative views are sought 
about the realist questions surrounding an intervention – “what works, for whom and in 
what circumstances?” (Pawson and Tilley 1991).  However, the planning, implementation 
and analysis of a semi-structured interview series is resource intensive and requires that 
the interviewer has well developed skills and is insightful about both the subject matter 
and also the potential sensitivities of participants (Alshenqeeti 2014) 
2.2.4 Discrete Choice Experiments 
Discrete choice experiments are a stated preference technique used in health economics. 
In this method, the researcher constructs a series of alternative choices based on a limited 
number of important attributes that describe a service, a product or an issue and 
administers as a questionnaire (Stirling and Dolan 2004).  Respondents choose from these 
alternative options for the choice series, which have different levels of the attributes, in 
order to infer the relative weighting attached to each level that has been assigned.  
Discrete choice experiments can be used to calculate the health gains available from 
different interventions, where the various dimensions of health are used as attributes; 
calculate the implied willingness to pay (willingness to wait) for those attributes where a 
value is included; express the relative value of different attributes, including non-health 
outcomes and process factors, in comparison to each other (de Bekker-Grob, Ryan and 
Gerard 2010).  Discrete choice experiments assume that the value of a product or service 
is based on the sum of its attributes and that an individual’s valuation and preference is 
dependent on the relative levels of these attributes. 
Discrete choice experiments have a series of implementation issues that should be 
acknowledged when using this method: the approach seeks to identify normative values, 
but thought should be given to the generalisability of the values identified (Reed Johnson, 
Lancsar et al 2013).  There are a range of psychological issues that should be addressed 
including the cognitive burden of the questionnaire, the potential for hypothetical bias and 
framing effects from the way that the questionnaire is written.  Technical issues also arise 
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when considering the sample size of scenarios, as representative from the full range of 
possible combinations (Reed Johnson, Lancsar et al 2013). 
2.2.5 Quasi Experimental Designs 
A central task of all research designed to evaluate causation is the approximation of what 
did happen compared to what would have happened, if the intervention or event had not 
occurred (Shadish, Cook and Campbell 2002).  A quasi-experimental evaluation is one in 
which the units of interest are not assigned to conditions randomly, but an attempt is still 
made to test the counterfactual hypothesis of what did happen compared to what would 
have happened.  In these research designs, units are often people, time periods or 
institutions.  Quasi-experimental design involves selecting groups, upon which a variable 
is tested, without any random pre-selection processes.  After selection, the experiment 
proceeds in a very similar way to any other experiment, with a variable being compared 
between different groups, or over a period of time.  The quasi-experimental approach is 
often convenient and, and for feasibility work, implementation is rapid to deliver and 
causes little disruption in situations where services are being provided. 
This inherent weakness in the methodology does not undermine the validity of the data, 
as long as they are recognized and allowed for during the whole experimental process.  
Quasi experiments resemble quantitative experiments, but the lack of random allocation 
of groups or proper controls, means that statistical analysis is more limited.   
In quasi-experiments, the cause of investigation is manipulable and occurs before the 
effect is measured. Since quasi-experimental control groups are not randomly assigned, 
they may differ from the intervention group in many systematic ways. The variance 
incorporated into such designs could theoretically provide plausible alternate explanations 
for the outcomes that are identified. Investigators may be prone to report the results more 
enthusiastically for quasi-experiments than for randomised studies.  The risk of 
investigator bias is therefore a further limitation (Kim, Nitsch, Wang and Bakhai 2006).   
Quasi-experimental approaches therefore provide less compelling support for inferences 
that are drawn from them (Craig, Cooper et al 2012). 
2.2.6 Cluster Randomised Controlled Trials 
In conventional randomised experimental designs, individual participants are randomly 
allocated to the intervention of interest or a control.  In cluster randomised designs, a 
group of individuals, a hospital or even a community is utilised as the unit of 
randomisation.  Cluster designs are particularly useful in health care setting where 
patients are nested within larger group settings (Mallick, Bakhai et al 2006) and patients 
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in one cluster may be more likely to have similar outcomes.  The cluster design has 
advantages when patients or clinicians may contaminate the intervention effect because of 
exchange of information within the cluster.  The cluster approach is useful for evaluating 
quality improvement strategies in healthcare interventions. 
In cluster randomised trials, statistical power is reduced in comparison to similarly sized 
conventional randomised designs.  Sample size calculations are therefore inflated using a 
cluster inflation factor to accommodate for the clustering.  Although the unit of 
randomisation is the cluster, the unit of reporting is at the patient level.  A statistical 
adjustment is made to adjust for the cluster size and number of clusters, as well as how 
closely related patient outcomes are within a cluster (intra-cluster correlation coefficient).  
The design effect indicates the amount by which the sample needs to be inflated.  A large 
design effect number requires more subjects than a conventional randomised trial design 
(Rutterford, Copas and Eldridge 2015). 
In the analysis of cluster randomised trials, failure to control for the correlation between 
individuals in the same cluster can lead to bias, over-estimating the treatment effect and 
increasing the chances of type one error; rejection of the null hypothesis (Hahn, Puffer et 
al, 2005).  The CONSORT (Consolidated Standards of Reporting Trials) guidance now 
takes account of the special features of cluster designs and requires a statement of the 
rational for the Cluster Effect for design and analysis of utilising a cluster design and 
acknowledgement of the implications (Campbell, Elbourne et al 2004).  In addition, the 
ethical issue surrounding the way being part of a cluster impinges on a study participant’s 
latitude to consent independently has been raised.  Other ethical issues such as the quality 
of scientific design and analysis, individual balance of risk and benefit especially for 
vulnerable patients, liberty to leave the study and the ability to exclude participants may 
also require consideration (Weijer, Grimshaw et al2011) 
2.2.7 Systems Thinking Approaches 
A systems thinking approach can be a useful way of considering the nature of the 
complex adaptive systems seen in health services.  Such an approach takes a wider 
perspective, considering interaction effects, feedback loops and emergence within the 
larger system
 
(Carey, Malbon, et al 2015).  This approach was developed from a system 
dynamic theoretical frame stance which aims to underpin the mechanisms driving 
dynamic behaviour by identifying causal relationships, feedback loops, delays and 
unintended consequences. Causal loop diagramming is a tool used to analyse complex 
systems. It is a qualitative visual aid used to communicate assumptions about a dynamic 
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system (Belue, Carmack, et al 2012). Visualizing complex adaptive systems can enable a 
better understanding of the behaviour of the system and its agents. A specific function of 
the tool is to elucidate feedback loops (Cavana and Mares 2004). . Use of such 
visualizations can be used to generate hypotheses which feed into theory-driven 
evaluation and exploration of potential causal mechanisms and routes to improvement 
(Renmans, Holvoet and Criel,  2015). 
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CHAPTER 3: 
DELIVERING HEPATITIS C TESTING AND TREATMENT IN 
COMMUNITY AND PRIMARY CARE SETTINGS 
Content 
The chapter comprises the paper Radley A, Robinson E, Aspinall EJ, Angus K, Tan L, 
Dillon JF.  A systematic review and meta-analysis of community and primary-care-based 
hepatitis C testing and treatment services that employ direct acting antiviral drug 
treatments – (BMC Health Service Research 2019; 19:765).  Radley conceived and wrote 
the first and subsequent drafts of the paper with clinical guidance from Dillon; Radley, 
Tan and Angus contributed to the review’s literature search, screening and data 
extraction. Robinson, Aspinall and Radley contributed to the meta-analysis and 
interpretation. All co-authors read and commented on the first drafts of the paper and 
approved the final version. 
Evidence Contributions 
The paper reports the results of Radley et al (2019): A systematic review and meta-
analysis of community and primary-care-based hepatitis C testing and treatment services 
that employ direct acting antiviral drug treatments.  The paper provides an overview of 
the evidence base, describing the published evaluations of care pathways that offer the 
newly introduced Direct Acting Antiviral (DAA) medicines into community and primary 
care environments. It reports the results of an updated systematic literature and meta-
analysis of the first studies to be published after the marketing of these medicines in 
2013.  The World Health Organisation Guidelines for the care and treatment of persons 
diagnosed with chronic hepatitis C virus infection promote simplified service delivery 
models; integration with other services; decentralised services supported by task-sharing 
and community engagement to address stigma and increase reach.  Previous medicines 
regimens used to treat HCV required intensive medical support and monitoring because of 
the heavy treatment burden and adverse effects associated with these drugs.  The 
consequences of this were that treatment was usually supervised by specialist medical 
teams in secondary care environments to ensure safety, but also that the target population 
– people who inject drugs – did not easily access the care provided, through a number of 
explanatory factors set out in Chapter 1.  Inertia in these established systems was 
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recognised by the Guidelines, which sought to overcome many of the barriers preventing 
the main group of people with HCV infection receiving curative treatment. 
Knowledge Translation Contributions 
The systematic review provides support for the development of an effective pharmacy-
based care pathway for testing and treatment of HCV.  The evidence assessed provides 
detailed knowledge of the range of pathways that have been established and evaluated, as 
well as the types of evaluations that have been undertaken.  The objectives of these 
evaluations, to link people into care; to carry out testing for BBVs; to establish them on 
treatment; to support them to complete treatment and to measure the achievement of a 
clinical cure (SVR) are fundamental in relating the work undertaken in this research 
programme to established literature. 
In addition, Radley has provided evidential support to the development of the report 
entitled Recommendations on hepatitis c virus case-finding and access to care: Report of 
the national short-life working group (August 2018), requested by the Scottish 
Government and undertaken through the Scottish Health Protection Network.  The 
findings of the systematic review and meta-analysis have been presented by invitation, to 
a series of national and international conferences on care and treatment of people with 
HCV infection. 
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3.1 A systematic review and meta-analysis of community and primary-
care-based hepatitis C testing and treatment services that employ direct 
acting antiviral drug treatments 
The following paper is a verbatim copy of Radley A, Robinson E, Aspinall EA, Angus K, 
Tan L, Dillon JF published at BMC Health Services Research 2019 (19) 765 
https://doi.org/10.1186/s12913-019-4635-7  
ABSTRACT 
Background: Direct Acting Antiviral (DAAs) drugs have a much lower burden of 
treatment and monitoring requirements than regimens containing interferon and ribavirin, 
and a much higher efficacy in treating hepatitis C (HCV).  These characteristics mean that 
initiating treatment and obtaining a virological cure (Sustained Viral response, SVR) on 
completion of treatment, in non-specialist environments should be feasible.  We 
investigated the English-language literature evaluating community and primary care-
based pathways using DAAs to treat HCV infection. 
Methods: Databases (Cinahl; Embase; Medline; PsycINFO; PubMed) were searched for 
studies of treatment with DAAs in non-specialist settings to achieve SVR. Relevant 
studies were identified including those containing a comparison between a community 
and specialist services where available.  A narrative synthesis and linked meta-analysis 
were performed on suitable studies with a strength of evidence assessment (GRADE).  
Results: Seventeen studies fulfilled the inclusion criteria: five from Australia; two from 
Canada; two from UK and eight from USA.  Seven studies demonstrated use of DAAs in 
primary care environments; four studies evaluated integrated systems linking specialists 
with primary care providers; three studies evaluated services in locations providing care 
to people who inject drugs; two studies evaluated delivery in pharmacies; and one 
evaluated delivery through telemedicine. Sixteen studies recorded treatment uptake.  
Patient numbers varied from around 60 participants with pathway studies to several 
thousand in two large database studies.  Most studies recruited less than 500 patients.  
Five studies reported reduced SVR rates from an intention-to-treat analysis perspective 
because of loss to follow-up before the final confirmatory SVR test.  GRADE 
assessments were made for uptake of HCV treatment (medium); completion of HCV 
treatment (low) and achievement of SVR at 12 weeks (medium). 
Conclusion: Services sited in community settings are feasible and can deliver increased 
uptake of treatment. Such clinics are able to demonstrate similar SVR rates to published 
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studies and real-world clinics in secondary care.  Stronger study designs are needed to 
confirm the precision of effect size seen in current studies. Prospero: CRD42017069873 
BACKGROUND 
Of the 71 million persons infected with HCV, 5.6 million (8%) currently inject drugs [1, 
2].  The World Health Organization (WHO) has defined global targets for HCV diagnosis 
and treatment, which represents a major step towards the aim of global elimination by 
2030 [3]. 
However, rates of uptake of HCV testing, linkage to care and treatment remain low across 
many countries [4].  Barriers to accessing funded Direct Acting Antiviral (DAA) drug 
treatment may be due to provider concerns regarding co-morbidities, adherence, and side 
effects management [5]. Social factors affecting treatment access have been categorised 
as social stigma, housing, criminalisation, health care providers’ attitudes and 
stigmatising practices, and gender [6]. Individuals may prioritise other needs and may be 
wary of the consequences of a diagnosis on their circumstances; health systems may 
present complex and rigid arrangements that must be navigated in order to access care 
[7].  The stigma associated with both injecting drug use and HCV infection is pervasive 
[8].  The concept of the care cascade has focussed attention on the performance of 
different pathways and the attrition of patients accessing testing, diagnosis, treatment and 
care [9]. 
It is common in many developed and developing countries, for specialist clinicians to 
provide HCV treatment, often from hospital outpatient facilities [10].  Recently, 
prescribing of DAAs has become common practice in many countries [10].  Treatment of 
HCV with these medicines is simple and well-tolerated [11]. The safety profile and high 
efficacy of DAAs means that HCV treatment can be delivered by a range of non-specialist 
clinicians including nurses, pharmacists and general practitioners, therefore providing 
enhanced access to virological cure (SVR).  [12].  The ease of transferring care to 
community and primary care environments is assisted by the use of treatment regimens 
that do not contain ribavirin or interferon [13].  Progress with implementing treatment 
pathways provided by non-specialists in community and primary care environments has 
been identified as one of the key steps in the elimination of HCV [14].  The World Health 
Organization’s Guidelines for the care and treatment of persons diagnosed with chronic 
hepatitis C virus infection promote simplified service delivery models: integration with 
other services; decentralised services supported by task-sharing; and community 
engagement, with the intention of reducing stigma and increase uptake of treatment [14].  
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This review was undertaken to identify rates of treatment uptake, treatment completion 
and achievement of sustained viral response for adults infected with hepatitis C using 
DAA-only treatment regimens in community and primary care-based care pathways, 
evaluated by studies using observational and experimental study designs.  Studies that 
compared community-based treatment care pathways with specialist care were actively 
sought.  
METHODS 
This systematic review was undertaken and reported according to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [15]. The 
methods of analysis and defined inclusion criteria were specified in advance and 
documented in a study protocol. The study was registered in PROSPERO 
(CRD42017069873).  The PICOS elements defined for this review are set out in Table1  
The rationale adopted in the design of the PICOS elements was intended to provide some 
answers to the questions raised by the WHO Guidance and its recommendations for 
simplified and decentralised treatment delivery models, integrated with other services in 
community and primary-care environments [14].  Therefore a population over 18 years 
old was selected, as being less likely to have gained their infection through vertical 
transmission.  Co-infected individuals with other blood borne virus infections were also 
excluded as their care was likely to be more complex, requiring specialist rather than 
simplified care.  Studies from prison populations were excluded since these individuals 
lived in contained communities.  Studies that utilised interferon and ribavirin-based 
treatment regimes as the primary intervention were also excluded, since monitoring and 
patient management requirements, made simplified and decentralised care less likely. 
Sustained viral response at 12 weeks (SVR12) was taken as a marker for virological cure; 
failure to achieve SVR may be attributed to both treatment failure and loss to follow-up 
[16].  Studies were restricted to the English language since study resources precluded any 
translation activities.  Published studies were utilised including conference abstracts, in 
order to capture results from early studies when the first DAAs were introduced into 
practice. 
Search strategy 
Published research was identified by formal searches of five electronic databases (Cinahl, 
Embase, Medline, PsycINFO, PubMed) from January 2013 to December 2017, as well as 
Google Scholar. The last search was run on 11 December 2017. Search topics included 
“hepatitis C”, “treatment” and “setting”. A comprehensive list of search terms related to 
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each of the search topics was used to develop a search strategy for each electronic 
database.  Search strings were formulated by using a combination of keywords and 
indexed subject headings (MeSH and EMTREE terms). Primary care was defined using 
the WHO accepted terminology that promotes Primary Care as a key process in the health 
system: “it is first-contact, accessible, continued, comprehensive and coordinated care” 
[17] and community environments being the geographical locations where groups of 
people live. 
The full search strategy is set out in supplementary file 1.  Reference lists of selected 
articles, citing articles and relevant review articles retrieved during the initial search were 
hand-searched and forward citation checks were undertaken to identify any additional 
studies. Abstracts from the selected scientific conferences were screened for review 
eligibility. 
Study selection  
Data retrieved through the study search strategy were imported into EndNote X8 
(Thomson Reuters, New York, NY, USA) and any duplicates removed. Titles obtained 
from the initial search strategy were screened and irrelevant citations were removed. 
Abstracts were then assessed using the inclusion and exclusion criteria by two reviewers 
independently (AR and LT) to establish a relevant pool of evidence for further evaluation. 
Full-texts from all abstracts identified for further evaluation and were double-screened 
independently by the two reviewers to assess whether they met the defined inclusion and 
exclusion criteria. In the event of a disagreement, the senior investigator (JFD) 
determined final inclusion. The lead author contacted conference abstract authors to 
attempt to obtain further study results if available. Studies published from identified 
conference abstracts were screened for review. 
Data collection process and data items collected 
Data from studies included for analysis were extracted by the lead author (AR) using a 
standardised data extraction form (Microsoft Excel 2010 Redmond, WA, USA). A second 
reviewer (ER) also independently assessed the extracted data, and disagreements were 
resolved by discussion until consensus was reached. The following variables were 
documented: first author, title, publication year, study design, study location, setting, 
intervention description, comparator description, sample size outcome description and 
number of participants achieving SVR12 (and percentage if applicable). 
Risk of bias assessment in individual studies 
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The risk of bias in individual studies was assessed by two reviewers (AR and ER) using 
the Cochrane Collaboration’s risk of bias tool for randomised studies [18] and the 
“Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in 
meta-analyses” [19].  For randomised studies, these outcomes were evaluated along the 
six domains: selection bias, performance bias, detection bias, attrition bias, reporting bias, 
and other bias. The domains deemed as ‘high risk’ of bias for each study per outcome 
were determined. Outcomes for the non-randomised studies were evaluated along seven 
domains: bias due to confounding; bias in selection of participants into study; bias in 
classification of interventions; bias due to deviations from intended interventions; bias 
due to missing data; bias in measurement of outcomes; and bias in selection of the 
reported result. The overall risk of bias for these studies was classified into five 
categories: low risk of bias; moderate risk of bias; serious risk of bias; critical risk of bias 
or no information. 
The NOS scale measures three items: selection of cases and controls including their 
definition and representativeness; comparability of cases and controls in design and 
analysis; and exposure ascertainment. The scale has a minimum score of 0 and a 
maximum score of 9. Risk of bias was rated as high, medium or low according to the 
scores obtained by reviewing the selection, comparator and exposure categories. Risk of 
bias was rated low if studies scored 8 or 9; medium risk if studies were scored as  6 or 7.  
Studies were rated as having a high risk of bias if they were scored as having 5 or less or 
scored zero for the comparator category [20]. 
We assessed the strength of evidence using GRADE [21]. The scheme evaluates a 
required group of domains (study limitations, directness, consistency, precision and 
reporting bias) and enables grading of the strength of evidence as High; Moderate; Low 
or Insufficient.  Use of this approach enabled us to summarise the outcomes and findings 
and make clear judgements about the effects of the interventions. 
Data analysis 
The characteristics and findings of the studies included were summarised and structured 
using tables. Studies evaluating similar service environments in community and primary 
care-settings were grouped together to facilitate comparison. 
Study designs, participants, interventions and reported outcomes varied significantly, and 
a meta-analysis was unable to be performed on all included studies. Studies were 
excluded from the meta-analysis if the reviewers considered them to be sufficiently 
flawed so as not to contribute meaningfully to the body of evidence [21]. 
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The characteristics and findings of included studies amenable to meta-analysis were 
summarised using tables and forest plots. Risk ratio (RR) and corresponding 95% 
confidence interval (95% CI) was calculated for each study outcome, using the initial 
number of eligible participants included and the number achieving the outcome of interest 
in each arm. Analyses were conducted using statistical package Stata v14.0 (College 
Station, TX, USA). 
Data synthesis 
Deriving Pooled Estimates of treatment uptake, treatment completion and SVR 
Treatment uptake, treatment completion and SVR and their exact 95% confidence 
intervals (CIs) were calculated assuming a binomial distribution. Pooled estimates were 
derived using random- or fixed-effects methods, according to whether significant 
heterogeneity (defined as I
2
 > 30%) was or was not present, respectively. Sensitivity 
analysis was used to assess the impact of study quality (restricting to studies with an NOS 
score ≥6) on the pooled estimate of SVR. 
Further sensitivity analysis was used to assess the impact of conference abstracts on the 
pooled estimate of SVR.  We identified studies using similar environments from which to 
deliver care and grouped them into categories. Factors identified as linking studies within 
categories were examined as well as factors that differentiated studies from each other.  
RESULTS 
Study Selection 
The searches yielded 9,137 publications after removal of duplicates (Figure 1).  This 
resulted in 121 articles retrieved for full text inspection and 17 included for analysis.  
Explanations for exclusion of studies at the full text stage are provided in Figure 1.  These 
included: did not fulfil inclusion criteria; no treatment intervention; review or opinion 
article; other (e.g. insufficient detail reported in conference abstract).  
Study characteristics  
Studies evaluated care pathways in primary care [22, 23, 24, 25, 26, 27, 28]; in integrated 
health systems (Extension for Community Healthcare Outcomes, ECHO) [29, 30, 31, 32]; 
in opioid treatment centres [33, 34, 35]; in pharmacies/pharmacist clinics [36, 37] and by 
telemedicine [38]. Characteristics and findings of included studies are set out in Table 2.  
These studies originated from United States of America (8); Australia (5); United 
Kingdom (2); and Canada (2).  The number of identified studies published as conference 
abstracts reflected the length of time that DAAs have been widely available outside 
specialist environments.  Six from seventeen studies were only available as conference 
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abstracts. There were two randomised controlled trials, four cohort studies, nine 
retrospective data analyses and two prospective non-experimental designs. All were 
conducted on populations at high risk of HCV infection, such as people who inject drugs 
and people on Opioid Substitution Therapy (OST) programmes. Table 3 describes the 
outcomes from the meta-analysis of selected studies and Table 4 defines the Strength of 
Evidence Assessment for identified studies answering the PRISMA objective.  Details of 
assessment of bias and design for studies are located in Supplementary Table 1 (non-
randomised) and Supplementary Table 2 (randomised)). 
Primary Care 
Seven studies evaluated interventions to enhance treatment uptake and achievement of 
SVR in primary care environments [22, 23, 24, 25, 26, 27, 28].  One study was a 
randomised controlled trial (RCT), two were cohort studies and four were non-
randomised studies.  Four studies utilised nurses in delivery of the care pathway. Three 
studies included uptake of testing and assessment in their description of care and all the 
studies discussed uptake of treatment and ascertainment of SVR. The RCT reported a 
significant difference between those commencing treatment in primary care arm than in 
the Standard of Care arm (SOC) (75% Vs 34%, p<0.001) and proportion gaining an 
SVR12 was significantly higher in the primary care arm than in the SOC arm (49% vs 
34%, p=0.043). 
Two studies reported a reduction in potential SVR rates because of failure of participants 
to complete the confirmatory blood test at 12 weeks after completion of DAA treatment. 
All studies reported increased access to treatment in primary care environments and high 
rates of SVR attainment.   
Integrated Health Systems (ECHO) 
Four studies provided evaluations of care through integration of specialist centres with 
primary care delivery [29, 30, 31, 32].  One study was a retrospective cohort study and 
three were non-randomised studies.  Three of the four studies utilised the “ECHO” care 
pathway in which hepatitis specialists support primary care providers through video-
conferencing and collaboration on specific cases, with a defined curriculum and active 
mentorship [39]. None of the studies discussed uptake of testing amongst their treated 
cohorts. All studies increased access to treatment and high rates of attainment of SVR. 
Opioid Treatment Centres 
Three studies evaluated care provision in dedicated setting where people with opioid 
addiction received harm reduction and treatment services [33, 34, 35]. All three studies 
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were non-randomised analyses of treatment data and assessed the uptake and completion 
of treatment by participants using these services. No assessment of the extent of testing of 
these populations was discussed.  All studies reported high rates of treatment uptake and 
treatment completion in diagnosed individuals.   These studies all described problems 
with retention of participants in the service post-treatment with consequent reductions in 
uptake of confirmatory SVR testing. 
Pharmacies / Pharmacist Clinics 
Two studies evaluated hepatitis C care provision by pharmacists in community and 
primary care settings [36, 37]. One study was a feasibility RCT that compared the 
delivery of a community pharmacy test and treatment pathway with standard hospital -
based care. One study was a non-randomised data analysis.  The RCT demonstrated an 
increase in testing uptake, when the participant received all care in a pharmacy 
environment and showed increased retention in care.  Data from this study also 
demonstrates a marked loss of patients from the care pathway when they were asked to 
attend the local hospital.  The non-randomised study concluded that patients treated in 
pharmacist clinics achieve high rates of SVR similar to non-pharmacist clinics 
Telemedicine 
A single cohort database study [38] compared treatment uptake and SVR rates in 
participants cared for through a telemedicine pathway (n=157) with participants cared for 
through a standard care pathway (n=1,130).  The study demonstrated increased access to 
care form under-served and remote areas and concluded that the telemedicine intervention 
achieved high rates of treatment initiation and SVR. 
Data synthesis 
The 12 studies eligible for meta-analysis examined treatment uptake, completion and 
SVR in a variety of primary care environments; integrated systems (ECHO) that linked 
specialists with primary care providers; opioid treatment centres; pharmacies / pharmacist 
clinics; telemedicine and specialist hospital care. The remaining five studies were 
unsuitable for meta-analysis due to non-reporting of the required outcomes, use of 
Pegylated interferon or insufficient time to achieve SVR. Across the 12 studies, the 
pooled estimate is shown in Supplementary Table 3.  Forest plots for suitable studies are 
set out in Figures 2, Figure 3 and Figure 4.  These plots demonstrate that across the 
variety of community and primary care environments, a consistent direction of effect to 
improve treatment uptake, treatment completion and achievement of SVR is seen.  
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Greater uptake was seen for the Primary Care and Pharmacy Locations, compared to the 
Specialist Care Location and comparable SVR rates were demonstrated (Table 2).  
In this analysis, heterogeneity was noted to be high so a sensitivity analysis restricting to 
higher-quality studies (NOS score ≥6) was performed. Despite this the heterogeneity 
remained high. A further sensitivity analysis was performed restricting the meta-analysis 
to published studies only. See Supplementary Table 2 in the appendix. This had no impact 
on heterogeneity. 
DISCUSSION 
This paper reviews evaluations of care pathways that utilise DAAs in a range of 
community and primary care settings.  The WHO Guidelines on care and treatment of 
persons diagnosed with chronic HCV infection promote simplified service delivery 
models; integration with other services; decentralised services supported by task-sharing; 
and community engagement to address stigma and increase reach [14].  The studies 
considered in this systematic review and meta-analysis therefore provide some evidence 
for the extent of implementation of these guidelines. 
The studies identified that met our inclusion criteria were grouped according to location: 
primary care; integrated health care systems (ECHO); opioid treatment centres; in 
pharmacies / pharmacist clinics; and through telemedicine.  These care pathways 
acknowledged the need to provide local services with reach into the communities where 
people with hepatitis C live their lives. 
In all three areas assessed in our study: uptake of treatment; completion of treatment; and 
attainment of SVR, a positive outcome was reported by all identified studies. This was 
seen across each of the distinct environments from which the care was provided. Since 
the positive outcomes were drawn from distinctly different pathways of care, further 
confidence might be inferred from this consistency of direction of effect . However, 
amongst the studies that met our inclusion criteria, there was a lack of studies using 
comparators from specialist centres.  Data contained in these studies nevertheless 
demonstrated high uptake of treatment and high rates of attainment of SVR: among 
populations of vulnerable people who normally struggle to access care. Studies that did 
include comparators showed no significant differences in uptake or SVR.  Several of the 
studies reported an increased uptake of treatment, but most reported equivalence.  Some 
studies reported lower rates of attainment of SVR, because of study participants failing to 
undergo a confirmatory blood test post-treatment, within the study timelines. With DAAs 
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SVR rates of greater than 97% are delivered if patients adhere to treatment, therefore 
completion of therapy can be a surrogate for SVR [16]. 
Previous systematic reviews have considered barriers and facilitators to care, as well as 
the views and experiences of people who inject drugs [7, 40].  These studies concluded 
that the target groups for HCV often had poor levels of knowledge about the infection and 
of the processes involved with testing and treatment.  A fear of stigma and discrimination 
and a reticence to discuss risk behaviours tended to prevent engagement.  These barriers 
could be addressed through educating participants, increasing awareness and redress of 
institutionalised stigma and integrating HCV treatment pathways into other services 
where the target group were likely to go. 
Increased uptake of testing has been observed when testing is offered at the same time as 
other routine care [4]; with integrated services for both opioid users and with mental 
health services. There are advantages to targeting services at populations with predicted 
high prevalence of HCV [41]. Provision of HCV treatment as part of a directly observed 
treatment arrangement, increased attainment of SVR [42].  Achievement of these factors 
within local health systems needs to be commonplace if the WHO target for elimination is 
to be met [43]. There is some evidence that this is now happening [44]. 
The results from this systematic review highlight the lack of well-controlled randomised 
controlled trials and comparative studies, with just two randomised controlled trials 
identified and four cohort studies. While the publication of such studies is an important 
step in building confidence that decentralisation of hepatitis C treatment can be 
accomplished, the paucity of evidence reflects the difficulty in funding pathways to care 
studies and the relatively recent removal of the restrictions on the use of DAAs. Two 
further studies have been commenced identify that further evaluations of interferon-free 
treatments in primary care environments are underway [45, 46]. 
As with most systematic reviews, the quality of the studies and the heterogeneity of the 
study populations included in the analysis present a limitation of this study.  The sensitivity 
analyses performed for our analysis did not have an impact on heterogeneity, meaning that an 
unexplained source of heterogeneity may be present.  These difficulties may reflect the variety of 
ways in which patients can access HCV treatment.  This may be positive and may be explained 
by the development of more patient centred pathways. These factors prevented a meta-analysis 
being achieved for many of the studies identified as eligible through the PICOS question defined 
for this review.  Many of the studies that met the inclusion criteria were only available as 
conference abstracts at the time of review, including one of the randomised controlled trials.  
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Nevertheless, over 10,000 participants were included in the identified studies.  All studies had a 
consistent direction of effect, providing optimism that future evaluations will confirm with 
precision the effect size that should be delivered by simplifying treatment pathways and 
decentralising them to primary care. In terms of further limitations, we acknowledge limitations 
in the chosen methods for the systematic review, including potential publication bias to 
the findings by excluding non-English language studies; or any other biases introduced by 
our chosen inclusion and exclusion criteria. 
CONCLUSION 
This systematic review and meta-analysis identified studies which demonstrate the 
feasibility of decentralising care and providing local services with reach into communit ies 
of people infected with HCV.  Such pathways may increase uptake of treatment and can 
provide sustained viral responses equivalent to those attained in specialist centres.  
Further studies are needed to confirm the promising start to the implementation of 
interferon-free treatment regimens. The successful implementation of such pathways to 
deliver successful patient outcomes is a key requirement for a “treatment as prevention” 
strategy as a pathway to elimination of HCV [47]. 
The references to this manuscript are provided in Appendix 9.1 
 
Abbreviations 
Direct Acting Antiviral        DAA 
Grading of Recommendations Assessment, Development and Evaluation GRADE 
Hepatitis C         HCV 
Human Immunodeficiency Virus      HIV 
Newcastle Ottawa Scale       NOS 
Opioid Substitution Therapy       OST 
Population; Intervention; Comparison; Outcome; Study Design  PICOS 
Preferred Reporting Items for Systematic Reviews and Mata-Analysis PRISMA 
People Who Inject Drugs       PWID 
Randomised Controlled Trial       RCT 
Risk Ratio         RR 
Standard of Care        SOC 
Sustained Viral Response       SVR 
Sustained Viral response at 12 weeks     SVR12 
World Health Organization       WHO   
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Table 1: Elements of the PICOS question defined for this review 
 Inclusion Exclusion 
Population Age 18 years and over 
Infected with hepatitis C  
Age less than 18 years 
Co-infection with Hepatitis B virus 
Co-infection with Human 
Immunodeficiency Virus 
Intervention Provision of hepatitis C treatment in any 
primary care and community 
environments 
Treatment using any direct acting 
antiviral therapy 
Care provider could be any health care 
provider 
Hepatitis C treatment in prison 
populations 
Treatment with ribavirin / interferon 
regimes as the primary intervention 
Comparison Care in any hospital or secondary care 
environment or no comparison group  
 
Outcome Treatment uptake, treatment completion  
and Sustained Viral Response outcomes 
 
Study 
design 
Observational studies, retrospective or 
prospective cohort studies, randomised 
trials; conference abstracts; qualitative 
and mixed methods studies 
Case studies; systematic reviews 
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Table 2: Characteristics and findings of included studies 
Care Location Year Country Design Intervention Comparator 
Number of 
participants 
Uptake 
(%) 
Sustained 
Viral 
Response 
(SVR) (%) 
Primary Care 
        
Bloom 201
7 
Australia Prospective cohort 
study of treatment 
uptake and SVR 
Adherence to 
Direct Acting 
Antiral 
treatment 
protocols 
Treatment by 
tertiary care 
provider 
1044 503 
(40.6) 
253 (50.2) 
Francheville 201
7 
Canada Prospective 
observational study 
design 
Specialist 
nurse-led care 
No comparator 
group 
242 93(38.4) 82(88.2) 
Kattakuzhy 201
7 
USA Non-randomised 
open label study 
Treatment by 
primary care 
providers 
(PCP) and 
nurse 
practitioners 
(NP) 
Standard care - 
Treatment by 
secondary care 
clinic 
NP 150 
PCP 160 
 
NP 134(89.3) 
PCP139(86.9) 
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McCLure 201
7 
Australia Retrospective data 
analysis of SVR 
Nurse-led care 
and GP remote 
consultation 
Specialist care in 
Tertiary centre 
Nurse-led 
70 
50(74.3) 
46(65.7) 
Miller 201
6 
USA Retrospective 
observational study 
Treatment by 
primary care 
providers 
No comparator 
group 
95  79(83) 
Norton 
201
7 
USA 
Retrospective 
cohort study of  
SVR 
Treatment in 
urban primary 
care centre 
SVR 12 in 
PWIDs and 
non_PWIDs 
89 
 
85( 95.5) 
Wade 201
8 
Australia Randomised 
controlled trial 
Testing, 
assessment 
and treatment 
in primary 
care 
Testing, 
assessment and 
treatment in 
tertiary care 
59 31(52.5) 14(23.7) 
Integrated 
Health Systems 
(ECHO) 
        
Abdulameer 201
6 
USA Retrospective data 
analysis of SVR  
VA-Echo 
model 
supporting 
primary care 
No comparator 
group 
588  318 (54) 
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providers 
Beste 201
7 
USA Retrospective 
cohort study of 
treatment uptake 
and SVR 
VA-Echo 
model 
supporting 
primary care 
providers 
Standard care - 
Treatment by 
unexposed 
primary care 
providers 
6431 1303 
(21.4) 
(58.2) 
Buchanan 201
5 
United 
Kingdom 
Retrospective data 
analysis 
Community-
based outreach 
clinic 
Standard care - 
Treatment by 
secondary care 
clinic 
77 24 
(31.2) 
 
Georgie 201
6 
USA Retrospective data 
analysis of SVR 
VA-Echo 
model 
supporting 
primary care 
providers 
Treatment by 
sub-specialist 
providers 
623  Genotype 1 
(GT1) (99) 
GT2 (98) GT3 
(79) 
Opioid 
Treatment 
Centres 
        
Butner 201
7 
USA Retrospective data 
analysis 
Opioid 
treatment 
No comparator 
group 
75 75.0 64 (85.0) 
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programme 
Morris 
201
7 
Australia 
Retrospective data 
analysis of 
treatment uptake 
and SVR 
Treatment in a 
community-
based harm 
reduction and 
treatment 
facility 
No comparator 
group 
127 122(96) 102(80.3) 
Read 201
7 
Australia Retrospective data 
analysis of SVR 
Treatment of 
PWIDs in 
primary care 
setting 
No comparator 
group 
72  59(81.9) 
Pharmacies / 
Pharmacist 
Clinics 
        
David 201
7 
USA Retrospective data 
analysis of SVR 
Pharmacy-
managed 
clinics 
Treatment by 
non-pharmacist 
providers 
204  (83.6) 
Radley 201
7 
United 
Kingdom 
Pilot cluster RCT 
of treatment uptake 
and SVR 
Treatment in 
community 
Pharmacy 
Treatment by 
secondary care 
clinic 
26 3(11.5) 3(11.5) 
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Telemedicine 
        
Cooper 201
7 
Canada Retrospective 
cohort study of 
treatment uptake 
and SVR 
Use of 
telemedicine 
Treatment by 
secondary care 
clinic 
157 35.0 18(11.5) 
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Table 3: Meta-analysis of studies examining treatment uptake, treatment completion and SVR among people with Hepatitis C treated in a 
variety of community settings or specialist hospital care 
Abbreviations: CI, confidence interval;  SVR, sustained virologic response a. Random-effects method used if I
2
 ≥ 30%. 
Inclusion Criteria Treatment Uptake Treatment Completion SVR 
 No. Of 
studies 
Heterogeneity 
       (I
2
) 
Pooled 
estimate  
(95% CI) 
No. Of 
studies 
Heterogeneity 
       (I
2
) 
Pooled 
estimate 
(95% CI) 
No. Of 
studies 
Heterogeneit
y 
       (I
2
) 
Pooled 
estimate 
(95% CI) 
Opioid Treatment 
Centres 
   2 77.7% 91.9 (82.2-
100) 
3 0.0% 82.3 (77.8-
86.8) 
Integrated Health 
System (ECHO) 
1 Not applicable 75.6 (68.0-
83.2) 
1 Not 
applicable 
96.8 (93.2-
100) 
2 84.6% 81.3 (66.9 -
95.5) 
Telemedicine 1 Not applicable 22.3 (15.8-
28.8) 
   1 Not 
applicable 
51.4 (34.8-
68.0) 
Primary Care 1 Not applicable 67.4 (53.9 – 
80.9) 
1 Not 
applicable 
100 
(97.95-
100) 
5 94.9% 74.4 (60.3 – 
88.5) 
Pharmacies / 
Pharmacist Clinics 
1 Not applicable 66.67 (58.3 – 
75.1) 
   2 89.0% 79.0 (79.2 – 
98.9) 
Specialist Care 2 0.0% 34.5 (31.79 – 
37.29) 
   5 96.8% 73.46 (60.9 
– 85.9) 
 
 
Table 4: Summary of key findings, outcomes and strength of evidence 
Outcome Study designs/ 
No. Studies  
Findings and Direction of Effect GRADE 
[21] 
1. Uptake of 
HCV treatment  
RCT – 2  
Cohort – 3 
Observational – 5 
Two RCTs assessed as having low 
risk of bias reported a positive effect 
on uptake with precision and a 
consistent positive direction of effect.  
One cohort study assessed as having 
medium-grade study limitations also 
reported a positive effect on uptake.  
Medium 
2. Completion 
of Treatment 
Cohort - 1 
Observational - 2 
One cohort study with medium study 
limitations reported a positive 
direction of effect on uptake. 
Low 
3. Sustained 
Viral Response 
(SVR) at 12 
weeks 
(%)(SVR12) 
RCT -2  
Cohort - 4 
Observational - 11 
Two RCTs assessed as having low 
risk of bias reported a positive effect 
on SVR but were imprecise in the 
estimate of effect size. Four cohort 
studies and 11 observational studies 
with over 10,000 participants all 
reported a consistent positive 
direction of effect, but with 
significant study limitations. 
Medium 
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3.2 Critical reflection 
This systematic review and meta-analysis was undertaken in order to understand the 
breadth and quality of the literature supporting the World Health Organisation’s guideline 
that delegation of hepatitis c testing and treatment services should be made to non-
specialist practitioners in primary care settings and that elements of care should be 
delegate to the wider team.  The circumstances making this possible are the introduction 
of a series of direct-acting antiviral (DAAs) drugs that have a small treatment burden and 
limited requirement for management and monitoring.  The first DAA medicines were 
released in 2013, with widespread availability occurring around 2015.  The high cost of 
these medicines (perhaps £30,000 per course) led to many administrations limiting their 
prescribing in order to manage the impact on medicines budgets.  The advocacy 
undertaken by third sector organisations and interested academics supporting the case of 
people who use drugs (PWIDs) was therefore to make the case that decentralised care was 
feasible, desirable and effective.  This study therefore was designed to critically evaluate 
the quality of evidence supporting this purpose. 
3.2.1 Critique of methods 
The methods used in this systematic review and meta-analysis are the same as those 
described in chapter two and set out in the paper, so an in-depth discussion of the 
strengths and weaknesses will not be repeated.  As an overview, the study used a 
systematic approach to reviewing the evidence base, registering the structured research 
question (PICOS) on the PROSPERO database (https://www.crd.york.ac.uk/prospero/) 
and following the PRISMA guidance (http://www.prisma-statement.org/). The strengths 
of the review include the use of independent reviewers to screen all titles and abstracts 
identified by the database searches and the use of an independent researcher to agree any 
disagreements between reviewers.  Decisions about study inclusion were agreed with an 
independent researcher and a thorough quality assessment was conducted for all studies.  
A meta-analysis was performed on a selection of included studies that were of sufficient 
quality and an estimate of direction of effect and effect size made for these studies.  A 
strength of evidence assessment was performed on the group of studies to provide an 
overview of the research exercise. 
As the study was conducted within finite time and resources, only papers in English were 
included and sources from grey literature were not identified.  Independent double 
screening was split between two authors. 
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3.2.2 Critique of analysis 
The relatively recent introduction of DAAs to clinical practice meant that studies 
identified from the database were often conference abstracts or reports of observational 
study designs and service developments.  This fact is reflected in the poor performance of 
a number of included studies in the assessment of bias analysis and high study 
heterogeneity for some of the topics, meaning that a reduced number of studies could be 
included in the meta-analysis  
However the definitions of care outcomes used in the testing and treatment of hepatitis C 
infection are relatively uniform in the literature, meaning that included studies adopted 
similar reporting points for data.  The relevant outcome points: a diagnosis of hepatitis c; 
the concept of viral load, the process of linkage to care and uptake of drug treatment; the 
attrition from treatment; and the achievement of a cure (sustained viral response at 12 
weeks post treatment-SVR12) were reported in a consistent manner.  
The meta-analysis did show a consistent direction of effect and the study identified that 
uptake of drug treatment from studies carried out in primary care settings was 
approximately twice that recorded for uptake of drug treatment in specialist care settings.  
The ability to aggregate studies and to use a random effects model to weight individual 
studies meant that a more conservative summary statistic was produced than by the fixed 
effects model (Higgins and Green, 2011).  The strength of evidence assessment used, also 
highlighted the areas where stronger and weaker support for the World Health 
Organisation guidance was available. 
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CHAPTER 4: 
DEVELOPMENT AND MODELLING OF AN INTERVENTION IN 
COMMUNITY PHARMACY 
Content 
Radley A, Melville K, Easton P, Williams B, Dillon JF. “Standing Outside the Junkie 
Door” – Services users experiences of using community pharmacies to access treatment 
for opioid dependency. J. Public Health 2017; 39 (4): 846-855. 
doi:10.1093/pubmed/fdw138 
Radley A, Melville K, Easton P, Williams B, Dillon JF (2017) was conceived by Radley 
and Williams. Radley and Melville undertook the qualitative interviews and jointly 
undertook the thematic analysis and interpretation. Radley, Easton, Williams and Dillon 
provided methodological and clinical advice. The paper and subsequent revisions were 
written by Radley and the final submission signed off by all co-authors. 
Radley A, van de Pol M, Dillon JF. Designing a hepatitis C testing service in primary 
care: a discrete choice experiment. International Journal of Drug Policy 2019; 65:1-7. 
https://doi.org.10.1016/j,drugpo.2018.12.008  
Radley A, van de Pol M, Dillon JF (2018) was conceived by Radley, van der Pol and 
Dillon. The questionnaire was designed by Radley and van der Pol using information 
from Radley et al (2017) as well as information gained from a literature review and 
published guidance on conducting discrete choice experiments. The analysis was led by 
van der Pol with input from Radley. The paper and subsequent revisions were written by 
Radley with input from van der Pol and Dillon and the final submission signed off by all 
co-authors 
Radley AS, Melville K, Tait J, Stephens B, Evans JEE, Dillon JF.  A quasi-experimental 
evaluation of dried blood spot testing through community pharmacies in the Tayside 
region of Scotland. Frontline Gastroenterology 2017; 8: 221-228. doi: 10.1136/flgastro-
2016-100776 
Radley AS, Melville K, Tait J, Stephens B, Evans JEE, Dillon JF (2017) was conceived 
by Radley, Evans and Dillon.  The protocol and study documents were prepared by 
Radley and Dillon. Training and mentoring of the community pharmacists was 
undertaken by Radley and Stephens.  Data acquisition was undertaken by Radley, 
Melville and Tait. Evans and Dillon provided methodological and clinical advice.  The 
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analysis was undertaken by Radley with input from Evans and Dillon. The paper and 
subsequent revisions were written by Radley with input from Evans and Dillon. The final 
submission was signed off by all co-authors. 
Evidence Contributions 
These papers report on the development and modelling work undertaken to initiate and 
describe the pharmacist-led intervention, as part of the process of acquiring increasing 
evidence to inform the design of a definitive experimental study of a complex 
intervention using the Medical Research Council’s Guidelines.  The structure of the work 
enabled an iterative increase in understanding of how to construct an intervention that 
was feasible and pragmatic 
The paper describing a focus group series (Radley et al 2016) illustrates the lived 
experience of people prescribed opioid substitution therapy and identifies a variety of 
themes that form a basis for a grounded approach to co-design of the intervention.  The 
work enabled the priorities and perspectives of people receiving care through a pharmacy 
to be explored.  Thematic analysis of the focus group content both confirmed issues 
discussed within the literature and contextualised the local delivery of care to this 
vulnerable group.  Actor Network Theory was used for a theoretical perspective from 
which to understand the interaction of human and non-human actors in producing the 
outputs from care. 
The paper describing a discrete choice experiment (Radley et al 2019) utilised themes 
identified from the focus group series plus several structural themes to design a 
questionnaire to evaluate the stated preferences of a cohort of people prescribed opioid 
substitution therapy.  Analysis of the stated preferences demonstrated the clear 
importance of being treated with dignity and respect to the study participants.  The 
importance of location, availability of test results, travel distance and incentives for 
participation in the service were also evaluated. 
The paper describing a quasi-experimental approach to blood-borne virus testing in 
pharmacies (Radley et al 2017) demonstrates the implementation of the first part of the 
intervention and explores initial participant and provider views about delivery.  Testing in 
a local pharmacy was demonstrated to be feasible, with uptake comparable to other 
providers. A process evaluation was undertaken and thematic analysis performed with the 
outputs available for comparison to the perspectives obtained in the focus group series 
and discrete choice experiment. 
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These papers are included here to record how the pilot and feasibility work have shaped 
and informed the subsequent development of the SuperDOT-C intervention.  The lessons 
learned from this work were used to inform development of an experimental protocol to 
evaluate the pharmacy pathway. 
Knowledge Translation Contributions 
Radley has contributed to the development and implementation of a community 
pharmacy-based hepatitis-C testing service commissioned by the Welsh Government 
(WHC /2017/048 Eliminating hepatitis (B and C)) and to similar work undertaken by the 
London Clinical Commissioning Groups.  The development work has been presented at 
local and international conferences as both poster and oral presentations and as a 
workshop format. 
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 4.1 “Standing outside the Junkie Door” Service Users’ Experiences of 
Using Community Pharmacies to Access Treatment for Opioid 
Dependency 
The following paper is a verbatim copy of Radley AS, Melville K, Easton P, Williams B, 
Dillon JF. “Standing Outside the Junkie Door” – Services users experiences of using 
community pharmacies to access treatment for opioid dependency. J. Public Health 2017; 
39 (4): 846-855. doi:10.1093/pubmed/fdw138 
ABSTRACT 
Aim: 
To explore experiences of service users attending a community pharmacy to receive 
opioid substitution therapy (OST). 
Method: 
Qualitative study involving seven focus groups undertaken within care centres and prison 
educational centre in Tayside, Scotland using 41 participants.  Thematic analysis 
undertaken of experiences of different groups of service users and carers.  
Results 
Participants described the social context surrounding attendance at community 
pharmacies. Their voices suggested that people prescribed OST may be treated differently 
from others accessing care through pharmacies. Participants felt they experienced stigma 
and discriminatory practices in pharmacies, elsewhere within the healthcare environment, 
and more generally in society. Participants explained that the way services were 
organised in pharmacies often denied them the right to confidentiality.  
However, there were positive experiences of care. The discriminating factor between 
good and bad experiences was being treated with dignity and respect. 
Conclusion 
Participants readily identified examples of poor experiences and of stigma and 
discrimination, yet valued positive relationships with their pharmacy. Constructive 
attitudes of pharmacy staff and the ability to form positive relationships improved their 
experience. The social exclusion delivered through stigmatisation mitigates against 
delivery of a recovery agenda and contributes to health inequalities experienced by this 
marginalised group.  
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INTRODUCTION 
Supervised consumption of Opioid Replacement Therapy (OST) has been the mainstay of 
treatment for people who use heroin for some time 
1
.  Drug users have attended 
pharmacies in Scotland to receive supervised administration of replacement drugs since 
the early 1990s. The shared care arrangement, between prescribers, specialist drug 
treatment services and community pharmacies reduces diversion of methadone into the 
illicit market and increases access to this treatment 
2
.  However, across Europe, treatment 
is mostly conducted in outpatient settings, which can include specialist centres, general 
practitioners and low-threshold facilities
3
. 
In practice, this means that service users attend a pharmacy on a daily or regular basis to 
receive doses of methadone or buprenorphine; this is intended to replace the consumption 
of heroin. The consumption of the OST dose may be supervised, or handed to the service 
user to consume off premises 
2
.  It is estimated there are 376,136 “problem drug users” in 
the United Kingdom, and 133,112 people who inject drugs (PWID) 
3
. The European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) defines PWIDs as “ever 
injectors” among people tested in drug service settings 5.  In Scotland, approximately 
59,000 people are identified as using drugs 
6
.  The number of opioid users prescribed 
treatment in 2011/12 was estimated at 149,000 in England and Wales 
7
. An estimated 
figure Scotland would therefore be 22,224 
8
.  
There is strong evidence that OST improves a range of important outcomes 
9
.  
Longitudinal studies identify that OST improves retention in treatment, reduces illicit use 
of substances and reduces levels of risk behaviours.  Reduced criminal activity and 
improved health and well-being have been reported 
10, 11, 12, 13, 14, 15
.  There is also 
evidence of a positive correlation between “treatment dose” (numbers of attendances) and 
outcome 
16
.  The contribution of supervised consumption to recovery may be double-
edged: creating a daily structure and reducing use of other opiates, but preventing 
engagement in recovery activities such as paid work.  Supervised consumption is a central 
component of the United Kingdom policy framework 
17
. Policy makers may view long-
term maintenance on OST either as a positive step for harm-minimisation or as a barrier 
to achieving a drug-free lifestyle: moving OST users to a drug-free lifestyle remains a 
challenge
18
. 
The success of OST depends on engagement with services and adherence to therapy.  The 
Drug Misuse and Dependence: UK Guidelines on Clinical Management 
17
 (also known as 
the Orange Guide) states that directly supervised OST by a professional for a period of 
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time provides the best guarantee that the medicine is being taken as prescribed.  
Supervised consumption as part of the recovery process may be protective and associated 
with a decrease in drug deaths and development of a therapeutic relationship.  The 
journey of recovery may mean the movement to unsupervised consumption over time 
19
. 
In practice, most OST is delivered by community pharmacists and increasing numbers of 
pharmacies provide needle exchange services 
20
.  Pharmacists and dispensing staff are 
central to the provision of OST 
21
. Service users therefore may have more contact with the 
pharmacist than any other healthcare worker 
22
. 
Despite growing evidence to support the delivery of therapeutic interventions through 
community pharmacies 
23
, there is evidence that outcomes obtained with OST can be 
improved 
24
.  A partial explanation for poorer outcomes may lie in service users’ 
interactions within and around community pharmacy services 
25, 26, 27, 28, 29
.  Stigma, 
combined with a poor self image and apparent negative treatment may provoke negative 
behaviour and precipitate conflict 
30
. Pharmacists may be reluctant to deal with a group of 
clients who may sometimes be abusive or intoxicated and may shoplift 
2
 
Although pharmacy service provision is extensive, there is little contemporary research 
describing the nature of these interactions with service users, associated problems, or 
likely solutions.  This study was conducted to explore the current experiences of service 
users attending a community pharmacy and receiving OST in Tayside, Scotland. 
METHOD 
The study was conducted within care centres and a prison educational centre as part of a 
local Public Health needs assessment. A focus group methodology was chosen to enable 
participants to share experiences within a supportive environment.  Utilisation of the 
group dynamic and involvement of participants in group discussions was employed to 
help manage impulsive behaviour and short attention span 
31
.  Effective management of 
these factors was believed to outweigh potential negative aspects of focus group approach 
including description of group normative experiences and the effect of inherent group 
hierarchies to suppress subordinate voices 
32
. 
Study documents were submitted to the East of Scotland Research Ethics Service, who 
confirmed this work did not require Ethical Approval.  Caldecott permission was gained 
to enable access to and analysis of patient information.  A topic guide was developed 
from evidence syntheses and refined during the study (Appendix). 
Sampling: 
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The study used a purposive sampling strategy to identify a diversity of likely views 
33
.  
Individuals were eligible for inclusion if they received OST from a community pharmacy 
or were the carer of someone prescribed OST.  We aimed to recruit around 40 
participants. Recruitment focussed on the following variables:  
-Place of Residence –large urban / other urban / accessible small town 
-Service Users detained by the Criminal Justice System 
-Perspectives of male and female service users 
-Perspectives of peer mentors (service users at an advanced stage of recovery)  
The sampling strategy was formulated to enable a diversity of views to be obtained, at 
different places within the network of actors and technologies 
34
.  Carers were included in 
the groups, since OST users experience long-term conditions at an earlier stage than the 
general population. 
Recruitment & consent: 
Potential contributors were identified through local support groups and care centres.  
Each person completed a consent form prior to participation. The patient information 
sheet was explained to each group by the facilitator to assist those with poor health 
literacy.  
Data collection: 
Seven focus groups with 41 participants (Table 1) were undertaken by AR and KM. 
Sessions were open-ended and ranged from 70–100 minutes.  The first focus group served 
as an internal pilot to test the discussion guide.  The seventh focus group with peer 
mentors, was undertaken to provide perspective on the findings from this study. In the 
local service configuration, peer mentors are experienced service users who have received 
OST for a number of years and are further along a recovery pathway: we listened to their 
reflections and perspectives on the themes that had emerged. 
 
Table 1: Participant details 
  Number of Participants 
Age group at 
participation 
Less than 35 years 
35 – 44 years 
45 – 54 years 
Over 55 years 
Did not disclose 
17 
5 
6 
4 
9 
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Sex Male 
Female 
31 
10 
Participant category Service User 
Carer 
38 
3 
Number recruited defined 
by sampling frame 
Large Urban Settlement 
Other Urban Settlement 
Accessible Rural Town 
Prison Educational Centre 
Women’s Group 
Peer Mentor’s Group 
10 
10 
6 
7 
4 
4 
 
Analysis: 
Data from each focus group were digitally recorded and transcribed verbatim. Both AR 
and KM undertook the coding and analysis (Box 1).  Analysis drew on the constant 
comparison method, which was operationalised within a general thematic approach 
35
. 
Analysis included five stages: familiarisation (reading and re-reading the transcripts), 
identifying a thematic framework (a key list of codes); applying the codes to the quotes in 
the transcripts; creating tables of quotes and comments to compare data across groups; 
mapping and integrating the key findings into a meaningful whole. Deviant cases were 
sought to identify opinions which modified or contradicted the analysis 
36 
Box 1:  Strategies Employed to Ensure Rigour and Trustworthiness 
Deviant cases were sought to falsify theory 
Iterative data collection utilise to ensure emergent themes could be explored 
A checking strategy was used within interviews to check interpretation 
Data analysis was conducted by more than one team member 
 
In our analysis we drew on the work of Duff who utilises Actor Network Theory to 
portray the assemblage of spaces, bodies and effects, to characterise the context of drug 
use as the interrelation of people and technology 
37, 38
. 
RESULTS 
Service users were reflective about the circumstances that led to them receiving OST 
from a pharmacy.  When asked about their experiences of attending a pharmacy, 
participants’ responses were often passionately voiced.  Focus group data demonstrated 
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interactions between different actors and technologies: with pharmacy staff; members of 
the public; pharmacy premises and adjacent environments; the rules used by the pharmacy 
to manage demands and workload.  
Our analysis identified three key themes (Box 2). These are illustrated with quotes 
demonstrating typical or divergent responses. Quotes are labelled with participant 
number, sex and age. 
 
Box 2- Themes Identified 
Theme 1 – The social context surrounding OST users 
Theme 2 – The interaction with pharmacy service delivery 
Experience of stigma 
Experience of discrimination 
Issue of time 
Issue of confidentiality 
Positive Experiences of care 
Service Users Explanations for their Experiences 
Theme 3 – Making things better 
 
The social context surrounding OST users 
Service users provided vivid descriptions of life on methadone. Participants followed a 
daily routine of attending pharmacies, obtaining money, and avoiding trouble (Box 3, 
Participant 16).  Some service users reflected on their preoccupation with obtaining 
drugs, legal and illicit. They felt that the centrality of OST in their life led to diminished 
horizons (Box 3, Participant 40).  The day-to-day reality of OST use was one of 
continuous poverty: lack of money was a constant challenge; searching for enough money 
to pay for daily expenses; having bus money; the difficulties in maintaining employment 
(Box 3, Participant 20). 
Box 3: The Social Context of OST 
We are all shoplifters and we have all been stealing to feed wer drug habit.  See 
when you first get out the jail you don’t get paid for about a month, so, after 3 days 
you are skint.  Until about a month later you need to walk all the way into the toon, 
sometimes its 4 or 5 miles just to get your Meth, and then you have to walk home 
another 4 or 5 mile back or you can go shoplifting to get money for the buses or 
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something.  Ken what, its just how it is and that’s how ye end up in the jail.   
Participant 20, Female 24 years. 
It does occupy…it occupies most of yir day and night coz yir always th inking aboot 
whar yir gona get money.  Participant 38, Male 37 years 
I thought it was a life saver at the start ken I thought it was great when I got on it and I 
got on it coz I thought it was another drug another charge and I wouldna wake up 
rattling.  I thought I’d get my methadone then I’d go score drugs like 2 fixes, 2 hits 
sometimes 3 or 4. 
That was my world, my hoose, the chemist and the boozer. Participant 40, Male 35 
years 
You are keeping yourself to yourself, you just got outa the jail and you are keeping 
your head down.   You are not going out stealin but you are goin to that chemist.   You 
are taking that chance every day and you are seeing other drug users, right and it’s like, 
encouraging you.  You are likely doing it, in a minute.  First day out and you are pissed 
off an somebody offers you something that will be it.  Participant 16, Male 32 years 
And if they know you then thats even worse.  That’s how I moved to somewhere I’m 
not from where I dinna know anybody and do you know what it’s a hell  of a lot better.  
It’s so much better, I dinna get offered at the chemist cause no-one knows is.  So even 
though they see me going through that door because I dinna speak to anybody or give 
away anything its brilliant honestly.  I couldn’t have made a better choice for me and 
my son to go somewhere where they dinna know my past, they dinna know who I am, 
they don’t know what I’ve done do you know what I mean it’s brilliant.  Participant 18, 
Female 28 years 
A lot of people work that take methadone, a small majority, but they do and they want a 
normal life.  That’s how they are on methadone coz they want a normal life they 
widdnae be on methadone if they didnae want a normal life. 
Participant 33, Male 38 years 
 
The attraction of OST waned over time. Some participants explained how methadone and 
drug use became less important to them and family life and employment increased in 
importance (Box 3, Participant 33).  Participants described how they changed their social 
networks to move away from drug use; they described the need for a ‘normal life’ (Box 3, 
Participant 18).   
The interaction with pharmacy service delivery 
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Service users’ often had both positive and negative experiences of community 
pharmacies.  Participants provided accounts of positive relationships and contributions to 
care but many examples of poor experiences and unpleasant relationships were described.  
Experience of stigma 
Participants described real and current experiences of stigma.  The idea that people would 
shun them was common. They felt set apart from other members of society (Box 4, 
Participant 18).  Service users sensed this treatment was unjust; other people had chronic 
conditions such as heart disease and diabetes, which were also self-inflicted, but were not 
discriminated against (Box 4, Participant 22).  People who abused prescription 
medication (benzodiazepines) were not treated as they were. Service users felt unfairly 
treated since they had chosen to change, through entering the OST programme.  
Experience of discrimination 
Participants felt that use of a range of different practices within pharmacies caused a 
distinction between people picking up a methadone prescription and people picking up 
other prescriptions (Box 4, Participant 8). Discrimination was conveyed in numerous 
ways, including restricted attendance times and additional bureaucracy (Box 4, 
Participant 20).  In two focus groups, service users described how they were asked to 
leave young children outside the pharmacy.  The women’s group was particularly 
reflective on how they were treated differently and used the powerful metaphor of 
“Apartheid”. 
The use of a separate entrance or hatch automatically identified them as receiving 
methadone.  Service users described using the hatch to receive their methadone and going 
to the “normal people’s counter” to receive other medication.  Even when a service user 
was prescribed unsupervised consumption of methadone, discriminative practices might 
prevent them taking their OST away from the pharmacy (Box 4, Participant 23). Service 
users were made to sign written agreements by the pharmacy. This was not done with 
other patient groups.  Participants described using two pharmacies: one to receive OST 
and one to obtain their other medicines; to enable them to be treated as other patients 
were. 
 
Box 4: The Organisation of Pharmacy Methadone Services 
Experience of Stigma 
And I was on the bus the other day and it was an old couple were like “yeah all they 
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junkies hanging about the chemist and it’s the ones who’ve got kids going in to that 
bit that I feel sorry for”  now they obviously didn’t know that they were talking to like 
a methadone user.  I felt like shit to be honest with you. Participant 18, Female 28 
years 
Yeah because I mean you wouldnae treat somebody different if they were a, a diabetic 
and they were standing in front of you eating a sweetie, ken I mean you wouldnae say 
tae them you shouldnae be dain that (mumbles). What’s the difference between an 
addict and somebody that’s say self inflicted a lot of heart disease is self inflicted,  
there’s loads of things that are self inflicted so why dae they single out addicts or 
alcoholics. Participant 22, Male 37 years 
The Issue of Discrimination 
“If there is any more than two in the shop, if there are any more than two drug addicts 
in the shop, you have got to stand outside until one comes out. You are not allowed 
any more than two people in the pharmacy at the same time. It doesn’t matter if its 
rain, sleet or snow, you stand outside. She frankly told us that she doesn’t want us in 
there when there’s people in there”  
Participant 8, Male 32 years 
what I mean because it is embarrassing ken you’re standing there buzzing this buzzer 
and you’ve got to wait until they decide to pick up that phone and let you in so then 
there could be loads of people walking past you and you’re standing there ken they 
could clearly a’ ken that you’re going awa’ in there for that.  Know what I mean. 
Participant 20, Female 24 years 
First day she got methadone from the chemist she went tae take it oot the shop she 
went “thank you”.  “Oh hang on you need tae take that” she says “ah no I’m 
unsupervised” and the guy says “Oh no he says I don’t do that, as far as I’m concerned 
I don’t want methadone in the streets” Participant 23, Female 27 years 
The Issue of Time  
It’s only half an ‘oor, well the chemist I’m it you’ve got to go in efter half 9 in the 
morning right, you can go in at any time during the day.  But it’s other chemists, you 
go in, you’ve got to be in the 2 ‘oors and if you’re no there for 5 o’clock well in the 
efternane if you’re no there til 5 past 4 and you’re meant to be there by 4 you dinna 
get yir methadone.  That’s wrang. 
Participant 40, Male 35 years 
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and some days I’d wait, wait, waiting, wait some mare.  I’d be waiting 15 minutes, 20 
minutes, 25 minutes in some cases until one day I got pig sick fed up o it coz I would 
see folk walking in from the doctors surgery and walking out before them walking in 
after them. I counted half a dozen folk one morning that walked in after the three o 
them and walked out before them with prescriptions in their hand.  Participant 34, 
Male 43 years 
The Issue of Confidentiality 
A couple of members of staff I would say are good but the rest of them nah, they look 
doon at you.  I’d come off my methadone and went into rehab in November there and 
came off it and then I went into the chemist, but into the actual normal bit of the 
chemist and there was a prescription coming up from the DPC for a sleeping tablet 
‘cause I wasn’t sleeping and when I went in the chemist was busy and the lady came 
over and she was like “could I help you” and I said yeah has a prescription come up 
from the DPC and she was like “what, for methadone?” right in front of everybody in 
that chemist.  And I looked at her, and they all knew what I’d just been through , and 
I’m looking, going, for methadone I dinnae think so, ken what I mean, and I was 
absolutely, I’d just couldnae believe that she’d done that.  Participant 18, Female 28 
years 
Positive Experiences of care 
 I got bloods ta’en and they think I’ve got pregnancy diabetes so I went in and was 
telling the woman that just through conversation and she said maybe it was just 
something that I ate that day and I said nah a’ I had was, I had my methadone then I 
went right to the doctors to get the blood ta’en and she went well that could be what it 
was ‘cause methadone’s got that much sugar. 
Participant 20, Female 24 years 
Whan eh got stabbed Al  did gie me a lot of coz they didnae stitch it, they left it open 
and it wiz quiet a big wide wound, mind that ain in my groin and it was mair A  than 
the nurses coz eh wiz seeing her every day coz eh was only seeing meh doctors once a 
week and she wiz gieing me mair advice on how to keep it clean masel, dressings and 
this that and the next thing. So it was good. 
Participant 26, Male 32 years 
Service Users Explanations for their Experiences 
You’ve got a lot of drug addicts that are gonna go about with baggage and go “oh I’m 
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an ex drug addict everybody’s looking down their nose at me”.  They’re gonna go 
about with that attitude and nine times out of ten they’re actually attracting that from 
people they may not have got it from coz they learn to protect themselves. But nine 
oot of ten because o the way they have been treated they go in wi that attitude because 
that’s the way that they have been treated”  
Participant 21, .Male 41 years 
The issue of time 
The issue of time was consistently raised; the time wasted in pharmacies waiting to 
receive methadone (Box 4, Participant 34). The use of restricted attendance times was felt 
to be a unfair (Box 4, Participant 40).  To complain about these arrangements risked 
getting put off the pharmacy list. This practice had real consequences and was used 
several times to explain why participants could not maintain employment.  The 
attendance pattern meant that employers could guess that their employee was on 
methadone.  The queue for methadone meant being brought into close proximity with 
undesirable people; drug dealers, people who might steal or create unpleasant situations.  
The issue of confidentiality 
Service users did not feel that their confidentiality was respected. Confidentiality in the 
pharmacy was undermined systematically: by the material and physical arrangements, by 
the procedures utilised to manage patients and through the actions and attitudes of staff 
members.  These arrangements were described by participants using words such as “the 
junkie door” and “segregation”.  Service users described how queuing to receive their 
methadone identified their reason for attendance to any onlooker. Participants related how 
staff members spoke about their consumption of methadone within hearing of other 
patients (Box 4, Participant 18). 
Positive experiences of care 
Participants readily described care which made a significant contribution to their well-
being.  An important and recurrent finding from this work was the value of being treated 
with dignity and respect.  Although focus group discussions always began with 
descriptions of poor experiences and difficult relationships, service users consistent ly 
spoke highly of “their pharmacist” and how the pharmacy they currently attended treated 
them well. 
There was good awareness of the nationally organised Minor Ailments Service 
39
, through 
which they could access a range of medication for free.  A variety of clinical interactions 
were described, from support with gestational diabetes to management of a traumatic 
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wound (Box 4, Participant 20, Participant 26).  Where care was highly regarded, it was 
because positive relationships with staff were formed and maintained. 
Service users’ explanations for their experiences 
Participants could understand the way that people treated them like this.  The reasons 
arose from their own behaviours (for example shop-lifting), but also through the way they 
were forced to act through circumstances (experiences of stigma and discrimination) and 
the lifestyle they had adopted.  There was a perception of shared responsibility for their 
treatment, with an acknowledgement that some service users expected poor treatment and 
acted accordingly (Box 4 Participant 21).  The idea that a public face was assumed by the 
service user in order to protect their feelings was described several times.   
Making things better 
Participants expressed a desire to use the same consultation room as other pharmacy 
users, so that their care could be undertaken in private. It was acknowledged that the 
numbers of service users using pharmacies made this unlikely.  Participants recognised 
the poor behaviours of a few individuals but there was general resentment that this led to 
all service users being treated in the same way.  Focus group participants wished for the 
pharmacy service to operate more flexibly and responsively to their needs and support 
their process of recovery more actively. Participants described the wish to be treated as 
individuals rather than as a group (Box 5). 
Box 5: Making things better 
As I say I have no complaints about the pharmacy that I use.  They’re very good, 
there’s a little consulting room you can sit.  They take you into the consulting 
room you take your methadone and you leave, it’s all done in private.  If the 
consulting room’s busy they use a wee space they’ve got through the back but 
they always ask you very nicely if you don’t mind going through there.  So, 
they’re great. Participant 23, Female 27 years 
You don’t need anything else if you have got respect. If you get handed your 
methadone with a smile and asked how you are doing today. Participant 9, Male 
38 years 
In the first instance its likely you would still need to go every day but then again I 
mean the medicine is there to support your recovery and so it is about how you 
move forward and it should be fitting into your life as well.  I mean the guys 
spoke earlier about they think it’s better that you need to go in every day because 
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they remember the 80’s when the streets were awash with methadone and stuff 
like that but it is a medicine like any other medicine and you know as you recover 
and as you change you become much more confident then the medicine should, it 
shouldn’t hamper your recovery. Participant 32, Male 42 years 
 
DISCUSSION 
Main findings of this study  
Participants in this research describe the social context surrounding attendance at 
community pharmacies: how the assemblage of networks of actors interplays with 
pharmacy services.  Accounts demonstrate that people prescribed OST are managed 
differently from other patients. Service users experience stigma and discrimination in 
pharmacies, other healthcare settings and generally in society. The organisation of care in 
pharmacies effectively denies service users confidentiality.  
Narratives about negative experiences were tempered by accounts of positive experiences 
of care. The discriminating factor between positive and negative experiences was that the 
service user was treated with dignity and respect.  Service users easily identify poor 
experiences but also valued positive relationships with their current pharmacy.  
What is already known on this topic? 
Perspectives on treatment recovery have been described by other researchers 
20, 31, 40, 41, 42, 
43
.  Evidence that service users are treated as an anti-social group has been reported 
44
 as 
has the detrimental consequences of pharmacy service organisation 
26
.   
Participants described a common experience of discrimination and stigmatisation when 
accessing routine healthcare 
45, 46, 47
. The parameters of stigma are well described 
48
.  The 
attitudes displayed by healthcare staff may mirror stigmatising attitudes across society 
49
.  
However, stigmatisation mitigates against recovery and continues the health inequalities 
experienced by this deprived and marginalised group 
50, 51, 52
. 
Most pharmacies in Scotland provide substance misuse services and many have created a 
separate facility for OST supervision 
53, 54
.  This practice may enhance a stigmatised 
identity, especially when coupled with explicit discrimination and prejudicial attitudes of 
staff 
22, 28
.  The use of waiting time to convey discrimination and create dependence is 
important 
26, 27
.  The restrictions on access and consequences on employability are 
described in several places 
45, 55
.  Employment is a key step in addressing health 
inequalities and social inclusion 
56
. 
87 
 
That drug misusers often steal and how this affects their treatment has been reported 
55
.  
A study of attitudes of community pharmacists reported that about ten percent of 
pharmacists had negative views 
53
. Work a decade later reported improved attitudes and 
increased service provision 
21, 57 
What this study adds 
This most striking finding of this study is that despite 25 years of service provision, 
problems with OST provision remain 
53, 57
.  Pharmacists may still be ill-prepared to 
manage difficult situations, when drug using clients behave aggressively or abusively, 
shoplift or are intoxicated 
2
.  The stigmatising attitudes experienced by service users are 
closely linked to policies on prohibition and criminalisation 
49
 
Limitations of this study 
This study draws on the qualitative insights of service users experiencing care within 
community pharmacies.  Use of a focus group methodology was clearly a viable method 
within the resource constraints of a public health needs assessment; however an 
ethnographic approach would contribute an alternative route to defining the effects of 
person place and time 
58
. 
The authors reflected that the strength of some contributions could have been influenced 
by the group dynamic; descriptions of poor experiences may have been better accepted 
31, 
32
. The use of a female group was therefore undertaken, since male contributions were 
observed to dominate. We purposively recruited a group of experienced service users 
acting as peer mentors, to a final focus group and used this narrative to gain reaction to 
the findings and comment on themes 
59
. 
CONCLUSIONS 
Stigma, combined with a poor self image and apparent negative treatment may provoke 
negative behaviour and precipitate conflict 
30
. Pharmacists may be reluctant to deal with a 
group of clients who may sometimes be abusive or intoxicated and may shoplift 
2
. 
The social exclusion delivered through stigmatisation, mitigates against delivery of a 
recovery agenda for this multiply deprived and marginalised group 
17
. 
Capitalising on the contribution that community pharmacy can make requires further 
work to improve the quality of relationships with service users.  Service users have 
expressed the desire for more knowledgeable staff, capable of responding effectively to 
the issues that they bring 
28
.  It is likely that education and training as well as role support 
is required as well as steps to change organisational cultures within pharmacies in 
particular and healthcare in general 
60
.  This change however is within the current policy 
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intention for modernising the delivery of pharmaceutical care from community pharmacy 
61
.  Further research is therefore required to confirm that a positive change in practice is 
achieved. The references for this paper are provided in the manuscript located at 
Appendix 9.2 
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Appendix: Experiences and Views of People Using Pharmacies to Obtain a Methadone 
Prescription 
i. Tea, coffee provided to participants as they arrived. This allowed individuals to 
talk to each other and establish introductions 
ii. Participants were asked to introduce themselves and to say how they would like to 
be referred to. 
iii. The purpose and confidentiality of the research was explained and clarified, along 
with general guidance to ensure a good quality recording was made (i.e. not talking at the 
same time as others). 
iv. The following questions were used to guide the discussion, with sensitivity to the 
issues that were important to participants and also to the opportunity of each participant 
to contribute the issues and observations that were important to them. 
Questions Justification 
Can you tell me about your 
experiences of obtaining your 
methadone prescription from a 
pharmacy? 
How would you describe your 
relationship with the pharmacist? 
Do you feel you are treated with 
dignity and respect at all by your 
community pharmacy? 
What positive features of getting 
treatment at a pharmacy would you 
like to see more of? 
What negative features of getting 
treatment at a pharmacy would you 
like to see less of? 
 
General views on treatment of substance 
misusers in pharmacies 
Specific experiences of substance misusers 
in pharmacies 
Are you aware of having a care plan in 
place with regards to your methadone 
treatment? 
Has anyone discussed the content/its 
meaning? Have you received a copy of 
your care plan? Would you like to 
receive a copy of your care plan? 
Do you think such a care plan would 
improve your relationship with the 
Making sense of the interaction with the 
pharmacist 
Establishing aspirations for the content of 
the service 
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pharmacist? 
What types of issues would be 
important to be discussed as part of 
the care plan? 
 
v. Group Finish: Participants were asked if there were further issues and observations that 
they had not been able to contribute. The facilitator gave a summary of the key points 
covered from field notes and asked participants of the summary covered the issues as they 
saw them.  
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4.2 Designing a hepatitis C testing service in primary care: a discrete 
choice experiment 
The following paper is a verbatim copy of Radley A, van de Pol M, Dillon JF. Designing 
a hepatitis C testing service in primary care: a discrete choice experiment. International 
Journal of Drug Policy 2019; 65:1-7. https://doi.org.10.1016/j,drugpo.2018.12.008 
ABSTRACT 
Background 
Ascertaining the acceptability of healthcare provision to service users is an important 
factor in promoting service uptake, especially for populations who are reluctant to access 
care. This study identified the attributes of a Hepatitis C (HCV) testing service for people 
prescribed Opioid Substitution Therapy (OST) and used their expressed preferences to 
guide design of a service, using an applied health economics approach. 
Materials and Methods 
Preferences of OST users were elicited using a discrete choice experiment.  Important 
attributes for HCV testing were partly pre-determined by the research question and also 
identified using literature review and focus groups. Predetermined attributes included 
choice of provider and financial incentives. Other important attributes were place of 
testing; travel distance; attitudes and staff undertaking testing; waiting time for test 
results and incentive payment.  The relative importance of defined attributes was assessed 
in 103 OST users attending 6 pharmacies from Dundee. 
Results 
OST users preferred testing at their “own pharmacy”, by their drug worker, followed by 
their general practitioner (GP).  Use of another pharmacy was the least preferred option. 
Being treated with dignity and respect was valued most highly, with waiting time for test 
results and travel distance also important.  Financial incentives were not considered 
important. 
Conclusions 
This study provides evidence that OST users prefer testing at their own pharmacy.  The 
addition of a pharmacy to the providers offering HCV testing may increase uptake and 
support policies to eliminate HCV from our communities.  Being treated with dignity and 
respect was highly valued and this suggests that testing uptake can be increased by 
developing positive relationships between OST users and test providers. Financial 
incentives were not found to be important. 
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INTRODUCTION 
The World Health Organisation Guidelines on Testing for Hepatitis B and C establish 
critical enablers for the provision of efficient and effective services. Suggested best 
practice includes implementation of simplified, decentralised care pathways, with task-
shifting to non-specialised staff (WHO 2017).  Additionally such services should be 
delivered in a way that is acceptable to service users, especially for populations who are 
reluctant to access care. It is important also to consider testing as part of the continuum of 
care to HCV cure rather than an isolated step (WHO 2017). 
In developed countries, people who inject drugs (PWIDs) are the major group affected by 
hepatitis C (HCV) infection (WHO 2016a). In communities where heroin is the principle 
drug injected research suggests that around 40% of people prescribed Opioid Substitution 
Therapy (OST) are infected (Aspinall, Doyle, Corson, Hellard, Hunt, 
Goldberg...Hutchinson 2015; Edlin, Kresina, Raymond, Carden, Gourevitch, Cheever, 
Cargill 2005).  In current HCV testing and treatment pathways within the United 
Kingdom, less than 10% of the OST population are tested for HCV and a similar pattern 
is seen across the world: a depressing repetition of waterfall plots shows people with 
HCV infection are lost to care at each step (Iveson, Grebely, Catlett, Cunnigham, Dore, 
Maher 2017). 
The barriers that prevent uptake of HCV testing and treatment have been characterised as 
system-level, practitioner-level and patient level (Grebely, Oser, Taylor, Dore 2013). At 
the system level services may still be based on a configuration designed to identify people 
suitable for interferon based treatment, with conventional pathways containing multiple 
steps (Arora, Thornton, Murata, Deming, Kalishman, Dion... Qualls 2011). These 
pathways may be further complicated by required actions by specific practitioners 
allowing access to services or remuneration for those services. At the practitioner level 
these restrictions also apply. Prejudice against PWIDs also operates with many 
practitioners having the expectation that people will not adhere to medical treatment. 
Health practitioners may not perceive HCV treatment as a legitimate activity within their 
practice and may not have the necessary skills and knowledge to be confident in 
discussing HCV treatment with the client group (Treolar, Newland, Rance and Hopwood 
2010).  At the patient level, people taking methadone may live in poverty and experience 
stigmatising and discriminating behaviour (O'Gorman, Driscoll, Moore, Roantree 2016). 
The need to travel to attend clinics decreases the numbers of people being tested (Astell -
Burt, Flowerdew, Boyle, Dillon 2011; Monnet, Ramee, Minello, Joost, Carel, Di Martino 
93 
 
2008; Papatheodoridis, Tsochatzis, Hardtke, Wedeyer 2014) and proximity to services 
may be more important in rural communities.  People who inject drugs may have shifting 
priorities between HCV treatment and other activities, may not have the relevant 
information about the treatment efficacy and side-effects of Direct Acting Antiviral 
(DAA) Medicines, may not seek out testing and treatment and may experience anxiety 
and confusion when offered opportunistic testing (Jones, Atkinson, Bates, McCoy, 
Porcellato, Beynon...Bellis 2014).  Low levels of health literacy may limit understanding 
of their health, illness and treatments (Kalichman, Benotsch, Suarez, Catz, Miller, Rompa 
2000). 
Delivery of HCV testing and treatment through community-based care pathways has been 
shown to be feasible (Wade, Veronese, Hellard, Doyle 2016) and dried blood spot testing 
(DBST) has been demonstrated to increase the uptake of testing from high-risk 
populations (Coats & Dillon 2015; Taheri 2010; McAllister, Innes, Mcleod, Dillon, 
Hayes, Fox 2014).  Testing in community environments in risk groups, can result in high 
levels of linkage to care (Tait, Stephens, McIntyre, Evans, Dillon 2013).  The use of 
DBST in non-traditional environments has dramatically increased detection of HCV 
(Morana, Zelenev, Lombard, Marcus, Gibson, Altice 2014).  
With appropriate training HCV testing can be carried out by a range of personnel, 
including community pharmacists (The Hepatitis C Trust 2018).  Pharmacy provision has 
particular potential for the OST population as they have daily interactions with 
pharmacies.  However, little is known about whether OST users would find testing at 
pharmacies acceptable and what other aspects of testing are important to them.  To 
optimise uptake, it is crucial that HCV testing is designed in line with users’ preferences 
(WHO 2016c). 
In this study, a Discrete Choice Experiment (DCE) was used to elicit the preferences of 
service users who access OST from pharmacies, to help co-produce the design of an HCV 
testing service.  DCEs are a commonly used stated preference technique for eliciting 
patient preferences for healthcare services in order to understand what attributes of a 
service are important and the relative importance of these attributes (Kjaer 2005).  
The design of a service often requires trade-offs between attributes that are important to 
patients.  For example, HCV testing can be provided at a pharmacy but the waiting time 
to test results may be longer compared to HCV testing by GPs.  DCEs can elicit and 
quantify how patients make trade-offs between these attributes.  DCEs are rooted in 
Lancaster’s theory which relates the utility or value of goods and services to the 
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characteristics or attributes of the goods or services.  DCEs present individuals with a 
series of hypothetical choices between different service configurations which vary in a 
number of characteristics or attributes (for example location of testing, waiting time etc).  
DCEs are also based on random utility theory (RUT) which means that the choice 
behaviour of individuals is assumed to be probabilistic rather than deterministic.  This 
means that the utility (or value) of the healthcare service has a systematic component 
(such as the attributes) that can explain the choices individuals make within the DCE and 
a random component which include unobserved factors that can explain choices such as 
psychological factors.   
A DCE approach has recently been used to elicit service user preferences for HCV 
treatment efficacy, the occurrence of adverse treatment effects and the degree of 
treatment burden (Mühlbacher, Bridges, Bethge and Nubling 2017). However no work 
has been identified that considers service users’ preferences in terms of HCV testing and 
how they may trade off the different attributes of the testing, such as provider (location), 
travel distance and waiting time for results.  The use of DCEs to predict uptake of 
treatment for new pathways of care is also a useful feature of this technique when 
addressing the need to deliver on the ambition to eliminate hepatitis C as a public health 
concern (Quaife, Terris-Presholt, Di Tanna, Vickerman 2018) 
MATERIALS AND METHODS 
The aim of this discrete choice experiment was to elicit OST user’s preferences for HCV 
testing, in order to aid the design of a testing service that was acceptable to use from their 
perspective.  The attributes and levels in the DCE were selected following recommended 
practice (Reed Johnson, Lancsar, Marshall, Kilambi, Mühlbacher, Regier...Bridges 2013).  
A number of attributes were predetermined by the research question.  The aim of the DCE 
was to examine whether OST users may prefer HCV testing in pharmacy over other 
settings and provider of testing was therefore a pre-determined attribute.  We were also 
interested in assessing the potential of using financial incentives, therefore financial 
incentive was also a pre-determined attribute (WHO 2016). A review of existing literature 
was undertaken to identify other attributes of HCV testing that are important to 
individuals.  The themes identified through this process included medical and community 
clinic provision; travel distance from the clinic; the requirement for attendance at a 
remote site; the experience of stigmatising behaviour; the use of point of care testing and 
difficulties with taking venous samples (Wade, Veronese, Hellard, Doyle 2016; Harris 
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and Rhodes 2013; Arain and Robaeys 2014; Jones, Atkinson, Bates, McCoy, Porcellato, 
Beynon...Bellis 2014).  
Focus Group Series 
In order to test the relevance of these possible attributes to the target group and to explore 
whether there were any other important attributes, a focus group series was undertaken 
with service users to establish their views of current services and especially of their 
experiences of using community pharmacies to access care (Radley, Melville, Easton, 
Williams and Dillon 2016).  Seven focus groups with a total of 41 participants (Table 1) 
were undertaken during 2015, in a range of settings, aiming to gain a diversity of views 
and experiences, until no new data (saturation) were achieved. Participants were people 
prescribed OST by the specialist substance misuse service in Tayside, who provide the 
majority of care for this group. Participants discussed comparative experiences of 
partners, family and associates who had undertaken testing and treatment for HCV. 
Table 1 – Focus group participant profile 
  Number of Participants 
Age group at 
participation 
Less than 35 years 
35 – 44 years 
45 – 54 years 
Over 55 years 
Did not disclose 
17 
5 
6 
4 
9 
Sex Male 
Female 
31 
10 
Participant category Service User 
Carer 
38 
3 
Focus Group Venue Large Urban Settlement 
Other Urban Settlement 
Accessible Rural Town 
Prison Educational Centre 
Women’s Group 
Peer Mentor’s Group 
10 
10 
6 
7 
4 
4 
Recruitment to the focus groups concentrated on the following variables:  
-Place of Residence –large urban / other urban / accessible small town 
-Service Users detained by the Criminal Justice System 
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-Perspectives of male and female service users 
-Perspectives of peer mentors (service users at an advanced stage of recovery)  
Sessions were open-ended and ranged from 70–100 minutes.  The first focus group served 
as an internal pilot to test the discussion guide.  The seventh focus group with peer 
mentors was undertaken to provide perspective on the findings from this study. In the 
local service configuration, peer mentors are experienced service users who have received 
OST for a number of years and are further along a recovery pathway: we listened to their 
reflections and perspectives on the themes that had emerged. 
Data from each focus group were digitally recorded and transcribed verbatim, before 
being coded and analysed by two researchers.  Analysis drew on the constant comparison 
method, which was operationalised within a general thematic approach (Richie and 
Spencer 1994).  
Focus group participants described a range of attributes that had significant overlap with 
those identified from the literature: stigma, waiting times, confidentiality of results and 
positive relationships with service providers. 
The final attribute list included the pre-determined attributes (who does the testing 
(provider) and incentive payment) as well as the most important other attributes identified 
through the literature review and focus groups (whether treated with dignity and respect; 
travel distance; and waiting time to test results).  The larger the number of attributes, the 
greater the cognitively complexity of the DCE and therefore the total number of attributes 
was kept to a manageable level.  Plausible levels were assigned to each attribute based on 
focus group responses and the local context for factors such as laboratory turnaround and 
travel distance.  Table 2 presents the attributes and their levels.   
Table 2 Definition of attributes and Levels 
Time  Distance  Money 
received  
Provider  Dignity/Respect  
1 week  0.5 miles  0  GP  Yes  
2 weeks  1 miles  £2  Drug Worker  No  
3 weeks  2 miles  £6  Usual Pharmacy   
4 weeks  4 miles  £12  Other Pharmacy   
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Figure 1 shows an example of a discrete choice scenario considered by participants.  
Figure 1 Example of choice set 
Given the number of attributes and their levels, the total number of possible combinations 
is equal to 512. This was reduced to 16 choice sets using a D-efficient main effects design 
with flat priors created in SAS (Statistical Analysis Software) (Burges, L and Street D 
2005).  An opt-out was included in each choice set.  The design is presented in Appendix 
1. 
Design of the Questionnaire 
The final study questionnaire contained three sections: Section 1 ascertained participants’ 
preferences on the levels within the 5 attributes; Section 2 presented the 16 discrete 
choices; Section 3 collected details of patient demography including age, sex, educational 
level and employment.  The cognitive burden of the choice sets in the questionnaire was 
of especial concern, because of awareness of potential issues with comprehension, 
literacy levels and attention spans in the respondent group (Borisova and Goodman 2004).  
Think aloud interviews were undertaken with 7 individuals to test the wording and check 
the understanding of the questionnaire design.  Respondents completed the questionnaire 
in the presence of one of the researchers who provided support where required 
(Kronenberg, Slager-Visscher, Goossens, van den Brink, van Achterberg 2014).  The 
 
  Test A Test B  
 
 Where?  Your Usual 
Pharmacy 
Your GP  
 Treated with Dignity 
& Respect? 
YES NO 
 Travel Distance? Half a Mile 2 miles 
 Time to get Results? Two weeks One Week 
 £ You Receive? £2 £4 
 
 Which Test Would 
You Take? ( only 
one) 
 Test A Test B No Test  
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administration of the questionnaire in a familiar environment was also chosen, to reduce 
participant stress and enable access. 
A total of 103 participants within six pharmacies in Dundee City that they used to access 
OST completed the questionnaire.  All participants completed a consent form before 
completing the questionnaire.  
Estimation procedure 
In each choice set an individual was presented with a choice between three options (j): 
test A, test B or no test.  It assumed that individuals will choose the option that they value 
most highly, that is, the option they receive the highest utility from.  
The utility that an individual (i) receives from an option (Vij) is a function of the 
attributes and levels included in the DCE: 
                                                               
                                                             +      
               
“Test” is the alternative specific constant which takes on the value of 1 if the option is 
either Test A or Test B and 0 if the option is No test.  “Other pharmacy”, “GP” and 
“Drug worker” are the provider, “Respect” is whether treated with dignity and respect, 
“Travel” is the travel distance in miles, “Time” is the waiting time for results in weeks 
and “Money” is the amount of money they receive if they take the test in pounds and ij is 
the random error term.  β and  are the parameters to be estimated.  The βs represent the 
average marginal utility of changes in the attribute.  These can be interpreted as follows.  
For the quantitative attributes, a one unit increase (for example, a 1 week increase in 
waiting time) reduces utility by the size of the β.  The qualitative attributes (provider and 
respect) are modelled using dummy coding.  In this case the coefficients represent the 
difference in utility between the attribute level (for example drug worker) and the base 
category (for example own pharmacy). The s represent the individual specific 
preference variation for the attributes.  A statistically significant  indicates that 
individuals vary in terms of how they value the attribute.  The distribution of the 
coefficients was assumed to be normal.  A fixed parameter was assumed for waiting time 
to stabilise the estimation process and allow for easier estimation of the willingness to 
wait (see below).  This means that respondents were assumed to have the same negative 
preference for waiting time.  The model was estimated using mixed logit regression in 
Stata using maximum simulated likelihood with 3000 Halton draws. 
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The relative importance of the attributes was assessed by estimating willingness to wait, 
calculated by dividing the estimated coefficient values of the attributes with the 
coefficient value of the waiting time attribute.  This indicates how much longer 
individuals are willing to wait for a unit change in an attribute.  For example, (β4/-β6) 
indicates how much longer individuals are willing to wait for their test results if they are 
treated with dignity and respect.   
RESULTS 
The sample characteristics of the respondents completing the discrete choice 
questionnaire are shown in Table 3. The sample closely mirrors the characteristics found 
in OST population in Dundee for the parameters of age (median age range 30-40 years), 
educational level (completed secondary school) and employment (registered unemployed 
or unable to work due to disability).  The sample however contains approximately fifty 
per cent female respondents, whereas females represent around a third of the base 
population. 
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Table 3: Sample characteristics for discrete choice experiment questionnaire 
 N % 
Gender   
   Male 52 50.5 
   Female 51 49.5 
Age   
Age 20-30 11 10.7 
Age 30-40 54 52.4 
Age 40-50 32 31.1 
Age >50 6 5.8 
Education   
Secondary school 65 63.1 
Other professional or technical 
qualification after leaving school 32 31.1 
University degree 5 4.9 
Missing 1 0.9 
Employment status   
Employed 12 11.7 
Unemployed and seeking work 44 42.7 
Unable to work due to illness or 
disability 45 43.7 
Retired 1 1.0 
Missing 1 1.0 
Test A was chosen in 39.5% of choice sets, Test B in 48.8% of choice sets and in 11.6% 
of choice sets the respondents chose no test.  Analyses of the “No Test” option identified 
that 68% of respondents did not choose this option for any of the discrete choice sets.  
Three percent of the respondents selected “No Test” for between 13 and 16 of the discrete 
choice sets. 
Table 4 shows the regression results.  The results show that individuals prefer to be tested 
at their own pharmacy.  The coefficient on drug worker is not statistically significant 
indicating that own pharmacy and drug worker are equally preferred.  Other pharmacy is 
the least preferred option. 
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Table 4:  Regression results for the discrete choice experiment 
 
 
Coefficient 
(β) 
p-value Standard 
deviation of 
the random 
parameters 
() 
p-value Difference 
in utility 
between 
best and 
worst level 
Relative 
size of 
utility 
difference 
       
Test 4.1687 <0.001 4.0466 <0.001   
Test location     0.959 21.7% 
   Other pharmacy -0.9240 <0.001 1.1801 <0.001   
   GP -0.5518 0.002 0.9328 <0.001   
   Drug worker 0.0348 0.835 0.7130 <0.001   
Treated with dignity and respect 2.1515 <0.001 1.9891 <0.001 2.152 48.7% 
Travel distance (miles) -0.2345 <0.001   0.704 15.9% 
Waiting time for results (weeks) -0.1138 0.003   0.398 9.0% 
Money received (£) 0.0174 0.104   0.209 4.7% 
N 4932      
Pseudo R
2 
0.2739      
AIC 2005.354      
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Being treated with dignity and respect, waiting time for test results and travel distance are 
all important to individuals.  The sign of the coefficients is as expected with OST 
respondents preferring to be treated with dignity and respect, shorter travel distance and 
shorter waiting times for tests results.  Money received is not significant suggesting that 
the use of financial incentives may not increase uptake of testing.  There was statistically 
significant preference variation for provider (other pharmacy, GP and drug worker) and 
being treated with dignity and respect.  There was no significant preference variation for 
travel distance or money received.  Further analysis (including latent class modelling) 
suggested that preference heterogeneity was not associated with any of the observed 
individual characteristics  
Table 5 provides further insights into the relative importance of the attributes by 
estimating the willingness to wait.  Being treated with dignity and respect is of particular 
importance to individuals.  They are willing to wait an additional 9.2 weeks for their test 
result if they are treated with dignity and respect.  They are willing to wait an additional 
3.9 weeks for their test result if the test is taken at their own pharmacy instead of another 
pharmacy and 2.4 weeks if the test if taken at their own pharmacy instead of their GP.  
Table 5: Willingness to wait analysis  
Willingness To Wait Additional weeks willing to 
wait for test result 
 Mean 95% confidence 
interval
* 
Having test at own rather than other pharmacy 3.9 1.8 - 6.1 
Having test at own pharmacy rather than GP 2.4 0.7 - 4.0 
Having test at own pharmacy rather than drug 
worker 0.1 -1.3 - 1.6 
Being treated with dignity and respect 9.2 4.9 - 13.5 
Reduce travel distance by 1 mile 0.5 0.1 - 0.8 
Receive an additional £1 for taking test 0.1 0.0 - 0.2 
*
 estimated using the delta method 
 
DISCUSSION 
This study has examined OST users’ preferences for hepatitis C testing using a discrete 
choice experiment, as a method to increase the acceptability of healthcare provision to 
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service users (WHO 2017). It provides supporting evidence of the importance of 
considering a range of factors when working to improve treatment access (Harris and 
Rhodes 2013). The results indicate that individuals prefer to be tested at their own 
pharmacy or by their drug worker.  These two options are preferred to testing by GP or 
other pharmacy.  Being treated with dignity and respect was the most important attribute 
with waiting time for test results and travel distance also being important to individuals.  
Being treated with dignity and respect was found to be the most important attribute for 
test decision making. 
In this study, money received did not have a significant effect, suggesting that the use of 
financial incentives may not increase uptake of testing.  However, it may be the case that 
respondents in our DCE ignored the incentives attribute because payments to produce 
changes in health behaviour remain controversial; individuals feel shame in accepting 
money for treatment of their stigmatised condition.  Monetary incentives have been found 
to be helpful in promoting testing for HIV (Rakotonarivo, Schaafsma, Hockley 2016); a 
recent study has found that financial incentives could be applied to support treatment 
adherence in HCV care (Wohl, Allmon, Evon, Hurt, Reifeis, Thirumurthy...Mollan 2017).  
A small pilot study of incentives to promote HCV testing in a prisoner and parole 
population found little discernible effect from offering incentives (Grebely, Oser, Taylor 
and Dore 2013).  This is in line with our DCE results but further evidence on the 
effectiveness of incentives in HCV testing is clearly required. 
This study adopted accepted best practice in the use of qualitative methods to inform 
attribute selection (Zaller, Patry, Bazerman, Noska, Kuo, Kurth, Beckwith 2016; Kjaer 
2005).  The use of focus groups provided the researchers with a range of perspectives on 
the experiences of methadone users when using pharmacies as a service.  The focus group 
series identified time as one of the important attributes.  The value of time has previously 
been assessed in patients prescribed OST (Clark, Determann, Petrou, Moro, Bekker-Grob 
2014) and is thought to be a good method of measuring relative importance.  We used 
willingness to wait for test results as a ‘currency’ for expressing the relative importance 
of the different attributes of HCV testing.  Willingness to wait has also been used with 
this patient group to evaluate treatment attendance (Borisova and Goodman 2003). 
Respondents in the focus group series reacted strongly to the issue of stigma and 
discrimination.  This finding was also identified in the subsequent discrete choice 
experiment, where a service in which respondents were treated with respect was valued 
125 
 
highly.  This suggests that getting providers to develop more positive relationships with 
OST users may be the most effective way to increase uptake of HCV testing.  
A number of limitations are noted for this study.  Firstly, the DCE choices were 
hypothetical.  Individuals’ real choices (the choices they would make in real life) may not 
always be the same as the choices they make in a hypothetical DCE.  This is referred to as 
hypothetical bias and is a general limitation of DCEs.  However, a recent review suggests 
that DCEs can make reasonable predictions of health related behaviour (Quaife, Terris -
Presholt, Di Tanna, Vickerman 2018).  Secondly, the lived experience of stigma was pre-
dominant in the focus group discussions and also the most important attribute within the 
DCE.  The strength of this response meant that being treated with dignity and respect was 
the first concern of participants and may have been a dominant attribute within the DCE.  
As a result the other attributes may have had little or no impact on decision-making.  As it 
is not possible to robustly assess whether any of the attributes are dominant within a DCE 
(Lanscar and Louviere 2006), this should be explored further using qualitative research.  
The cognitive burden of the choice sets questionnaire was carefully assessed by the 
authors, who were cognisant of potential issues with literacy, comprehension and 
attention span (Kronenberg, Slager-Visscher, Goossens, van den Brink, van Achterberg 
2014).  The method requires that the participant makes a series of decisions between a 
series of sixteen alternatives, in order to estimate which attributes are most important in 
decision-making.  Strategies such as administration of the questionnaire by one of the 
authors, was used to ensure that respondents were able to provide accurate responses.  
Female participants were relatively over-represented amongst those choosing to take part 
in the DCE.  The choice-set questionnaires were administered in the consulting rooms of 
pharmacies, where the female participants could obtain privacy to express their views.  
DCEs ask respondents to make hypothetical choices.  Disparities between revealed and 
stated preferences have been termed hypothetical bias.  Hypothetical bias may originate 
from a number of sources, including where choice tasks do not fully reflect reality, where 
respondents have incomplete preferences or if respondents perceive a vested interest in 
over- or under- reporting the importance of particular attributes (Quaife, Terris-Presholt, 
Di Tanna, Vickerman 2018).  Such an effect may be important for respondents where the 
lived experience of stigma is such an important factor in decision making. 
CONCLUSION 
Provision of simplified, decentralised care for treatment of HCV is one of the key 
enablers for achieving the WHO target for HCV elimination (WHO 2016).  The use of 
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task sharing with non-HCV specialists is also important to increase the service capacity 
available for care provision. This study demonstrates the acceptability for provision of 
testing in community pharmacies and evidence that the addition of a pharmacy to the 
range of providers offering testing can make a contribution to the elimination of Hepatitis 
C from our communities.  Being treated with dignity and respect was clearly the most 
important attribute of a testing service and this study provides evidence that uptake of 
HCV testing can be increased by developing more positive relationships between OST 
users and providers. 
The references for this paper are provided in the manuscript located in Appendix 9.3 
Appendix 1.  DCE design 
Option Choice Provider Respect Distance Wait Money 
Test A 1 Drug worker No 4 4 2 
Test B 1 Other 
pharmacy 
Yes 2 2 6 
Test A 2 GP No 1 2 0 
Test B 2 Own pharmacy Yes 2 3 12 
Test A 3 Other 
pharmacy 
No 2 1 2 
Test B 3 Drug worker Yes 1 2 6 
Test A 4 Other 
pharmacy 
Yes 0.5 2 2 
Test B 4 Drug worker No 2 4 0 
Test A 5 Other 
pharmacy 
Yes 1 4 0 
Test B 5 GP No 4 1 6 
Test A 6 GP Yes 4 3 0 
Test B 6 Drug worker No 1 1 2 
Test A 7 Other 
pharmacy 
Yes 4 3 6 
Test B 7 GP No 2 2 12 
Test A 8 Drug worker Yes 2 3 0 
Test B 8 Own pharmacy No 4 4 12 
Test A 9 Other No 4 2 0 
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pharmacy 
Test B 9 GP Yes 0.5 4 6 
Test A 10 GP No 0.5 3 12 
Test B 10 Own pharmacy Yes 4 2 2 
Test A 11 Other 
pharmacy 
Yes 1 1 12 
Test B 11 Own pharmacy No 2 2 6 
Test A 12 GP No 1 1 6 
Test B 12 Drug worker Yes 0.5 2 12 
Test A 13 Drug worker No 0.5 3 2 
Test B 13 Own pharmacy Yes 1 4 12 
Test A 14 GP Yes 1 3 2 
Test B 14 Other 
pharmacy 
No 0.5 4 6 
Test A 15 Own pharmacy No 1 3 2 
Test B 15 Drug worker Yes 4 1 12 
Test A 16 GP Yes 2 4 2 
Test B 16 Own pharmacy No 1 3 12 
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4.3 A quasi-experimental evaluation of dried blood spot testing through 
community pharmacies in the Tayside region of Scotland 
The following paper is a verbatim copy of Radley AS, Melville K, Tait J, Stephens B, 
Evans JEE, Dillon JF.  A quasi-experimental evaluation of dried blood spot testing 
through community pharmacies in the Tayside region of Scotland. Frontline 
Gastroenterology 2017; 8: 221-228. doi: 10.1136/flgastro-2016-100776 
ABSTRACT: 
Objective: Comparison of uptake of dried blood spot testing (DBST) for Hepatitis C 
infection (HCV) between community pharmacies and established services.  
Design: Quantitative evaluation of a service development with qualitative process 
evaluation undertaken in parallel. 
Setting:  Six pharmacies from 36 community pharmacies within Dundee City, a large 
urban settlement with high levels of socioeconomic deprivation. 
Participants:  Patients in receipt of Opioid Substition Therapy (OST) not tested for 
Hepatitis C within 12 months.   The 6 pharmacies provided OST for approximately 363 
patients from a cohort of 1,385 patients within Dundee City. 
Intervention: Provision of DBST by pharmacists. 
Main Outcome Measure: Receipt of DBST between January and December 2014 
Results: 43 of 143 service users with no record of testing from the 6 community 
pharmacies accepted a DBST.  Of 561 from remaining 1022 service users with no record 
of testing, 75 were tested for HCV (30% Vs 13%). The OR for increased uptake of testing 
within the 6 pharmacies was 2.25 (95% CI 1.48 to 3.41, Z statistic = 3.81 p= <0.0001) 
compared to other services.  The DBST taken by the pharmacies provided 12 patients 
with a reactive test. The process evaluation identified key themes important to staff and 
recipients of the service.  A logic model was constructed. 
Limitations:  Non-experimental service evaluation performed in community pharmacies 
records service activity in one location across single time period. 
Interpretation:  Some evidence that DBST from community pharmacies may be feasible. 
Service users received the service positively. Staff reported that DBST was 
straightforward and achievable. 
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BACKGROUND 
Hepatitis C (HCV) is a blood-borne viral infection causing liver disease.  Around 1% of 
the population may be infected with HCV and around 0.8% are chronically infected 
1
. The 
greatest risk of acquiring the virus in the UK is through injecting drug use. Patient 
outcomes from HCV infection vary, with 25% clearing the infection spontaneously and 
the remainder becoming chronically infected, risking development of cirrhosis and 
hepatocellular carcinoma. People infected with HCV may show no symptoms, presenting 
with incurable, end-stage disease.  A recent Public Health England report highlighted that 
less than 3% of those known to be infected with HCV are being treated and less than half 
of those infected are known
2
.  The largest single infected group are those on opiate 
substitution therapy (OST)
 3
. Research suggests around 40% of people receiving OST 
have HCV 
4, 5
. 
The conventional NHS pathway of care is that patients with a history of intravenous drug 
use or those currently prescribed OST should be offered HCV testing 
1
. Testing is 
commonly available from a range of primary care and third sector providers. Once 
diagnosed, patients may be referred to nurse led treatment pathways, based around 
hepatology or infectious disease teams in secondary care. 
In current pathways, less than 10% of the OST population are tested for HCV.  Of those 
tested, at very best 25% start treatment in one of the dedicated centres, with 70-80% 
successfully completing. This means that only 2-3% of this vulnerable population receive 
adequate treatment 
2
.  The new highly effective Directly Acting Antiviral (DAA) drugs 
achieve cure rates in excess of 90%, with once or twice daily tablets for 8-12 weeks and 
few side-effects 
6
. 
The use of Dried Blood Spot Testing (DBST) in non-traditional environments has 
dramatically increased detection of HCV 
7, 8
. DBST has been shown to be a reliable 
alternative to taking venous blood samples and determining HCV status in drug injectors.  
With appropriate training it can be carried out by all staff.  Several practice-based 
projects have sought to implement DBST into pharmacy practice 
9
. 
Pharmacists have daily interactions with patients receiving methadone and we 
hypothesised that this relationship could be wielded to deliver increases in rates of testing 
using a DBST approach.  To test this we employed a quasi-experimental design 
10
 to 
compare the uptake of DBST for HCV in a small group of community pharmacies, with 
uptake in established services (those in substance misuse services, general practices and 
in third sector organisations). 
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METHODS 
A quasi-experimental design was chosen as a pragmatic route to evaluate the feasibility 
and scalability of a service development in community pharmacy, because of 
uncertainties about the effect size and nature of the intervention 
11
. 
This study was carried out in the city of Dundee, within the Tayside region of Scotland, a 
large urban settlement with significant socio-economic deprivation 
12
.  There are 36 
community pharmacies that provide OST for approximately 1,385 patients, within a total 
population of 148,000 
13
.  Six pharmacies were trained to offer DBST.  Pharmacies were 
selected if they provided OST supervision for at least 30 patients and staff were willing to 
participate.  Patients in the comparator group were prescribed OST and attended a 
community pharmacy that did not offer DBST.  
Design of the Intervention 
Focus group interviews  
A focus group series was undertaken before implementation to identify service user 
responses to the offer of testing, utilising a co-production approach 
14
. A purposive 
sampling strategy recruited 41 participants in 7 focus groups, to gain a diversity of views 
(Table 1).  All interviews and focus group discussions were recorded as digital audio files 
and transcribed in full for thematic analysis 
15
.  Analysis drew on the constant comparison 
method, operationalised within a general thematic approach 
16
.  
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Table 1: Focus Group Participant details 
  Number of Participants 
Age group at 
participation 
Less than 35 years 
35 – 44 years 
45 – 54 years 
Over 55 years 
Did not disclose 
17 
5 
6 
4 
9 
Sex Male 
Female 
31 
10 
Participant category Service User 
Carer 
38 
3 
Focus Group Venue Large Urban Settlement 
Other Urban Settlement 
Accessible Rural Town 
Prison Educational Centre 
Women’s Group 
Peer Mentor’s Group 
10 
10 
6 
7 
4 
4 
Development of Programme Theory 
Figure 1 describes a logic model that was constructed to explicitly identify targets for 
evaluation and data collection.  The process evaluation took cognisance of Normalisation 
Process Theory 
17
 using the core constructs of coherence, cognitive participation, 
collective action and reflexive monitoring to conceptualise the processes involved with 
effectiveness of implementation. 
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Implementation of DBST 
Staff from the six community pharmacies were trained to perform DBST to consenting 
patients
18
.  DBST employs a finger prick of blood, spotted onto protein saving paper.  The 
sample was tested by Medical Microbiology for HCV, HIV and Hepatitis B antibodies  
7
.  
Fourteen staff members from the pharmacies attended a 2 hour interactive teaching 
session.  The six pharmacies were notified which of their OST patients had no history of 
HCV testing, as identified by the central virology laboratory.  Testing for HCV was 
offered to each of these individuals.  All individuals with a reactive antibody HCV test 
were offered referral to the specialist hepatitis service. 
Participants’ comments during the training were noted and each pharmacy was visited 
several times to discuss progress.  Notes of these interactions and e-mails from 
participants were retained for analysis.  Testing took place during the last quarter of 2014.  
Post-Testing Interviews 
Semi-structured interviews were conducted with (i) 8 service users and (ii) 10 
professionals taking part in the study, with all 6 pharmacies represented.  The interviews 
were conducted using two topic guides developed in line with the research aims and 
programme theory. All interviews were recorded as digital audio files and transcribed in 
full for thematic analysis
15, 19
.  These data contributed to assessment of feasibility and 
acceptability (including barriers and facilitators); identifying any unintended 
consequences of participation. Transcripts were inductively analysed to identify themes 
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emergent from the interviews.  A deductive analysis was also undertaken to compare 
findings with programme theory. 
Quantitative Data collection and analysis 
Data on demographic information, risk factors, laboratory tests, referral, follow-up and 
treatment were collected. The age structures of the intervention and comparator groups 
were compared by t-test, as were data on DBST taken by the pharmacies.  An odds ratio 
was calculated for the numbers of service users undertaking testing at pharmacies  
compared to non-pharmacy services. 
RESULTS 
The age structure of the 143 service users (26% of all OST users) with no record of 
testing from the 6 pharmacies, together with the 1022 service users of the comparator 
group are presented in Table 2. 
Table 2: Age structure of service users prescribed OST in Dundee 
Age Intervention 
Cohort 
Intervention 
Cohort (%) 
Comparison 
Cohort 
Comparison 
Cohort (%) 
Total 
Population 
Total 
Population 
(%) 
<19 0 ~ 0 ~ 0 ~ 
20-
24 
14 4% 23 2% 
37 3% 
25-
29 
51 14% 133 13% 
184 13% 
30-
34 
112 31% 256 25% 
368 27% 
35-
39 
86 24% 239 23% 
325 23% 
40-
44 
61 17% 185 18% 
246 18% 
45-
49 
26 7% 120 12% 
146 11% 
50-
54 
10 3% 48 5% 
58 4% 
55- 3 1% 16 2% 19 1% 
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59 
60-
64 
0 0% 2 0% 
2 0% 
65-
69 
0 0% 1 0% 1 
0% 
 363 100% 1023 100% 1386 100% 
Analysis of the age structure of intervention and comparator groups was undertaken. A 
significant difference between the two groups was detected using the two-sided t-test 
(p<0.05). The intervention group were younger by 1.75 years (mean age of 35.6 years) 
compared to the comparison group (mean age of 37.4 years).  The study design meant that 
intervention and comparison groups were not randomised, and therefore equal mean ages 
of the two groups were not expected.  
During the test period, 43 (30%) of the 143 service users from the six community 
pharmacies accepted a DBST.  Within the comparator group 561 from 1022 service users 
had no history of DBST and a total of 75 (13%) patients were tested for HCV by other 
providers of DBST (30% Vs 13%). The OR for increased uptake of testing within the six 
pharmacies was 2.25 (95% CI 1.48 to 3.41, Z statistic = 3.81 p= <0.0001) in comparison 
to the other services (Table 2).  The six pharmacies identified 12 patients with a reactive 
test.  The uptake of DBST by each of the six pharmacies is presented in Table 3. No 
significant difference in uptake between the sites could be detected at the p<0.05 level 
using two-sided t-testing. 
Table 3: Uptake of testing by pharmacy site 
Pharmacy Site Number of Eligible 
Patients 
Number of tests 
taken 
(% of eligible 
patients) 
Number of Positive 
Tests 
A 23 13 (57) 3 
B 22 11 (50) 4 
C 30 5 (17) 3 
D 26 10 (38) 1 
E 26 3 (12) 1 
F 16 1 (6) 0 
Totals 143 43 (30) 12 
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Understanding of context for delivery 
Themes identified from transcript analysis of the focus groups provided information 
about the context for delivery
20
.  Focus groups discussions demonstrated an 
understanding of HCV including latency and effects on general health (Figure 2).  
Participants could talk about cirrhosis and cancer.  Participants knew about the burden of 
treatment of interferon-based regimes.  Several clients knew about the cost of the new 
treatments. 
Hepatitis C was viewed as a “dirty disease” caught from sharing needles.  It was 
unacceptable to admit to having HCV and participants feared social exclusion if found 
out.  Participants described the shame they expected to feel if their family discovered they 
had HCV and spoke about “letting them down”.  The fear of being found out contributed 
to reticence about testing. 
What factors influenced client recruitment and participation? 
The transcripts from the post-test interviews demonstrated that service users had both 
positive and negative perceptions of testing.  Interviewees clearly thought that pharmacies 
were a good place to be tested and valued this service and the positive relationships built 
with pharmacy staff.  Lack of money meant travelling to a local hospital was a barrier to 
clinic attendance.  Service users talked vividly about their diminished horizons: they felt 
this was due to their dependence on drugs and lack of money. Pharmacies however were 
viewed as part of the local community. 
Some service users’ previous experiences of stigma and discrimination when attending a 
pharmacy led to caution and suspicion when they were offered testing.  One client 
complained that they were offered DBST stood at the dispensary counter, rather than in 
the private consultation room.  Clients with negative experiences suggested staff would 
need intensive training before offering the service.  Some clients expressed the wish for a 
better explanation about how the test worked and what the results might mean.  Clients 
with positive experiences raised no issues for service improvement. 
Several interviewees distinguished themselves from other “junkies”.  These interviewees 
would describe their plans for recovery and would describe their relationship with a 
partner or young family.  These individuals believed that service users with more chaotic 
lives were less likely to be tested. 
What feedback on staff training and implementation was received? 
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Staff interviewees had clear views about successful implementation.  Staff considered that 
strong leadership and involving all the team were necessary.  Comments such as “a great 
opportunity”, “an obvious thing to do” and “a no brainer” were made.  The degree of 
enthusiasm for new roles and positive relationships with patients were important.  Only 
one individual viewed the development “as a step beyond what pharmacies do”.  There 
were some initial anxieties expressed about potential contact with infected blood.  Some 
staff viewed DBST as a pharmacist’s role, whereas others thought it was a team role.  
The training was evaluated positively, with comments received about the simplicity of 
DBST.  Several teams took lancets and protein-saving cards with them to practice the 
technique.  Implementation was viewed as most successful where all the team were 
involved. 
Some staff expressed concern about offering DBST when prescription dispensing 
workload was high. An identified solution was to use time slots when workload was less.  
Time barriers were most important where DBST was seen as a pharmacist role 
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Figure 2: Examples of focus group quotations 
What do service users understand by hepatitis C infection and how they obtain testing and 
treatment? 
Perceptions of disease  
“my daughter and partner have it. It can lie dormant. it makes you feel very tired and you 
have no appetite” (Participant 5, Carer, December 11) 
 “You could have hepatitis even though, you could be stable on methadone for years then 
find out you’ve got hepatitis” (Participant 35, 22 April) 
Perceptions of testing and treatment 
I think more people have got it done since they started doing that ‘cause it’s easier 
(DBST) (Participant 37, 22 April) 
 “What they do is they have a look at your white blood cells count and things like that and 
how your system is reacting to it and whether or not.  See, when you get the finger prick 
test for Hepatitis it’ll, if you have been exposed to the Hepatitis virus at all, it wi ll come 
back positive.  That doesn’t necessarily mean to say that you have got Hepatitis, so what 
they then is they will do a blood test and start talking about counts and things like that as 
its really confusing” (Participant 19, 25 February)  
You see my partner is really skinny as it is and I think he will loose, everybody;s different 
are they, I think he will loose a lot of weight and I think it affects them mentally as well 
(Participant 33, 7 March) 
Preferences for obtaining treatment 
It would have tae be someplace where dinnae have tae travel everywhere where its 
gonnae cost them money that they have nae always got that’s, that’s what I feel is a big 
thing having tae travel tae Ninewells all the time (Participant 27, 5 March) 
I think that’s one of the things that’s gonnae be down tae the individual, it depends on 
how chaotic their lifestyle is otherwise there’s gonnae be a lot of money wasted there.  
And I take it this new stuff isnae cheap coz it never is when its first introduced. 
(Participant 22, 5 March) 
“Well I say your pharmacy because like I say you’re there every day, you’re only, some 
people dinna even go to the DPC once a month.  So and then you forget your 
appointment, some people forget their appointment at the DPC but you’re guaranteed to 
go for your methadone every day so” (Participant 36, 22 April) 
Aye but you could be going tae the pharmacy for anything you see, so this again de-
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stigmatising.  Nobody knows what they’re in there for, it could be a drug problem it could 
be… anything (Participant 19, 25 February) 
 
DISCUSSION 
Key findings 
This study provides some evidence that pharmacies may be a feasible site from which to 
offer DBST.  People receiving OST were more likely to accept a DBST from a pharmacy 
than from other local providers.  The evaluation of the implementation provides some 
evidence of the context for delivery and the mechanisms that may lie behind the outcomes 
observed
20
.  Contextual factors included: expectations and experiences of stigma and 
discrimination; fears about confidentiality; the limited horizons of people receiving OST 
and the poverty they experience.  Identified mechanisms that may influence uptake 
included the presence of established relationships with pharmacy staff; a pre-existing 
reason for attending the pharmacy for OST and the proximity of the pharmacy within the 
local community. 
Review of programme theory 
The programme theory provided a useful structure from which to consider the process 
evaluation and enabled a series of insights into the barriers and facilitators to effective 
implementation.  In particular, we valued insights into the context that testing in 
pharmacies created for service users and the meaning that such testing may have.  The 
evaluation also provided an indication about how the attitudes and behaviours of staff 
towards the intervention contributed to success or otherwise. 
A number of barriers to uptake of testing and treatment including fear of blood tests
21
, 
adverse socioeconomic and family circumstances, as well as fear of treatment side-effects 
were identified in other studies as well as being identified in this study
22
.  Evidence 
suggests that offering DBST may increase the uptake of HCV testing, when compared to 
venepuncture, although this finding may also reflect increased availability and access 
when a DBST technique is used 
7, 23, 24
. Community-based settings for HCV services may 
also increase acceptance and uptake of testing 
25,
 
26, 27, 28
.  Provision of on-site testing may 
also have positive effects on uptake, due to the proximity of the testing offer
23
. 
Different settings have been used to increase the uptake of testing and treatment including 
testing from methadone maintenance services
29, 30,
 in city homeless shelters
23
 and mental 
health sites
26
.  Little work has utilised the daily interaction with community pharmacists 
to increase testing, follow-up and treatment adherence.  A pilot project introducing DBST 
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in a community pharmacy was undertaken in England in 2009
31, 32
.  The pilot concluded 
that community pharmacies provide a useful route to diagnosing HCV patients and could 
successfully reach at-risk groups. The pilot service was most successful when pharmacists 
worked closely with local drug services and where pharmacists were proactive in 
discussing risks with clients.  Several limitations were noted, including the availability of 
consultation rooms in pharmacies, the provision of adequate staffing to manage the 
normal workload of a pharmacy and also the motivation and commitment of the 
pharmacist to support this new activity.  Similar factors were identified in this current 
study.  The provision of clinical standard consultation rooms is now very common in 
Scotland. 
The stigma associated with both OST prescription and HCV infection was strongly 
recognised in this study.  A systematic review of qualitative research into Hepatitis 
testing, recommended framing the positive outcomes of testing in terms of responsibility 
for individual health and the health of family and community, building positive 
relationships and targeting stigmatising attitudes
23
. 
Limitations 
The primary limitation of the current feasibility study is the small group of pilot 
pharmacies.  Further work is now required to establish stronger evidence that pharmacies 
can positively influence uptake in a greater variety of locations. 
The intervention group had a slightly lower average age than the comparator group.  
Since patients on OST undertake a pathway to recovery, a younger patient group may be 
expected to have a less stable situation than an older group and be less motivated to 
engage in healthcare interventions. 
Some variance in service delivery is common place in pharmacies and in health services 
generally. The variance may be explained by a range of factors including staffing levels, 
building configuration, profile of the client group, as well as staff attitudes.  With more 
experience of delivering training for and services, as well as role acceptance, it is 
expected that some of the variance will diminish. 
INTERPRETATION 
The study design provided a rapid and simple method of demonstrating that the systems 
required for DBST testing can be established successfully in community pharmacies.  The 
daily attendance at the pharmacy provides an unexploited opportunity to deliver health 
interventions.  OST recipients usually lived a short walk from their pharmacy 
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An increase proportion of OST service users accessed DBST from a pharmacy, compared 
to other providers.  Knowledge of potential issues with implementation should assist with 
creation of effective service delivery.  Further work to evaluate the outcomes associated 
with this service configuration is required
34
. The identified barriers to the uptake of 
testing in this study were overcome by local availability of the pharmacies and positive 
relationships with pharmacy staff. 
The references to this paper are located in the manuscript provided in Appendix 9.4 
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4.4 Critical Reflection 
This early phase of my research programme required a steep personal learning curve, both 
in terms of developing and documenting plans for research, but also in terms of becoming 
familiar with the procedures and implementation of research administration and 
governance.  
Focus Group Study: The focus group study provided my first comprehensive 
conversations with the group of people who receive methadone prescriptions from 
pharmacies, even though these were through the medium of the focus group discussions 
we undertook.  The focus group sessions were set up through third sector organisations 
and support groups, who both helped with the organisation and with the identification of 
participants.  I was partnered at the focus groups by a colleague who led the substance 
misuse services and prescribed medicines for a caseload of clients that she looked after.  
Professor Williams provided guidance and support on method development and 
implementation. 
The types of experience related within the focus groups were often very professionally 
challenging for me to listen to.  These experiences provided me with a first real 
understanding of how stigma and discrimination are built in to systems and organisations. 
Prior to this work, I had no proper understanding of how stigma affected people using 
pharmacy services.  An appreciation of how pharmacies operate services and how policies 
that were seemingly organised to ensure safety and efficiency, in fact cause 
discrimination and abuse was a key factor in the adoption of Actor Network Theory as a 
conceptual framework used to underpin the analysis of the transcripts. The focus group 
study provided a series of rich narratives to illustrate the motivation for this.  For 
example, the pharmacy policy of only dispensing opioid substitution therapy (OST) for 
two hour periods in the morning and afternoon meant that the people receiving their 
supervised prescription, all had to arrive within a short space of time.  This concentration 
of people who inject drugs (PWIDs) provided an attractive opportunity for drug dealers, 
who would loiter around the vicinity of the pharmacy.  This phenomenon had a number of 
consequences for the behaviour of the recipients of the OST, who were brought into close 
contact with people they might like to avoid.  The title of the paper “Standing outside the 
junkie door” is a quotation from one of the focus group sessions undertaken, and relates 
to the practice by pharmacies of enforcing separate entry arrangements for PWIDs and 
keeping them apart from “the normal people”.  The separate entrance and the need to 
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queue outside and be admitted one-by-one meant that the individuals prescribed OST 
were denied confidentiality. 
My professional manager also found the work challenging and objected to my plans for 
publication, because of the potential for damage to be done to professional relationships. 
To ensure that the pharmacy professionals had the opportunity to comment and provide 
“balance”, I was required to present my results to a range of committees including the 
Area Pharmaceutical Committee, the Pharmacy Contractors Committee, Public Health 
Pharmacy Network, the Royal Pharmaceutical Society and the Chief Pharmacist at the 
Scottish Government.  I completed the consultation and published the manuscript.  
Interestingly, not one of the bodies that I presented the results of the research to 
challenged my findings and I was able to undertake use the findings to provide awareness 
training for community pharmacy staff and present the findings about stigmas to a series 
of professional meetings. 
Discrete choice Experiment: In order to better understand the theoretical basis of the 
method, I attended a four day course at the Health Economic Research Unit of Aberdeen 
University.  This course covered the underpinning principles and used practical worked 
examples to apply this knowledge.  The course was particularly useful in helping me to 
understand the way that the analysis is performed and some of the subtleties behind the 
calculations. 
The findings from the focus group series were used directly to inform the selection of 
attributes for the discrete choice experiment.  In preparing the manuscript for the focus 
group series, I undertook a rapid review of the literature surrounding provision of OST 
and identified key concepts that would make likely attributes for the research project.  
Many of the attributes identified from the literature search were confirmed through the 
focus group discussions.  Themes such as stigma and discrimination, time, relative 
poverty and health literacy were easily identified as important factors that could be 
evaluated through this method. 
I also undertook the task of piloting and administering the questionnaire and collating and 
presenting the results for analysis.  The questionnaires were administered in the 
consulting rooms of pharmacies.  The routine for this was to sit in the room and ask for 
the pharmacy staff to send through clients who might be interested in completing the 
survey, then providing them with an information leaflet and an explanation of what the 
study entailed.  The following day, I sat in the consulting room of the pharmacy and 
waited for the clients to attend the pharmacy and then come and speak to me. 
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The positive relationships between the pharmacy staff and the clients of the pharmacies I 
had chosen meant that this was a relatively easy exercise (although with long periods of 
waiting).  The interviews were undertaken in six pharmacies and just over one hundred 
participants were recruited from a potential population of about two hundred clients.  The 
analyses of the questionnaires demonstrated how the client group lived around the 
pharmacy, did not usually complete school and were not employed.  The people who 
chose to take the questionnaire were always friendly and willing to participate in 
something different and were very happy to explain why they selected the options they 
did.  The clients that attended these pharmacies had good experiences of the pharmacies 
they had settled with. 
One of the most memorable reactions of participants to the questionnaire was their 
reaction to the “treated with dignity and respect” option.  Participants reacted very 
strongly to this option and often related previous poor experiences. The strong reaction to 
this option often dominated the participants’ responses to the questionnaire, with the 
“treated with dignity and respect” option overshadowing other options.  Discrete choice 
experiments, as a stated preference technique, are subject to hypothetical bias – where 
people say they would do something in theory, which they do not enact in practice.  I 
reflect that the stated preference of the participants to be treated with dignity and respect 
was so strongly felt that it is likely that they would act on this. 
Quasi-Experiment Evaluation: The implementation of this study required that I designed 
and delivered training to pharmacy staff from the study sites and created an operational 
route for pharmacies to submit blood tests that they had taken and receive results.  The 
organisation of this made significant use of the relationships that I had established in 
Tayside and my knowledge of the people and services and how they worked.  In 
particular, there was a need to negotiate with the Pharmacy Superintendent’s Head Office 
to enable pharmacy multiples to participate in the study, which required tenacity and 
patience. 
The design of the study was supported by Dr Evans who provided advice on use of the 
quasi-experiment method.  Use of this approach enabled additional value to be gained 
from a small-scale pilot of part of the care pathway that had been designed and provided a 
platform for working through some of the factors that would be required to successfully 
deliver a full study. 
The quasi-experimental evaluation of dried blood spot testing was undertaken in the same 
pharmacies as the discrete choice experiment.  Pharmacy staff were trained during a 
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series of evenings in one of the pharmacies in Dundee that had a seminar room.  Staff 
took readily to the dried blood spot testing procedure and enjoyed the chance to undertake 
something different.  The relationships built during the previous work meant that the staff 
members understood what was required and were generally enthusiastic. 
The pharmacies were successful in engaging their clients to undertake a test.  This is a 
consequence of the positive relationship that the pharmacies had with their clients, but 
also may have been influenced by the conversations that had been undertaken during the 
discrete choice experiment.  The interviews undertaken with clients as part of the study 
identified that the relationships with the pharmacy staff were valued, but also that the 
local situation of the pharmacy meant that the participants did not need money for bus 
fare and the competing priorities of the day, did not sidetrack them from taking a test.  
The pharmacy staff who were interviewed also responded positively to the opportunity to 
do something different and to take on a task that gave them some autonomy. 
The use of a logic model and the adoption of a realist approach to the process evaluation 
were as a result of a series of study days provided at the University and consequent 
discussions with Professor Williams.  The interviews were transcribed and then analysed 
using a Framework Approach, employing a simple spreadsheet to collect and organise the 
themes and quotations. 
4.4.1 Critique of methods 
Focus Group Study: The methods utilised for the focus group series are presented in 
chapter two and in the paper, therefore and a further in-depth discussion of the strengths 
and weakness of this approach will not be repeated.  However, in summary, a focus group 
approach produces a normative dialogue of the issue under discussion, by the groups of 
participants.  Care has to be taken to manage dominant voices and to gain a balanced 
account of the views of all participants.  The facilitator of the focus group must be aware 
of reflexivity.  Measures should be put in place to support vulnerable participants both 
during and after focus groups discourses, so that any distress that they experience may be 
managed (von Benzon and van Blerk L 1995).  
One of the journal reviewers of the focus group manuscript suggested that a focus group 
methodology was not the best way to identify this type of data and that an ethnographic 
approach would be preferable to the approach I had selected.  I defended my choice in the 
response to reviewers, from the perspective of being able to deliver a purposive sample 
from a range of locations of interest and being able to use the focus group discussion 
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dynamic to encourage the sharing of different experiences.  The use of an ethnographic 
approach would require intense and long term investigation in order to collect data and 
record sequences of events: conversations between people and their relationships and 
therefore be used to document the experiences of the people using pharmacy services.  
Such as approach would be resource intensive and would deflect from my primary 
objective of designing and evaluating a care pathway to treat hepatitis C.  
The themes emerging from the focus groups were very prominent and were easily 
identified by myself and my co-investigator with whom I undertook the focus groups and 
jointly undertook the thematic analysis and interpretation.  The point where saturation of 
themes was reached and no new perspectives were being described probably occurred 
after the fourth focus group.  The purposive sampling plan we had devised meant that we 
continued with the series and in particular, arranged a group with women’s voices (since 
female focus group participants were less vocal than the males), and also undertook a 
peer mentor group.  The motivation for this being that peer mentors would have a more 
longitudinal and reflective view of their experiences with methadone.  The peer mentor 
session was also undertaken as a way of addressing the concerns of my professional 
manager: the views expressed by peer mentors were less likely to be from people with a 
particular grievance to air. 
Discrete Choice Experiment Study:  The methods used for this stated preference study are 
discussed in chapter two, with the strengths and weakness of the approach being set out 
also in the published paper.  These will therefore not be repeated here. However 
generally, discrete choice experiments provide a means to systematically organise the 
preferences of a cohort of participants for the relative importance of a series of attributes 
that describe a product or service.  Discrete choice experiments have a series of 
limitations that include the cognitive burden of the questionnaire and the number of 
choice sets presented, the potential for the hypothetical choices made by participants to 
difference from the choices they would make in the real world and the difficulty in 
selecting a representative sample of scenarios from the full range of possible 
combinations that are available (Reed Johnson, Lancsar et al 2013).  In this study, the 
cognitive burden was managed through administration of the questionnaire rather than 
leaving the clients to complete it themselves.  The language used in each of the scenarios 
was piloted with a “think aloud” group who were able to discuss how they understood 
each question.   
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Quasi-Experimental Evaluation: The approach used in a quasi-experimental evaluation 
together with the general advantages and disadvantages attributable to the method are 
discussed in chapter two and in the paper.  These points will therefore not be repeated, 
but in general, a quasi-experimental evaluation provides weaker evidence of causality due 
to the non-random allocation of the comparator group. This leads to the possibility of 
systematic bias being present in the data that may affect analysis, meaning that 
researchers should be cautious in drawing inferences and conclusions since a range of 
alternative explanations for the data may be feasible. 
The construction of a logic model to identify key stages of the intervention and critical 
points for data collection, proved to be a useful way of thinking through the processes 
involved in the study.  Normalisation process theory was also invoked as a systematic 
tool for considering how the new processes involved in the intervention were 
incorporated into the work systems in each pharmacy (Murray, Treweek et al 2010).  This 
proved to be most useful since the extent of testing each pharmacy actually achieved was 
very variable.  A series of themes were identified which staff used to explain this finding. 
Where the whole pharmacy team took on the task, then the pharmacy was very successful 
and recruited a larger number of clients.  Where the testing was made the responsibility of 
just one member of staff (perhaps the pharmacist), then fewer tests were performed.  This 
result was thought to be about how well the team functioned and how effectively the 
pharmacist was able to display leadership of the team, which is coherent as assessment 
made using the theory. 
4.4.2 Critique of analysis 
Focus group study: The analysis of the study was achieved using a Framework approach 
in which two researchers familiarised themselves with the transcripts (reading and re-
reading the transcripts), identifying a thematic framework (a key list of codes); applying 
the codes to the quotes in the transcripts; creating tables of quotes and comments to 
compare data across groups; mapping and integrating the key findings into a meaningful 
whole.  The management of the data achieved using an Excel spreadsheet rather than 
NViVo (QSR International). For this study with a small number of transcripts to consider, 
this proved manageable and straightforward. 
The identification of Actor Network Theory as a theoretical standpoint from which to 
undertake the analysis proved helpful (Latour 2005).  Once the concept of non-human 
actors being able to influence behaviours and actions of human actors was understood, the 
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interactions seen became significantly clearer.  In particular, the influence of 
organisational policies and the way these changed the way that clients in the pharmacy 
reacted to the pharmacy staff, other customers and each other was particularly helpful. A 
comparative theoretical approach that was also considered is the risk environment 
perspective (Harris and Rhodes 2013), in which a person’s actions are held to be shaped 
by “critical transitions”. The influence of non-human actors in the behaviours of clients 
visiting pharmacies to receive their methadone, was a key factor in choosing Actor 
Network theory. 
The researchers were aware of the dominance of male voices in some of the groups and 
for this reason chose to organise a women’s group to help acknowledge any possible 
imbalance in the data collected through a purposive sampling strategy.  This proved to be 
worthwhile, in terms of the quality of some of the narrative that was gained, although the 
dominant themes were still present.  Similar findings were identified in the peer mentor’s 
group when this was analysed. 
Discrete Choice Experiment: The analysis of the study was carried out using a standard 
approach using SAS (Statistical Analysis Software) (Burges, L and Street D 2005).  
Professor van der Pol provided the expertise and supervision for this analysis and also 
explored a conditional logit analysis and latent class modelling using Stata (Timberlake 
Consultants Ltd).  However, the outcomes from these analyses showed that preferences 
did not systematically vary by the observed individual characteristics and so the simple 
analytical model was adopted for the paper. 
The most prominent finding of the study was the importance of dignity and respect.  The 
strength of this finding makes it likely that this attribute is indeed the dominant factor that 
guides whether a person takes up the offer of testing.  The positive relationship developed 
between the client and the pharmacy, also has face validity since these relationships are 
likely to be maintained over a number of years once a client is settled at a pharmacy.  It is 
however likely that the strength of response to the opportunity to be treated with dignity 
and respect, meant that the range of other attributes received less consideration from 
participants.  The strength of reaction to the dignity and respect attribute also means that 
this finding is also less likely to be subject to hypothetical bias. 
Quasi-Experimental Evaluation: In the analysis of this study, the data from all existing 
testing facilities were available as routinely collected data and it was a relatively simple 
exercise to gain the data for testing from these services and to use as the comparator.  An 
analysis of the age profile of the pharmacy cohort showed significant differences in the 
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age profile when compared to the general population of tested participants: the pharmacy 
cohort were younger. This finding was rationalised within the study through the fact that 
younger participants would be at an earlier stage in their recovery journey and that these 
clients were likely to have a more chaotic lifestyle and therefore be less inclined to accept 
the offer of a test than older patients.  However, the imbalance does show that some 
systematic differences were present in the study, as suggested by the discussion of the 
methodological approach in chapter two.  
The process evaluation was a useful exercise to help establish explanations for the 
findings seen.  The realist approach of “what works, for whom, in what circumstances” 
was an essential tool in helping to understand that the context for delivery of the 
intervention varied according to each location.  The evaluation interviewed a series of 
clients who had undertook the test and staff who had provided the test.  The semi-
structured interview approach was helpful in enabling candid views to be expressed, out 
of hearing of other patients or a pharmacy manager. The opportunity to probe an 
expressed statement with a follow-up question also proved to be helpful in gaining an 
understanding of how the intervention had worked in practice 
Overview of the development and modelling:  The focus group, discrete choice 
experiment and quasi experimental evaluation studies provided the opportunity to gain 
significant insights into the parameters that might affect the operation of a pharmacist -led 
testing and treatment intervention.  In particular, the findings around the importance of 
stigma and discrimination and also the manner in which clients formed positive 
relationships with a particular pharmacy were most informative. 
Apparent weaknesses in particular methodological approaches were felt to be minimised 
by the ability to triangulate findings between different methods. The coherence of 
information generated by the programme and the building of expertise and knowledge 
about how the intervention was likely to operate, built confidence in the development of 
feasibility work to implement the full pathway.  
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CHAPTER 5: 
FEASIBILITY ASSESSMENT AND EVALUATION OF A CARE 
PATHWAY FOR TESTING AND TREATMENT OF HEPATITIS C 
INFECTION IN COMMUNITY PHARMACIES. 
Content: 
Radley A, Tait J, Dillon JF. DOT-C: A Cluster Randomised Feasibility Trial Evaluating 
Directly Observed Anti-HCV Therapy in a population receiving opioid substitute therapy 
from community pharmacy. International Journal of Drug Policy 2017 DOI: 
10.1016/j.drugpo.2017.05.042 
Radley A, Tait J, Dillon JF (2017) was conceived by Radley and Dillon.  Radley and 
Dillon undertook the protocol preparation. Radley prepared the ethics submission and 
designed study documentation.  Radley undertook study staff training and acted as 
principal investigator.  Radley and Dillon provided methodological, professional and 
clinical advice. Radley and Tait undertook the collection and preparation of the data.  
Radley undertook the analysis of the data.  The paper and subsequent revisions were 
written by Radley and the final submission signed off by all co-authors. 
Radley A, de Bruin M, Inglis S, Donnan PT, Dillon JF.  Clinical effectiveness of 
pharmacy-led versus conventionally delivered antiviral treatment for Hepatitis C in 
patients receiving opioid substitution therapy: A study protocol for a pragmatic cluster 
randomised trial. BMJ 2019.  DOI: 10.1136/bmjopen-2017-021443 
Radley A, de Bruin M, Inglis S, Donnan PT, Dillon JF (2019) was conceived by Radley, 
de Bruin and Dillon.  Radley prepared the ethics submission and designed study 
documentation.  Radley undertook study staff training for all sites with Inglis and acted as 
principal investigator for Tayside sites. Inglis contributed to staff training and acted as 
trial manager.  Radley, de Bruin, Donnan and Dillon provided methodological, statistical, 
professional and clinical advice.  The paper and subsequent revisions were written by 
Radley and the final submission signed off by all co-authors. 
Radley A, de Bruin M, Inglis S, Donnan PT, Hapca A, Barclay ST, Fraser A, Dillon JF.  
Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment 
for Hepatitis C in patients receiving opioid substitution therapy: a pragmatic cluster 
randomised trial. (Prepared for submission to The Lancet November 2019) 
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Radley A, de Bruin M, Inglis S, Donnan PT, Hapca A,  Barclay ST, Fraser A, Dillon JF 
(2019) was conceived by Radley, de Bruin and Dillon.  Radley prepared the ethics 
submission and designed study documentation.  Radley undertook study staff training 
across the 5 research study sites and acted as principal investigator for the three Tayside 
study sites.  Barclay acted as principal investigator for the Glasgow site and Fraser acted 
as Principal Investigator for the Grampian site.  Radley, Barclay and Fraser contributed to 
local intervention implementation, practice and patient recruitment, study monitoring and 
data collection.  Inglis contributed to staff training and acted as senior trial manager  and 
performed the randomisation.  Radley, de Bruin, Donnan, Barclay, Fraser and Dillon 
provided methodological, statistical, professional and clinical advice.  Radley and Hapca 
devised the statistical monitoring plan and did the analysis. Radley and de Bruin designed 
and implemented the process evaluation. The first draft of the paper and subsequent 
revisions were written by Radley with contributions by all co-authors. 
Evidence Contributions 
These papers report on the feasibility trial and subsequent work undertaken to design a 
definitive experimental study of a complex intervention: a community pharmacy care 
pathway for testing and treatment of hepatitis C.  This chapter therefore reports on the 
application of the learning gained from the development phase of the research 
programme. 
The feasibility randomised controlled trial was undertaken to test the different elements 
of the pathway as a coherent whole.  The study required that the pharmacy staff in the 
intervention arm recruited and tested patients, then diagnosed hepatitis C infection and 
assessed patients for treatment, before delivering treatment and confirming a cure.  
Interviews with pharmacists and study participants were undertaken in order to gain 
views and perspectives on the operation of the study pathway and of any insights into the 
operation of the delivery of the study that could optimise the effectiveness and efficiency 
of the definitive study. 
The published study protocol describes the work that was undertaken to plan and prepare 
for the definitive trial of the pharmacist-led pathway.  The paper sets out the experimental 
design and planned analysis and describes the administration of the study.  The protocol 
also includes some commentary on how the preparatory work included in the research 
programme aimed to provide a pragmatic intervention and evaluation, capable of being 
delivered in practice. 
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The SuperDOT-C manuscript reports on the final stage on implementation of the research 
programme and the contribution to the evidence base on the ability of community 
pharmacy services to test and treat hepatitis C. The analysis demonstrates a strong 
indication that community pharmacists can increase the numbers of people with hepatitis 
C that access care and achieve a cure for the infection. 
Knowledge Translation Contributions 
This work has been presented to the Scottish Directors of Public Health and Scottish 
Government representatives, as well as to a United Kingdom-wide pharmacy conference.  
The clinical results have been reported at a conference at the Royal College of Physicians 
of Edinburgh. Study outcomes have been presented at local and international conferences 
as both poster and oral presentations and in workshop formats. 
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5.1 DOT-C: A Cluster Randomised Feasibility Trial Evaluating Directly 
Observed Anti-HCV Therapy in a population receiving opioid substitute 
therapy from community pharmacy 
The following paper is a verbatim copy of Radley A, Tait J, Dillon JF. International 
Journal of Drug Policy 2017 DOI: 10.1016/j.drugpo.2017.05.042  
ABSTRACT: 
Background 
Direct-acting antiviral therapy (DAAs) for hepatitis C infection (HCV) have a much 
smaller burden of treatment than interferon-based regimes, require less monitoring and 
are very effective. New pathways are required to increase access to treatment amongst 
people prescribed opioid substitution therapy (OST). 
Method 
An exploratory cluster randomised controlled trial with mixed methods evaluation was 
undertaken to compare the uptake of dried blood spot testing (DBST) and treatment of 
people with genotype 1 HCV infection in a conventional service pathway versus a 
pharmacist-led pathway in a population receiving OST. 
Results 
Pharmacies randomised to the conventional pathway obtained 58 DBST from 244 patients 
(24%):15 new reactive tests and 33 new negative tests were identified. Within the 
pharmacist-led pathway, 94 DBST were obtained from 262 patients (36%): 26 new 
reactive tests and 54 new negative tests were identified.  Participants in the pharmacist-
led pathway were more likely to take a DBST (p<0.003).  Of participants referred for 
treatment through the conventional pathway, 4 patients from 15 with new reactive tests 
(27%) attended clinic for assessment. In the pharmacist-led treatment pathway, 20 
patients from 26 with new reactive tests (77%) attended for assessment blood tests.  
Participants in the pharmacist-led pathway were more likely to proceed through the 
assessment for treatment (p<0.002).  One participant completed treatment through the 
conventional pathway and three patients completed treatment through the pharmacist -led 
pathway.  The process evaluation identified key themes important to service user 
completers and staff participants. 
Conclusion  
The study provides evidence that testing and treatment for HCV in a pharmacist led-
pathway is a feasible treatment pathway for people who receive supervised OST 
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consumption through community pharmacies.  This feasibility trial therefore provides 
sufficient confirmation to justify proceeding to a full trial  
INTRODUCTION 
Hepatitis C (HCV) is a blood-borne viral infection (BBV) causing liver disease.  Around 
0.8% of the Scottish population are chronically infected with HCV (Scottish 
Intercollegiate Guidelines Network, 2013).  A recent Public Health England report 
highlighted that less than 3% of those known to be infected with HCV are being treated 
and less than half of those infected are known (Public Health England, 2018).  The largest 
single infected group are those on opioid substitution therapy (OST) (Arain, 2014). 
Research suggests around 40% of people receiving OST have HCV infection (Aspinall, 
2015; Edlin 2005). 
The world-wide burden of HCV infection has been estimated as 71.1 million infections 
(62.5—79.4), with the largest group being genotype1 (Polaris Observatory HCV 
Collaborators 2017).  The increased morbidity, mortality and economic impact of the 
infection are of concern to both industrialised and developing countries (Lavanchy, 
2009). 
The paradigm shift resulting from the introduction of Direct-Acting Antiviral therapy 
(DAAs) has changed the narrative around HCV, with a realisation that HCV could be 
eliminated in people who inject drugs (Lima, 2015).  There is optimism that the use of 
DAAs offers a high chance of clearance of HCV infection from the population (Grebely, 
2014).  Treating all patient groups with HCV would yield substantial benefits (van Nuys, 
2014) but there are concerns that the infrastructure and treatment capacity to deliver the 
required health outcomes are not generally available or of insufficient scale (Leask, 
2016). 
Treatment uptake for HCV amongst people who inject drugs is currently low (Weissing, 
2014) and prospective patients may have a number of barriers to overcome in order to 
access care (Fernandez-Montero, 2014).  There are identified deficiencies in the extent of 
screening and diagnosis of at-risk populations, as well as improvements required in 
access to treatment initiation and clinical monitoring (Artenie, 2015): People who inject 
drugs may find it difficult to consistently attend medical clinics (Papatheodoridis, 2014).  
However, the delivery of HCV testing and treatment through community-based care 
pathways has been shown to be feasible (Wade, 2016) and Dried Blood Spot Testing 
(DBST) has been demonstrated to increase the uptake of testing from high-risk 
populations (Coats and Dillon, 2015). 
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Creating the complex interventions necessary to eliminate HCV infection requires that 
well-designed cross-disciplinary programmes are put in place (Suther and Harries, 2015) 
using different strategies to increase screening, testing and diagnosis (Brouard et al, 
2015).  The potential of community pharmacy practices to make a greater contribution to 
the health of their local populations has been recognised for some time (Anderson et al, 
2009).  Pharmacists have long had a major role in delivering OST to this group of patients 
with a high prevalence of HCV (Anderson, 2007) and pharmacist involvement in 
delivering HCV treatment through multi-disciplinary clinics has been described for some 
time (Kolor 2005, Arora 2011) 
The Tayside region of Scotland has sequentially developed integrated HCV treatment 
services over the last two decades, moving from standard secondary care-based hospital 
outpatients, onto nurse-supported treatment services, then to a HCV managed care 
network (MCN) including a widespread dry blood spot testing programme in drug 
services and development in our outreach services across the region. This most recent 
development includes providing treatment within drug services and prisons (Tait 2016).  
The network aims for wide involvement in BBV testing and follow-up, with healthcare 
professionals such as drug workers, GPs, prison nurses and social workers taking the 
opportunity to discuss referral and treatment with patients. 
A cluster randomised feasibility trial was therefore designed to optimise the research 
design and consider whether a pharmacist-led testing and treatment pathway could be 
both effective and successful, before being more widely implemented (Bowen et al 2009).  
The study was designed with a mixed methods approach to evaluate: whether people who 
receive OST for pharmacies could be recruited to the study; whether pharmacies could 
successfully complete all elements of the testing and treatment pathway; which elements 
of the pathway work well and which elements are less successful; to make an estimate of 
the effect size in terms of how many participants complete each stage of the pathway 
(Eldridge et al 2016; Arain et al 2010). 
In preparing to undertake this study, work was undertaken using a co-production 
approach in partnership with OST patients (Radley et al, 2016) and has developed the 
intervention through using the views of patients and staff to identify barriers and 
facilitators to effective care (Radley et al, 2017).  The DOT-C study utilises the existing 
pharmacy environment and therapeutic relationships to smooth the pathway into HCV 
therapy and co-administer OST with anti-HCV therapy under the supervision of the 
pharmacist.  The conventional care pathway requires referral and attendance of the patient 
155 
 
at another site and treatment according to the established standard of care. This feasibility 
study therefore aims to address questions about increasing testing and uptake of 
treatment, through a simplified community pharmacist-led care pathway for patients with 
genotype 1 HCV and to incorporate these colleagues into the work of the MCN. 
METHODS 
Trial design: 
A cluster randomised feasibility trial of directly observed anti HCV therapy versus 
conventional care in HCV positive patients attending a pharmacist delivered OST 
program.  
Study protocol: Ethics approval was received for this study (15/ES/0086) from East of 
Scotland REC2 on 2 July 2015. Caldicott Guardian approval was given on 25 July 2015  
Participants: 
Approximately 2,200 patients are prescribed OST within the Tayside region of North East 
Scotland. Around 85% of these patients receive daily supervision of their OST 
consumption through the 92 community pharmacies. At least 40% of these patients will 
be infected with HCV, 40% of infections are Genotype 1 virus (Hutchinson et al, 2006).  
Trial inclusion criteria  
Pharmacies were eligible to participate in the study if they could offer DBST for HCV or 
be trained to do so.  Pharmacies required around 30 patients to ensure adequate 
recruitment. 
Patients were eligible to be consented to the study if they were prescribed OST with 
supervised administration by a pharmacist and had a reactive DBST. Only genotype 1 
patients were included.  Genotype 3 patients were excluded because of the requirement to 
provide interferon-based regimes at the time of the study. 
Randomisation: 
Eight pharmacies were randomised into two groups: conventional care and pharmacist -led 
care.  Randomisation was carried out using http://www.randomization.com.  The subjects 
were randomized into one block using the seed 12576 along with the number of subjects 
per block/number of blocks and (case-sensitive) treatment labels.  The pharmacy provided 
the level of randomisation, so patient allocation was dependent on the pharmacy attended. 
Interventions: 
All pharmacy staff involved with the study received training on good clinical practice, 
study procedures and documentation. Patients confirmed as having genotype 1 HCV 
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infection were assessed for suitability for treatment with ledipasvir 90mg/sofosbuvir 
400mg (Harvoni
®
, Gilead) (EMC, 2016). 
Conventional care pathway 
In these pharmacies, the pharmacist opportunistically discussed with the patient the 
possibility of HCV infection and provided verbal and written information about testing 
and or treatment.  If the patient consented and had not been recently tested, a DBST was 
taken and sent to the local laboratory. In Tayside, the DBST reports Anti-HCV, Hepatitis 
B surface antigen (HBsAg) and Anti-HIV. DBSTs reactive for anti-HCV are confirmed 
through venepuncture and PCR to determine genotype and viral load. 
The local laboratory sent back the result of the DBST to the pharmacist, with results for 
HCV, hepatitis B and HIV (NHS Tayside MCN, 2012).  The identity of each patient 
approached and the result of their DBST was recorded on a screening log.  For patients 
with a reactive DBST, a standard referral letter was sent to the treatment centre and an 
appointment letter issued, inviting the patient to attend a clinic.  For patients admitting to 
a recent HCV test, a standard referral letter was also sent to the treatment centre as 
described above.  For patients attending the appointed clinic, assessment and treatment 
was carried out as normal within the standard of care. 
Pharmacist-led pathway 
In these pharmacies the pathway was identical to the conventional pathway, except that 
patients with a reactive DBST were assessed by the pharmacist for treatment.  For 
consenting patients, the pharmacist completed a pre-treatment checklist of co-morbidities, 
medical history and concomitant medication.  The patient was invited to attend a local 
phlebotomy service and have a panel of blood tests taken including markers of liver 
fibrosis (Castera, 2012) and viral parameters (genotype and load). The pharmacist used a 
Fib 4 test result to identify patients that required further assessment and input from the 
hospital-based multi-disciplinary team (Sterling 2006).  Patients with a score of 3.25 or 
above were excluded from the study and referred to the multi-disciplinary team.  These 
bloods were part of standard care for HCV treatment and are not research specific (i.e., 
they were also part of the conventional pathway). If the pharmacist identified no contra-
indications to HCV therapy, the patient was commenced on treatment. Prescriptions were 
written by a pharmacist independent prescriber.  In patients with potential 
contraindications or queries about suitability, the pharmacist contacted the central clinical 
co-ordinator for medical review. Unsuitable patients were referred for assessment outside 
the study, through the conventional care pathway. Patients received daily HCV treatment 
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at the same time as their OST, (usually on 5 or 6 days, so a modified version of DOT).  
For weekend doses (when the patient self-administered), the pharmacist and patient made 
a brief if-then action plan (an implementation intention) and coping plan (to overcome 
anticipated barriers)
 
(Gollwitzer and Shearer, 2006). 
Outcomes: 
Participating pharmacies were asked to test all consenting and eligible patients from the 
cohort who attended the pharmacy.  Trial outcomes were (1.) The proportion of OST 
patients accepting the offer of testing, (2.) the proportion of patients undertaking 
assessment for treatment, (3.) the proportion of patients completing treatment. The study 
endpoint was when all patients had completed the study care pathway or had dropped out.  
Analysis of data: 
 We have summarised study data as means (standard deviations), with t tests or chi 
squared tests used, respectively, to compare between-group baseline parameters.  The 
outcomes from the participant flows were assessed by chi squared and non-parametric 
significance testing. Since this was a feasibility study, no sample size calculation was 
performed. 
Data collection 
Baseline information on age, sex, concomitant medication, co-morbidities and assessment 
outcomes was collected. Subsequent data was collected on a daily administration log 
which recorded attendance and any treatment side-effects.  Participants completing 
treatment were invited for a blood test at twelve weeks to ascertain SVR.  Recruitment 
commenced in November 2015 with the study being completed in September 2016. 
Process evaluation 
A logic model was constructed to explicitly identify targets for evaluation and data 
collection and is reported elsewhere (Radley et al, 2017).  The evaluation examined the 
processes involved with effectiveness of implementation (Murray et al, 2010).  
Semi-structured interviews were conducted with (i) 6 service users and (ii) 8 
professionals taking part in the study, with all 8 pharmacies represented.  The service 
users who had completed treatment or who had been asked to attend for assessment blood 
tests were interviewed where possible. Interviews were conducted using topic guides 
developed in line with the research aims and programme theory. All interviews were 
recorded as digital audio files and transcribed in full for thematic analysis (Richie and 
Spencer, 1994). Transcripts were inductively analysed to identify themes emergent from 
the interviews.  These data contributed to the assessment of feasibility and acceptability 
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(including barriers and facilitators), that had been gained from this and previous work 
(Radley et al, 2016, 2017). 
Resource utilisation of conventional and pharmacist-led pathways 
The stages and inputs contained within the conventional treatment pathway were defined 
through discussion and agreement within the multi-disciplinary team.  The stages and 
inputs contained within the pharmacist-led pathway were defined by the study protocol 
and reviewed and agreed by the study team. 
Cost collection methods 
NHS Reference costs, published micro-costing studies, and Personal Social Service 
Research Unit costs (PSSRU) (Shepherd et al, 2007), were used for the unit costs of 
managing patients while on treatment.  
Monitoring costs refer to the costs of monitoring the patient while they are treated with 
DAA therapy. Monitoring unit costs were predominantly taken from a micro costing 
(NHS Reference Costs, 2015) and were inflated to 2014/2015 costs using the Hospital 
and Community Health Services (HCHS) Pay and Prices Index (Stevenson, 2012 et al). 
NHS Reference Costs were also consulted as a possible source for this analysis. Al though 
these sources were broadly aligned, more detailed costing data was available, which was 
essential for this analysis (NHS Reference costs, 2015; Curtis and Burns, 2015).  
The unit costs used to estimate the total monitoring costs and service costs for each 
pathway are displayed in Table 4. Service costs refer to the costs of services (e.g. 
pharmacist time, nurse time, consultant time) provided to the patient while they are 
treated with DAA therapy. Unit costs were predominantly taken from PSSRU Unit Costs 
of Health and Social Care 2015. Unit costs are calculated from NHS reference costs and 
have been uprated using the HCHS pay & prices inflator (Shepherd et al, 2007).  
Assessment of pathway costs 
Using the pathway map, monitoring and services costs were summed to cost both the 
conventional and Pharmacy Pathway. Service unit costs were multiplied by the staff time 
taken to complete that activity to provide the cost per activity.  
RESULTS 
Baseline parameters: 
There was no significant difference between the age distributions of participants in the 
conventional pathway (m=38, sd = 7) and in the pharmacist-led pathway (m=37, sd = 8); t 
(504) =1.65, p=0.100 (Table 1).  Chi Square testing showed no significant differences for 
sex (p<0.4) or the hepatitis C test status parameters between the two participant groups 
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(p<0.7). The testing and treatment status of both groups at baseline were compared.  
Mann Whitney U Testing demonstrated no significant differences between the hepatitis C 
testing parameters (Ustat>UCrit ɑ=0.05). 
Recruitment and participant flow: 
Of 506 patients attending the 8 pharmacies for OST, 175 were identified as having no 
record of a previous test (35%) for HCV (Table 2) through a data linkage exercise linking 
OST prescription records with laboratory testing records.  Pharmacies randomised to the 
conventional pathway obtained 58 DBST from 244 patients in receipt of OST (24%). Of 
these, 15 new reactive tests and 33 new negative tests were identified. The pharmacists 
also tested 2 participants who were known positives and repeated tests on 8 participants 
who had been tested in the last twelve months. 
Within the pharmacist-led pathway, 94 DBST were obtained from 262 patients in receipt 
of OST (36%).  Of these, 26 new reactive tests and 54 new negative tests were identified.  
The pharmacists also tested 4 participants who were known positives and repeated tests 
on 10 participants who had been tested in the previous twelve months.  The difference 
between these variables was significant (p<0.003).  Participants in the pharmacist-led 
pathway were more likely to take a DBST. 
Variability in uptake of testing per site was also assessed to evaluate the relationship 
between number of tests and numbers of OST patients attending each pharmacy (Table 3). 
A significant difference was identified between pharmacies in the conventional pathway 
(p<0.002). A significant difference was also identified between pharmacies in the 
pharmacist-led pathway (p<0.00002).  The uptake of testing of OST patients was 
therefore shown to vary significantly between different pharmacies participating in the 
trial in both pathways. 
Outcomes from testing and treatment: 
When a DBST was found to be reactive, participants had either to attend an appointed 
clinic in the conventional pathway or attend a local phlebotomy service in the pharmacist-
led pathway (Table 2).  Of the participants referred through the conventional pathway, six 
from fifteen patients attended at clinic for assessment (27%). Of the participants assessed 
for treatment in the pharmacist-led pathway, twenty from twenty six patients attended for 
assessment blood tests (77%).  The difference between these variables was significant 
(p<0.002). Participants in the pharmacist-led pathway were more likely to proceed 
through the assessment for treatment.  Of note, a larger number of genotype 3 patients 
were seen in the pharmacist-led arm, than the conventional pathway arm (7 versus1), and 
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these patients were therefore unable to proceed to treatment in this study.  A number of 
reasons for exclusion from treatment were responsible for patient attrition from the 
pathways, including spontaneous clearance of HCV and identification of a genotype 3 
HCV infection. 
In this study, one participant completed treatment through the conventional pathway and 
three patients completed treatment through the pharmacist-led pathway.    A flow chart of 
patient disposal is presented in Figure 1 
Process evaluation 
Interviews were held with participants who had either completed the pathway or who had 
tested positive but not yet attended for assessment blood tests. Examples of quotations are 
set out in Figure 2. 
How did participants feel about treatment in pharmacies? 
The transcripts of participant interviews demonstrated positive perceptions of treatment in 
pharmacies.  Interviewees clearly thought that pharmacies were a good place to receive 
care and valued the positive relationships built with pharmacy staff.  Lack of money 
meant travelling to a local hospital was a barrier to clinic attendance. Pharmacies 
however were viewed as part of the local community.  Participants were apprehensive 
about experiencing stigma and discrimination if people knew of their HCV infection.  
Participants noted that treatment with DAAs initially made them feel sick and tired, 
although this quickly faded.  On completion of the course of treatment participants 
expressed positive views about their future and described plans to move their life on.  
What feedback on implementation was received from staff? 
Interviews were held with a member of staff from each pharmacy in both pathways. Both 
pharmacists and pharmacy support staff were interviewed. Examples of quotations are 
found in Figure 2. 
Staff interviewees had clear views about what factors led to successful implementation. 
Staff considered that strong leadership and involving all the pharmacy team were 
necessary prerequisites for success. The intervention was less successful in areas where 
this was lacking.  The degree of enthusiasm for new roles and positive relationships with 
patients were also important.  Where the testing and treatment service was seen as the 
sole responsibility of the pharmacist, the pharmacies managed to complete fewer tests.  
Pharmacist availability was a limiting factor where this occurred.  Less tests were 
completed in pharmacies were the staff felt under pressure because of dispensing work 
load.  Where the service was seen as a team responsibility, the service was more 
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successful and the intervention was able to cover a greater number of patients.  Positive 
relationships with patients were a key factor. Where these relationships were weaker, the 
acceptance of testing and the progress into treatment was less successful.  In pharmacies 
with strong patient relationships, the service was seen as part of the range of ways that the 
health of the patients was improved. There were some initial anxieties expressed about 
potential contact with infected blood, but respondents said that these fears soon faded.  
The patient assessment was felt to be straightforward and easy to accomplish. 
Staff appreciated that participants often needed time to come around to the idea of being 
tested and entering treatment.  The need for off-site phlebotomy was recognised as a 
weakness in the pharmacist-led care pathway. 
Resource utilisation of conventional and pharmacist-led pathways 
The different levels of input and intervention in the conventional and pharmacist -led 
pathways are demonstrated in Figure 3.  The total cost of the conventional Pathway was 
estimated at £933 (£643 service cost, £290 monitoring cost), and the cost of the Pharmacy 
Pathway was estimated £238 (£143 service cost, £95 monitoring cost) (Table 4). 
Therefore, utilising solely the pathway costs, the difference in the cost per patient was 
£695 (£499 service cost, £195 monitoring cost).  The costs associated with the pharmacy 
setting are around one quarter of the cost of treating a patient in a conventional setting 
(assuming the same cost of DAA treatment). In terms of staff capacity, the pharmacy 
pathway model uses four hours less service resources than the conventional pathway 
(6.66 hours with conventional pathway versus 2.66 hours with pharmacy pathway).  
DISCUSSION 
Main study findings 
This feasibility study provides evidence that community pharmacies can successfully 
provide DBST to patients attending for OST and that progression to treatment is feasible.  
More participants accepted a DBST in a pharmacist-led pathway than in the conventional 
pathway, where there was no requirement to attend a hospital clinic for treatment.  
Interviews with participants identified a number of explanatory factors for this.  This 
study found that more participants undertook assessment for treatment in the pharmacist 
led pathway, where the care pathway was delivered entirely in the pharmacy.  Both 
patient and staff experiences and views demonstrated how the pharmacist-led pathway 
overcame some of the barriers that prevent people prescribed OST accessing testing and 
treatment. 
Strengths and weaknesses of the study 
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The criteria set out for evaluating the success of the feasibility trial included whether 
people who receive OST for pharmacies could be recruited to the study; whether 
pharmacies could successfully complete all elements of the testing and treatment 
pathway; which elements of the pathway work well and which elements are less 
successful; to make an estimate of the effect size in terms of how many participants 
complete each stage of the pathway (Arain 2010).  The study has provided evidence that 
these criteria can be met: OST patients can be recruited and pharmacies can guide patients 
through all stages of the pharmacist-led pathway. 
The need to attend for off-site phlebotomy led to some loss of potential patients in the 
pharmacist-led pathway and this weakness should be addressed in the design of the f inal 
pathway for full trial, with perhaps the inclusion of peripatetic phlebotomy services 
visiting pharmacies. This study demonstrated that three participants could access 
treatment in the pharmacist led pathway compared to one participant in the conventional 
pathway.  However, a series of further aspects also provide encouragement that a 
significant effect size is present, including the reduced losses at clinic attendance stage in 
the pharmacist-led arm.  Notably, demonstration of a larger effect size in the pharmacist-
led arm was impaired because of a larger proportion of patients spontaneously clearing 
infection and a great number of genotype 3 patients being identified in this arm, which at 
the time of the study could not be treated with interferon free regimens. 
Some variation in uptake was observed between pharmacies in both pathways.  
Additional factors may explain this variation, such as the degree of enthusiasm of the 
pharmacy staff for new roles, the relative burden of dispensing workload in the pharmacy 
and the leadership shown by the pharmacist. This variance may be addressed through 
growing acceptance of this service as part of what a pharmacy should offer.  
A further limitation is the access of pharmacies to electronic laboratory results services .  
Although, these are now being implemented into pharmacies in some areas, this resource 
is not yet widely available.  The consequence of this, as identified in this study, was that 
some patients received duplicate blood tests. Additional variables such as length of time 
of OST and the dispersal of co-morbidities and BBV co-infection may also act as 
confounders.  The use of pharmacies as study sites precluded assessment of medical notes 
to assess these factors systematically, but the DBST taken from clients assessed Hepatitis 
B and HIV co-infection, as well as HCV.  Collection of data on length of time on OST 
will be build into the design of the full trial.  The study protocol required that co-infected 
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patients were directly referred to the standard care pathway. A further large scale study is 
now being implemented to fully assess the potential of this pathway.  
Interpretation of findings 
Previous pilot work from this programme has explored the context for delivery and the 
mechanisms that may lie behind the outcomes observed (Radley, 2017).  Contextual 
factors have previously been identified by other authors, including: expectations and 
experiences of stigma and discrimination; fears about confidentiality; the limited horizons 
of people receiving OST and the poverty they experience (Harris et al 2013, Wade et al 
2016).  Identified mechanisms that may influence uptake included the presence of 
established relationships with pharmacy staff; a pre-existing reason for attending the 
pharmacy for OST and the proximity of the pharmacy within the local community.  The 
work undertaken in this study, has confirmed that the local nature of the pharmacy and 
the pre-existing reasons for attendance are key mechanisms in recruitment for testing and 
that good quality relationships between pharmacy staff and participants, supports 
recruitment (Edlin et al 2005).  The barriers to completion of either of the care pathways 
were also confirmed: that participant may be anxious about what the results might mean 
for them, or mistrustful of the way they might be treated.  Although the pharmacies 
provided a familiar environment within their local community, hospitals represented an 
unfamiliar setting.  The health literacy required to navigate the journey from the 
participant’s normal setting to attend multiple hospital-based appointments was a 
significant barrier (Arora et al 2011). For the pharmacist-led arm of the study, even the 
attendance at an external venue for a single phlebotomy appointment was a significant 
barrier, leading to patient loss from the pathway. 
Treatment pathways that increase access and uptake of treatment of DAAs are required.  
Uptake of testing and treatment is currently low (Weissing, et al, 2014) and authors 
across the world have identified many common barriers that must be overcome by 
potential patients to treat the HCV infection (Wade et al 2016, Konerman and Lok, 2016).  
There are identified deficiencies in the amount of screening and diagnosis undertaken for 
at-risk populations, as well as improvements required in access to treatment initiation and 
clinical monitoring (Artenie et al, 2015): The infrastructure to deliver sufficient treatment 
to enable eradication is not generally available or of sufficient scale (Leask and Dillon, 
2016). People who inject drugs may find it difficult to consistently attend the medical 
clinics that are the mainstay of standard of care (Papatheodoridis et al, 2016).  Delaying 
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treatment because of funding problems risks patients being lost to follow-up (Fox and 
McCombe, 2016). 
Creating the complex interventions necessary to eliminate HCV requires that well-
designed cross-disciplinary programmes are put in place (Suther and Harries, 2016) using 
a variety of strategies to increase screening, testing and diagnosis (Brouard et al, 2015).  
The delivery of HCV testing and treatment through community-based care pathways has 
been shown to be feasible (Coats and Dillon, 2015). 
There have been a number of different routes chosen to provide primary care-based 
treatment pathways.  A targeted general practice-based screening intervention has been 
recommended, since low diagnostic yields limited the effectiveness of non-targeted 
approaches (Anderson et al, 2009).  Current work aims to produce a scalable general 
practice model (Roberts et al, 2016).  Community-based, nurse-led care for HCV has 
shown been shown to be effective (Wade et al, 2015). The change away from interferon-
based regimes should improve the proportion of people who are willing to undertake 
treatment (Lewis et al, 2016). 
As well as the benefits that arise from harnessing the established OST care system already 
implemented in the pharmacy, such as improved regime adherence, there are further 
benefits gained through developing a new pathway designed to take advantage of DBST 
and the reduced burden of DAA treatment. The lower cost of primary care premises 
compared to hospital clinics as well as the simplified testing and monitoring 
requirements, is responsible for the lower estimated cost of the pharmacist -led pathway. 
These lower costs are likely to prove favourable even if current hospital-based standard of 
care pathways are also simplified and made more efficient. Although the conventional 
care pathway reported in this study required twelve attendances to complete treatment, 
other authors have reported pathways with up to eighteen stages (Arora 2011)  With 
current pathways, the use of DAAs is cost-effective at all stages of liver disease (Leidner 
et al, 2015, Liu et al, 2012).  With primary care based care pathways capable of recruiting 
greater numbers of people with HCV infection, cost-effectiveness of these medicines may 
increase further (Bennett et al, 2015).  A coordinated programme delivered through a 
managed care network has increased the numbers of people accessing treatment and 
shortened the time for people with HCV infection to achieve an SVR (Tait et al, 2016).  A 
multi-disciplinary approach to care has been demonstrated to improve care.  
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CONCLUSIONS 
This feasibility study provides further evidence that service users prescribed OST can 
access testing and treatment through a pharmacy.  Use of a pharmacist-led pathway may 
remove some of the barriers that prevent OST patients accessing testing and treatment 
through conventional pathways. 
A number of the identified barriers to the uptake of testing in this study were overcome 
through the local availability of the pharmacies and positive relationships with pharmacy 
staff.  The use of community pharmacy delivered care has the potential to contribute to 
elimination of HCV in the United Kingdom.  Further work to evaluate the outcomes 
associated with this service configuration is now on-going (NHS Research Authority, 
2016). 
The references to this paper are located in the manuscript provided in Appendix 9.5 
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Table 1: Baseline characteristics of trial population by group allocation 
Characteristic Conventional pathway (%) Pharmacist-led 
Pathway 
 
    
Participants (n) 244 262  
    
Male 165 (68) 167 (64)  
Female 79 (32) 95 (36) p=0.358 
Age (years)    
20-24 3 (1) 7 (3)  
25-29 22 (9) 40 (15)  
30-34 65 (27) 64 (24)  
35-39 56 (23) 55(21)  
40-44 44 (18) 55(21)  
45-49 36 (15) 26(10)  
50-54 14 (6) 8(3)  
55-59 4 (2) 4(2)  
60-64 0  2(1)  
65-69 0 1 p=0.100 
Hepatitis C Status    
Continued Follow-Up in 
Treatment 34 (14) 32 (12) 
 
Previous SVR Completed 
Treatment 20 (8) 21 (8) 
 
Last Test Negative 89 (36) 90 (34)  
No Record of Previous Test 80 (33) 95 (36)  
Referral, Did Not Attend 4 (2) 10 (4)  
Attended, Did Not 
Complete 14 (6) 14 (5) 
p=0.622 
Positive Test, No Referral 3 (1) 0 - 
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11 DNA at clinic post -referral 
1 genotype 3 
1 Spontaneous clearance 
0 Prison 
1 Deceased 
Table 2: Participant Flow and outcomes 
Population 
  Pool of 2,200 patients in Tayside receiving OST 
Cohort 
  506 patients receiving OST in 8 participating pharmacies 
   
 Conventional Pathway Pharmacist-Led Pathway 
 244 OST patients 262 OST patients 
Tested         p=0.003 
  
 58 DBST taken 94 DBST taken 
Assessed                  p=0.002 
   
   
   
   
   
Follow-
Up 
  
   
   
Treatment 1 patient treated 3 patients treated 
 1 completed treatment at 12 
weeks 
3 completed treatment at 12 weeks 
 
  
15 new reactive tests 
33 new negative tests 
2 known HCV retested 
8 re-tests of recent negative tests 
 
26 new reactive tests 
54 new negative tests 
4 known HCV retested 
10 re-tests of recent negative 
tests 
6 No assessment blood test 
7 genotype 3 
9 Spontaneous clearance 
1 Prison 
0 Deceased 
168 
 
 
Table 3 Patient Outcomes – Uptake of testing and treatment by pharmacy site 
 
Site 
No. 
Patients 
No record of 
previous test 
DBST 
(%) 
Known 
positives 
Repeat 
test 
New 
positives 
New 
negatives 
1 68 25 11 (16) 0 0 0 11 
2 76 26 21(28) 2 2 7 10 
3. 62 19 9(15) 0 3 2 4 
4. 38 10 17(45) 0 3 6 8 
Totals 244 80 58(24) 2 8 15 33 
        5 84 39 43 (51) 1 1 10 31 
6 51 19 7(14) 0 0 2 5 
7 86 21 20(23) 3 6 5 6 
8 41 16 24(59) 0 3 9 12 
Totals 262 95 94(36) 4 10 26 54 
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Figure 1:  Percent Attrition of Patients with Reactive Tests for Conventional and Pharmacist-Led Pathways  
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Figure 2: Examples of quotations from service users and staff participants 
Service Users  
How did Hepatitis C affect your life? 
“I already knew I had Hepatitis C, I got diagnosed with it  more than 10 years ago. I had 
always been waiting for the time ... my life just never seemed to get to a point where it 
was stable enough to do it” Participant 1, male 
“A couple of years ago I said to one of my pals there wus somethin’ wrang wi’ us, I was  
just tired, no strength to go any place” Participant 2, female 
What was your experience of treatment in the pharmacy? 
“I recognise that this is a big plus, being able to get a tablet every day at the chemist is so 
ease, so convenient”. Participant 4, male 
“When you got to the hospital sometimes you feel like you are being treated differently 
and I just found that in here(in the pharmacy) it was a more warmer environment and 
friendly” Participant 6 male 
Has completing treatment made any differences to you? 
“But I honestly feel different; I feel like my old self ken, I feel better” Participant 1, male  
“Going forward now it more just that, eh I want to go back to college and get into youth 
work if I can.  I have a prospectus as home, so my future .. what I see is me hopefully 
doing something along lines”. Participant 2, Female 
 
Staff 
 How did you feel about taking part in the study? 
“I was quite excited about it, quite looking forward to doing it, it was something quite 
different for pharmacies to do, we would get more involved with the methadone patients, 
so I was very interested and keen for it”. Staff Member 7, Female 
How did you manage the participants and help them to complete the pathway? 
“you build up your conversations and your style of conversations, the more you gain in 
confidence, the better the client feels and they also like to understand that we are learning 
and developing with them, they like to feel part of something too”. Staff member 3, 
Female 
“We did try quite a few times to get him to go but he kept said he would be going, in fact 
I think once he said he had gone but he wasn’t able to get tested, but I don’t know if 
that’s true or not”.  Staff Member 5, Male 
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Table 4: Monitoring costs and service costs -Conventional Pathway Costing Results  
Stage Reason 
Activity  
(Estimated Staff Time hrs) 
Cost 
(per activity) 
1 Dried Blood Spot Test 
Specialist Nurse (0.33) £41 
Dried Blood Spot Test £40 
2 
Outpatient 
appointment 
Specialist Nurse (0.66) £83 
Liver Panel  £5 
3 
Outpatient 
Appointment 
Ultrasonographer (0.5) £20 
Fibroscan £55 
4 
Appointment Medical 
Clinic 
Consultant (0.5) £69 
Liver Panel  £5 
5 
Radiology 
Appointment 
Ultrasonographer (0.5) £20 
Ultrasound Liver  £63 
6 
Medical Clinic 
Appointment 
Consultant / Registrar (0.33) 
£24 
7 
Outpatient Clinic 
Appointment 
Specialist Nurse (0.5) £63 
Liver Panel  £5 
8 Prescription 
Pharmacist Prescriber (8a) 
(0.5) 
£36 
9 Outpatient Review 
Specialist Nurse (0.33) £41 
Liver Panel  £5 
10 Outpatient Review 
Specialist Nurse(0.33) £41 
Liver Panel  £5 
11 Outpatient Review 
Specialist Nurse (0.33) £41 
Liver Panel  £5 
12 Outpatient Review 
Specialist Nurse (0.33) £41 
Liver Panel  £5 
13 Outpatient Review 
Specialist Nurse (0.33) £41 
SVR £50 
14 Outpatient Review 
Specialist Nurse (0.33) £41 
SVR £5- 
15 Discharge Specialist Nurse (0.33) £41 
Total Pathway Cost  £933 
     Service Cost  £643 
     Testing Cost  £290 
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Pharmacy Pathway Costing Results  
Stage Reason 
Activity  
(Estimated Staff Time hrs) 
Cost  
(per activity)  
1 
Pharmacy Attendance 
for Methadone 
Pharmacist (0.33) £17 
2 
Dried Blood Spot Test 
in Pharmacy 
Pharmacy Assistant (0.33) £3 
Dried Blood Spot Test £40 
3 
Assessment Blood 
Tests 
Specialist Nurse (0.33) £25 
Liver Panel  £5 
4 
Patient Assessment in 
Pharmacy 
Pharmacist (0.5) £25 
5 Prescription 
Pharmacist Prescriber (band 
8a) (0.5) 
£25 
6 
Outpatient Review 
(SVR test) 
Specialist Nurse (0.33) £25 
SVR £50 
7 
Discharge from 
Service 
Specialist Nurse (0.33) £25 
Total Pathway Cost £238 
Staff Cost  £143 
Testing Cost £95 
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5.2 Clinical effectiveness of pharmacy-led versus conventionally 
delivered antiviral treatment for Hepatitis C in patients receiving opioid 
substitution therapy: A study protocol for a pragmatic cluster 
randomised trial SuperDOT-C 
The following paper is a verbatim copy of Radley A, de Bruin M, Inglis S, Donnan PT, 
Dillon JF. BMJ Open 2018.  DOI: 10.1136/bmjopen-2017-021443 
ABSTRACT 
Introduction: Hepatitis C Virus (HCV) infection affects 0.7% of the general population, 
and up to 40% of people prescribed Opioid Substitution Therapy (OST) in Scotland. In 
conventional care, less than 10% of OST users are tested for HCV and less than 25% of 
these initiate treatment. Community pharmacists see this group frequently to provide OST 
supervision. This study examines whether a pharmacist-led ‘test & treat’ pathway 
increases cure rates for HCV. 
Methods and Analysis: This protocol describes a cluster randomised trial where 60 
community pharmacies provide either conventional or pharmacy-led care. All pharmacies 
offer dried blood spot testing (DBST) for HCV. Participants have attended the pharmacy 
for OST for 3 months; are positive for HCV genotype 1 or 3; not co-infected with HIV 
and/or hepatitis B; no decompensated liver disease; not pregnant. For conventional care, 
pharmacists refer HCV positive participants to a local centre for assessment. In the 
pharmacy-led arm, pharmacists assess participants themselves in the pharmacy. Drug 
prescribing is by nurse prescribers (conventional arm) or pharmacist prescribers 
(pharmacy-led arm). Treatment in both arms is delivered as daily modified directly 
observed therapy (DOT) in a pharmacy. Primary trial outcome is number of sustained 
viral responses (SVR) at 12 weeks after treatment completion. Secondary trial outcomes 
are number of tests taken; treatment uptake; completion; adherence; re-infection.  An 
economic evaluation will assess potential cost-effectiveness. Qualitative research 
interviews with clients and health professionals assess acceptability of a pharmacist -led 
pathway. 
Ethics and Dissemination: This protocol has been ethically approved by the East of 
Scotland Research Ethics Committee 2 (15/ES/0086) and complies with the Declaration 
of Helsinki and principles of Good Clinical Practice. Informed consent is obtained before 
study enrolment and only anonymised data is stored in a secured database, enabling an 
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audit trail. Results will be submitted to international peer-reviewed journals and presented 
at international conferences. 
ClinicalTrials.gov Identifier: NCT02706223 
Protocol version 3.0.  Date 27 May 2016 
Strengths and limitations of this study 
Real world study developed using the Medical Research Council (MRC) Guideline on 
complex interventions 
Potential to provide answers to an extremely topical question around approaches to 
eliminate a disease, in line with a World Health Organisation (WHO) target.  
Utilises a community pharmacy-based pathway in NHS Scotland, but not wider primary 
care systems 
Relies on close and integrated working between a specialist hepatitis service and 
community pharmacy services 
 
BACKGROUND 
Hepatitis C (HCV) is a blood-borne viral infection causing liver disease. Around 0.7% of 
the Scottish population are chronically infected with HCV [1]. Patient outcomes from 
HCV infection vary, with 25% clearing the infection spontaneously and the remainder 
becoming chronically infected, risking development of cirrhosis and hepatocellular 
carcinoma [2]. A recent Public Health England report highlighted that less than half of 
those infected with HCV have been identified, and of those identified less than 3% of 
those known to be infected with HCV are being treated [3]. The greatest risk of acquiring 
the virus in the UK is through injecting drug use [4] and evidence suggests around 40% of 
people in Scotland receiving Opioid Substitution Therapy (OST) have HCV infection [5]. 
Only a small proportion of this high-risk and vulnerable population are receiving 
adequate treatment, despite having daily healthcare interaction with a pharmacist and the 
availability of a curative intervention with widely available Direct Acting Antiviral 
(DAA) medication [6]. 
The conventional care pathway in the United Kingdom recommends that patients with a 
history of intravenous drug use, or those currently prescribed OST, should be offered 
HCV testing annually [3]. Testing may be available from their GPs, drug workers, drug 
agencies, social workers, community pharmacies and needle exchanges [7]. Once 
diagnosed, patients can be referred to established treatment pathways, usually based 
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around hepatology teams in secondary care. In these established treatment pathways, less 
than 10% of the OST population are tested for HCV annually. Of those tested, at most 
25% start treatment in one of the dedicated centres and 70-80% successfully complete 
treatment, with treatment failure primarily caused by non-adherence and non-persistence 
to treatment [8]. Similar patterns are observed in other countries [9]. The inefficiency of 
established treatment pathways leads to increased preventable deaths from HCV and viral 
transmission within the injecting population [10].  
A variety of reasons may explain the low rates of HCV testing, treatment uptake, and 
treatment completion. People who inject drugs (PWID) may encounter a number of 
barriers that prevent them from accessing care, including perceptions and experience of 
stigma and discrimination, issues with the organisation of care and the treatment policies 
of providers or payers [11]. There are identified deficiencies in the extent of screening 
and diagnosis of at-risk populations, as well as the need to simplify pathways to enable 
treatment initiation and clinical monitoring [12]. People who inject drugs may f ind it 
difficult to consistently attend medical clinics [13]. 
The WHO has set an ambitious goal to eliminate HCV as a public health threat by 2030 
[14]. Creating the complex interventions necessary to eradicate HCV requires that well -
designed cross-disciplinary programmes are put in place using different strategies to 
increase screening, testing and diagnosis [15]. Strategies that demonstrate increase testing 
and treatment uptake include the provision of integrated HCV care pathways; with drug 
use and psychiatric services delivered by a multidisciplinary team, and with case 
management services [16]. The delivery of HCV testing and treatment through 
community-based care pathways has also been shown to be feasible and DBST has been 
demonstrated to increase the uptake of testing from high-risk populations [17]. Hence, a 
more central role in the treatment of HCV for community-based pharmacists who are 
seeing these clients on a daily basis, could – in theory – lead to increased HCV treatment 
success rates through higher HCV testing, treatment uptake, adherence, and treatment 
completion rates. 
In preparation for the current trial investigating the clinical benefits of pharmacy-
delivered HCV treatment, pilot work was undertaken guided by the MRC theoretical 
framework for developing and evaluating complex interventions [18]. Initial work 
involved using a co-production approach in partnership with OST patients. This work 
identified the current experiences of patients in accessing HCV testing and treatment and 
in accessing OST in pharmacies [19]. The attributes of an ideal service were identified 
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and an estimate of potential uptake made [20]. The implementation of DBST in 
pharmacies was undertaken and the experiences of patients and providers recorded [21]. 
A pilot trial has been undertaken to test each stage of the pharmacy-led care pathway and 
to look for confirmation that an appropriately powered definitive multicenter randomised 
controlled trial would be feasible [22]. The PRECIS-2 tool was used to assess that the 
design decisions were concordant with the purpose of the trial (Supplementary file 1) 
[23].  
The aim of this research is to examine the impact of pharmacy-delivered HCV treatment 
on HCV treatment success rates amongst OST users. Our research questions are:  
Trial 
(1) Does a community pharmacist-led HCV treatment pathway increase treatment success 
rates (sustained virological response, or SVR) compared to the conventional pathway?  
(2) Does a community pharmacist-led HCV treatment pathway lead to a higher uptake of 
HCV testing?  
(3) Does a community pharmacist-led HCV treatment pathway lead to a higher uptake 
and completion of HCV treatment? 
(4) Is adherence and persistence to HCV therapy in the pharmacy setting similar to that in 
the Conventional pathway? 
(5) What is the re-infection rate at 12 months after end of treatment in all patients with 
SVR, and for the pharmacist-led pathway compared to the conventional pathway? 
Health Economics Study 
(6) Is the pharmacist-led pathway potentially a cost-effective method of testing and 
treating HCV in people prescribed OST? 
Qualitative Study 
(7) Is the pharmacist-led pathway an acceptable way to offer testing and treatment for 
people prescribed OST infected with HCV and are there any unexpected consequences? 
METHODS:  
Design 
Super DOT-C is a cluster randomised trial of pharmacy-led anti HCV therapy versus 
conventional care in HCV infected patients attending community pharmacies. Sixty 
pharmacies will be enrolled to this study across 5 hubs in Health Boards in NHS 
Scotland. Pharmacies (and thus their patients) participating in the trial will be randomly 
allocated to conventional care pathway or the pharmacy-led pathway. 
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Pharmacies at each site are randomised into two groups: conventional care and 
pharmacist-led care. Randomisation will be carried out using 
http://www.randomization.com. The subjects are randomized into one block along with 
the number of subjects per block/number of blocks and (case-sensitive) treatment labels. 
The pharmacies in each hub provide the level of randomisation, so patient allocation is 
dependent on the pharmacy attended. 
Eligibility Criteria 
Eligible pharmacies are community-based, offer DBST for HCV by trained pharmacy 
staff in line with approved practice in their particular NHS board and have at least 30 
patients on OST to ensure adequate recruitment. Patient inclusion criteria are having 
HCV Polymerase Chain Reaction (PCR) positive to genotype 1 or 3, are OST users and 
willing to have their pharmacists supervise their antiviral drug use. Patient exclusion 
criteria are having another genotype than 1 or 3, evidence of current or previous 
decompensated liver disease, Human Immunodeficiency Virus (HIV) infection, surface 
antigen of Hepatitis B Virus (HBV) HBsAg positive with detectable HBV DNA, 
aggressive or violent behaviour towards the pharmacist, being pregnant, and not being 
able to provide informed consent. 
Interventions: 
Medication provided 
The anti HCV treatment provided in both pathways is identical, i.e: 
For HCV genotype 1 sofosbuvir/ledipasvir for 8 weeks 
For HCV genotype 3 sofosbuvir/daclatasvir for 12 weeks  
Study Site Staff Training  
Staff from each study site will receive training on Good Clinical Practice, quality control, 
use of study documentation, ensuring common practice, and consenting participants. In 
addition training to establish testing for blood borne viruses is provided and information 
on hepatitis C and its treatment is provided. Staff in the pharmacy-led arm are trained on 
how to interpret laboratory bloods and to perform a Fib4 calculation [24]. 
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Table 1: Treatment pathways: similarities and differences 
 Conventional care Pharmacy pathway Contrast 
Hepatitis C 
Virus testing 
Opportunistic HCV 
testing on presentation 
for OST therapy 
Opportunistic HCV 
testing on presentation 
for OST therapy 
The same procedure is 
provided in each of the 
study arms 
Hepatitis C 
Virus test 
confirmation 
Test result is 
communicated and - if 
positive – referred for 
assessment in local 
treatment centre 
Test result is 
communicated and – if 
positive - assessment 
directly undertaken in 
the pharmacy 
Assessment for 
treatment is carried 
out at the pharmacy 
when the participant 
visits to obtain OST, 
not at a different site 
with a different 
provider 
Treatment 
initiation 
Suitable patients are 
prescribed treatment by 
a nurse prescriber at the 
local treatment centre 
and access treatment 
through DOT at their 
pharmacy 
Suitable patients are 
prescribed treatment 
by a pharmacist 
prescriber and access 
treatment through 
DOT at their 
pharmacy 
Treatment initiation is 
carried out at the 
pharmacy and not at a 
different site with a 
different provider 
Treatment 
monitoring 
Treatment monitoring is 
carried out by the 
specialist team in their 
clinic 
Treatment monitoring 
is carried out at the 
pharmacy 
Treatment monitoring 
is carried out at the 
pharmacy not at a 
different site. 
Monitoring in the 
conventional pathway 
requires additional 
clinic visits 
Treatment 
completion 
Sustained Viral 
Response testing is 
carried out by DBST at 
the pharmacy 
Sustained Viral 
Response testing is 
carried out by Dried 
Blood Spot Testing at 
the pharmacy 
The same procedure is 
provided in each of the 
study arms  
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Conventional Care Pathway 
At the start of the pathway pharmacists will opportunistically discuss HCV infection with 
their OST patients. The pharmacist will record on a screening log which of the OST 
patients attending the pharmacy they have approached. Those with unknown HCV status 
will be offered testing using a DBST in the pharmacy [25]. Patients identified as having 
HCV antibodies will have a post-test discussion with the pharmacist. During this 
discussion the pharmacists will obtain informed consent and explain about HCV 
treatment using a standard infographic (supplementary file 2). Next, the pharmacist will 
offer them referral to the conventional care pathway for assessment and treatment at a 
local treatment centre. Information will be provided verbally and by offering standard 
leaflets about HCV. If the patient attends an appointment at one of the local treatment 
centres, a member of the specialist hepatitis team will invite the patient to undertake 
assessment for treatment for HCV. Assessment comprises of a pre-treatment checklist of 
medical co-morbidities, medical history, and concomitant medication to look for drug-
drug interactions. The patient will undergo phlebotomy in the local treatment centre to 
check full blood count, urea and electrolytes, liver function testing, including markers of 
liver fibrosis [24] (Fib4, APRI, AST:ALT ratio) and viral parameters (genotype and 
load), as assessment for treatment. Patients who are referred for assessment and treatment 
will be managed according to the standard local treatment pathway. Daily supervised 
OST treatment is delivered by the pharmacy, in which the doses of methadone or 
buprenorphine are provided by the pharmacy staff, who observe consumption. In both 
arms of the study DAA treatment is delivered jointly with OST in their normal pharmacy; 
which would qualify as DOT during weekdays, although at weekends patients usually 
self-administer. Prescriptions will be provided by a nurse prescriber and dispensed at the 
participant’s normal pharmacy. For doses that patients have to self-administer and the 
weekend doses when there is no OST distribution, the pharmacist and patient will make a 
brief if-then action plan (an implementation intention) and coping plan (to overcome 
anticipated barriers) [26]. The study related data collection will be undertaken by the 
specialist hepatitis team.  
Pharmacist-Led Pathway 
Potential participants are offered testing, recruited and consented as in the conventional 
pathway.  In the pharmacy-led pathway however, the pharmacist will offer them anti-
HCV therapy delivered solely within the pharmacy. The patients who decline study 
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participation will be entered in the screening log. For the patients who do consent, the 
pharmacist will complete a pre-treatment checklist of medical co-morbidities, medical 
history, and concomitant medication to look for drug-drug interactions. The patient will 
undergo phlebotomy in the pharmacy for safety blood tests, as in the conventional 
pathway and the pharmacist will assess this information to determine suitability for 
treatment. 
 If there are no contra-indications to therapy, the patient will commence the treatment. In 
patients where there are contraindications or queries about suitability, the pharmacist will 
contact the central clinical co-ordinator for advice. The pharmacist-led pathway requires 
an assessment which includes identification of concurrent specific medical conditions, 
screening of safety bloods, calculation of a Fib-4 score, assessment of interacting 
concurrent medication and assessment of factors likely to impinge on treatment 
compliance. Potential participants with a FIB-4 score of > 3.25 are referred on to the 
Conventional Care Pathway for review.  The Pharmacist-led Pathway therefore excludes 
this group from being entered into the trial.  Instead, they are assessed for treatment 
through the Conventional Care Pathway where they are reviewed in hospital by a medical 
consultant who decides if it is safe to proceed with treatment and if yes, may select 
different drugs’. Unsuitable patients are therefore referred to the conventional pathway 
for assessment outside the study and provided with standard clinical care. Prescriptions 
for treatment will be provided by pharmacist prescriber.  
Each time that patients pick up their medication from the pharmacy, a daily log is 
completed, recording any occurrence of side-effects or adverse events. 
Participants who do not attend the pharmacy for seven consecutive days will be 
discontinued from the study since they will be deemed to have discontinued their course 
of DAA treatment and will have had their OST prescription suspended. 
Participants are likely to be retained within the study through the mechanism of daily 
attendance for receipt of supervised OST; this is a powerful mechanism making people 
return to the pharmacy.  It is intended that data will still be collected on participants who 
may not complete their course of treatment, since partial completion may produce an SVR 
also. 
The primary study outcome (SVR 12 weeks after treatment completion) is assessed by 
DBST in the pharmacies for both study arms. 
Outcomes and measures 
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The denominator for the outcomes on treatment uptake is the number of people using 
OST at the pharmacies participating in the respective arms. For the primary outcome, the 
numerator will be the number of patients with Sustained Viral Response at 12 weeks post 
treatment completion (SVR12) after allocation to treatment arm, measured through a test 
for the presence of HCV RNA (polymerase chain reaction). 
For the secondary outcomes on treatment uptake, the numerators are the number of 
patients who (a) undergo HCV testing, (b) initiate HCV treatment, (c) complete the 12-
week HCV course, (d) number of patients with SVR at 12 months (to assess the impact of 
potential reinfection). 
Study schedule 
For both arms, screening for HCV by DBST is undertaken prior to recruitment (t0); 
participant consent (t1) is followed by 8 or 12 weeks of treatment according to HCV 
genotype (t12), 12 weeks post-treatment a final SVR test is taken to determine the study 
outcome (tendpoint) 
Sample Size: 
Approximately 22,000 patients are prescribed OST across Scotland [26]. Around 85% of 
these patients receive daily or regular supervision of their OST consumption through one 
of the 1200 community pharmacies. It is expected that at least 40% of these patients will 
be infected with HCV, and that around 46% and 48% of infections will be with Genotype 
1 and Genotype 3 respectively [9]. The pharmacies acting as cluster sites for this trial 
have around 1,800 patients attending for supervised OST administration. Sixty 
community pharmacies based around 5 study sites within Scottish NHS Boards, will be 
coordinated through the Tayside Clinical Trials Unit (TCTU) of the Tayside Medical 
Science Centre, University of Dundee. 
As the pharmacy-led pathway is a specific population-based intervention, the number of 
patients on OST treatment at each pharmacy will be the denominator for calculating 
DBST uptake. The HCV infection status of all the OST patients in the denominator 
population is not known. National data repeatedly shows approximately 40% of Patients 
on OST are HCV positive, as this is a randomised trial it can be assumed that the rate of 
HCV positivity in the OST patients/pharmacies randomised to the pathways should be the 
same. The study will be powered through rates of HCV therapy offered. Approximately 
3% of HCV positive OST patients enter HCV therapy per year via conventional 
pathways, with 2.5% of the total eligible population achieving SVR per annum. If it is 
estimated that the new pathway increased this to 15%, a sample in each arm of 141 (2N = 
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282) will give 90% power at the significance level. The clustered design requires inflation 
to account for intracluster correlation, so if the average infected subjects per pharmacy is 
12, the Inflation Factor for sizes of cluster assuming an intra-cluster correlation of 0.05, is 
1. 55. This leads to a need for 2N = 437. 
The sample of 60 pharmacies with an average of 30 OST patients per pharmacy gives 
1800 OST patients, assuming 40% HCV positive, gives 700 to 800 potential patients for 
study. This gives significant protection against any changes in baseline SVR success 
rates, but also against pharmacy drop-outs or local issues that prevent an enrolled 
pharmacy from participation. This is trial of a pathway so all eligible patients are the 
denominator for the power calculation, not the patients who actually enter the pathway 
and are treated. 
The randomisation of the pharmacies will be stratified by associated hub centre. The 
endpoint of the study is the effectiveness of the pathway so any drop-outs are part of the 
study outcomes, so there is no need to increase the sample size to allow for a dropout rate.  
DATA COLLECTION, MANAGEMENT AND ANALYSIS 
Analysis of the trial will follow the principles outlined in the ICH E9 ‘Statistical 
Principles for Clinical Trials’ and carried out by the UKCRC registered Tayside Clinical 
Trials Unit (TCTU). Prior to data lock an agreed Statistical Analysis Plan (SAP) will be 
finalised covering the pre-specified statistical analysis.  
The primary outcome of SVR will be assessed as a binary outcome for subjects and so 
will utilise logistic regression modelling. The numerator will be the number of subjects 
achieving SVR at 12 weeks and the denominator will be total number of patients using 
OST and having an HCV infection diagnosed at the participating pharmacies. 
Additionally results will be expressed as a proportion of the estimated HCV infected 
subjects on OST. The estimated number of infected patients will be based on national 
survey data and the empirical rate discovered in the trial (allowing for patients who refuse 
testing). In order to account for the clustered nature of the trial, a mixed-effects logistic 
regression model will be performed with the parameter indicator of trial arm in the model 
and a random parameter to account for within cluster correlation as well as stratified by 
hub. As all patients will have either achieved SVR or not and we will assume that drop-
outs / lost to follow-up are failures, there will be no missing data in the primary outcome. 
Extra- binomial variability or over-dispersion will be examined in the logistic model and 
if present alternative modelling such as negative binomial models will be considered. 
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This will also be adjusted by therapy and genotype; the two factors are interdependent 
determining length of therapy. 
Secondary binary outcomes - will be analysed in the same procedure, initially as intention 
to treat with all eligible patients as the denominator and then to explore the steps in the 
pathway by per protocol analysis in particular to analyse on treatment success:  
Proportion of HCV tested: within the duration of the study of those attending pharmacy 
sites for OST, for the conventional and for the pharmacist-led arm 
Proportion that initiate HCV treatment within the duration of the study of those identified 
with HCV, for the conventional and for the pharmacist-led arm.  
Proportion that complete the course of those initiating treatment: Multiple logistic 
regression modelling will explore the patient and pharmacy characteristics that are 
associated with the secondary outcomes and primary outcome. Patient outcomes 
considered will be: 
-age 
-gender 
-deprivation,  
-employment,  
-co-morbidity, 
-psycho-social variables assessed. 
 
Pharmacy characteristics considered will be: 
-geographic location 
-type of pharmacy service 
-size of OST population. 
Determination of re-infection: As the determination of possible re-infection is an 
important and stated secondary outcome in this study, all patients will be invited to 
consent for a further DBS HCV PCR one year after end of therapy or at end of the study, 
whichever is first. Those patients who achieve SVR will be invited to participate at their 
pharmacy.  People prescribed Opioid Substitution Therapy (OST) are retained in the 
service for many years, since their progress of recovery and becoming drug-free is slow. 
In addition, movement out of Dundee, which is relatively geographically isolated, is 
minimal. We are therefore confident that we can identify all patients still in receipt of a 
prescription for OST and invite them to be re-tested for Hepatitis C.  Since the network of 
pharmacies providing OST, are also trained to provide testing, we believe this is feasible 
185 
 
Data management 
An EXCEL database will be used to hold the study related data. This will be managed and 
controlled by the coordinating pharmacist in NHS Tayside with site specific data being 
transcribed from a paper Case Report Form (CRF) formulated in line with the EXCEL 
database, with the study protocol and in line with the requirements of the investigators. 
Development and validation of the study database, quality control and extraction of data 
will be done according to study sponsor procedures. Extracts for analysis will be based on 
the data tables provided by the study team. 
Health Economic Assessment 
Economic analysis will be undertaken alongside the trial, utilizing the costs, resource use 
and effectiveness data generated within the trial. The number of SVRs achieved at the end 
of the trial will be combined with the cost data to calculate the incremental cost per cure.  
A longer term analysis incorporating the cost and benefits of potential lifetime gains 
through citizenship will be undertaken. 
Qualitative Assessment 
The qualitative research will take the form of a process evaluation building on previous 
exploratory and preparatory work (22). It will contribute to the assessment of the 
feasibility and acceptability to service users and providers of a pharmacy-led testing and 
treatment pathway (including identification of barriers and facilitators and unintended 
consequences of participation). 
Interviews will be conducted with small samples of (i) consenting study participants and 
(ii) professionals providing the pharmacist led pathway by researchers at University of 
Dundee.  
Qualitative interviews will be conducted with consenting participants and professionals 
using semi-structured topic guides developed in line with the research aims. Topics will 
not be explored in a prescriptive manner but as part of an open discussion. This flexible 
format will enable additional salient topics and insights to emerge. In broad terms, the 
focus for the different respondent groups will be as follows: 
One-to-one interviews with consenting participants (all of whom have engaged with the 
service) will explore views on issues around the delivery and promotion of the 
pharmacist-led pathway, their response to the offer and delivery of treatment, and any 
unintended consequences.  
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Interviews with professionals will explore issues around implementation of the 
intervention and the trial elements, identify challenges and ways they have been 
overcome, and perceived response among participants. 
With the interviewee’s consent, all interviews and focus group discussions will be 
recorded as digital audio files, which will then be transcribed in full for thematic analysis. 
Transcripts will be organized using a thematic framework based on topics specified in the 
topic guide and emerging themes identified through a process of familiarization with 
transcript texts. 
Patient and Public Involvement 
In developing the research question and outcome measures for study, pilot work was 
undertaken using focus groups of people prescribed OST and their carers’, to explore 
their experiences of using community pharmacies [19].  The priorities and experiences of 
people prescribed OST were further evaluated through a discrete choice experiment, 
which was used to aid the design of the pharmacy-led pathway [20]. A process evaluation 
was employed as part of the development of the DBST intervention in pharmacies, where 
recipients were asked about their experiences and preferences for testing for hepatitis C 
[21]. The process evaluation approach was also repeated as part of a feasibility study in 
which the assessment and treatment of hepatitis C in this group was piloted, to further 
understand how the intervention would be accommodated by participants [22].  The 
information gained from this exercise has been fed back to groups of service users 
attending the local community support and harm reduction centre.  Patients have not been 
involved in the recruitment to this study 
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DISCUSSION 
Liver disease has become a major cause of premature death in the developed world and 
HCV is a major contributor to this burden [27]. The care of people infected with HCV 
therapy has undergone a paradigm shift due to the efficacy of direct acting antiviral drugs 
and the consequent simplification of therapy, with highly effective treatment choices 
marketed across the world [28]. However, new and more effective pathways of care are 
urgently required in order to enhance testing and linkage to care and treatment [16]. 
These novel pathways of care need to be carefully evaluated both for efficacy and cost-
effectiveness compared to traditional pathways, as well as for unintended consequences. 
This pragmatic, cluster-randomised trial can provide strong evidence of the effectiveness 
of a pharmacist delivered care pathway for HCV eradication therapy in patients receiving 
OST. A comparison will be undertaken with the current clinical care pathway where 
patients are referred to a conventional clinic to receive their HCV treatment.  Trial design 
has aimed for high applicability in design decisions [24] and this trial is expected to 
directly inform the future organisation of care. 
Ethics and Dissemination 
The study will be conducted in accordance with the principles of good clinical practice 
(GCP). 
In addition to Sponsorship approval, approval was received for this study (15/ES/0086) 
from East of Scotland Research Ethics Committee 2 on 27 May 2016. Caldicott guardian 
approval was given on 16 December 2016 to allow NHS Tayside to pass information to 
the cluster community pharmacies about the HCV test status of patients that they are 
seeing to provide OST supervision. NHS R&D approvals have been obtained from each 
health board taking part in the study. 
Harms 
Regular follow up of the participants will occur daily in the DOT arm during the study 
treatment period by a pharmacist familiar in the trial methodology. For those participants 
allocated to the conventional therapy, regular clinical follow up will occur in line with 
prevailing conventional NHS standard of care. At each visit participants will be 
monitored for expected Adverse Events (AEs) as per the Summary of Product (SmPC) 
characteristics for the drug treatments used in this study. This is in line with the current 
standard of care for the NHS and only AEs outside these criteria will formally be 
recorded as Adverse Events 
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Bloods for viral load would be performed as outlined in the Study Schedule, at the pre 
treatment visit and at 12 weeks post completion of therapy, as per the attached study 
schedule. Data on testing, referral, initiation of (and adherence to), therapy are routinely 
collected for the HCV clinical data base and these data will also be utilised.  
In addition baseline and end of treatment checking of prescribed and non-prescribed 
medications and drug use, as documented in the study concomitant medications log, will 
be carried out to investigate the relationship between any adverse events and drug 
interactions. 
Consenting Participants 
Potential participants will be approached by pharmacy staff familiar with the trial 
methodology and trained in Good Clinical Practice. They will be provided with 
information on the study verbally and via the Patient Information Sheet (PIS) and be 
given at least 24 hours to consider participation. 
At their return visit for screening they will be interviewed by the study pharmacist and 
asked to sign an informed consent form, once they are satisfied that they have had 
adequate explanation from the pharmacist explaining the trial to them. 
Confidentiality 
The data will be collected by the researcher (treatment delivering pharmacist or nurse) on 
a paper CRF with subsequent transcription to electronic CRF. Electronic storage will be 
in an encrypted form on a password protected device. The medical notes will act as 
source data for past medical history & blood results 
All laboratory specimens, evaluation forms, reports, and other records will be identified 
in a manner designed to maintain participant confidentiality. All records will be kept in a 
secure storage area with limited access to study staff only. Clinical information will not 
be released without the written permission of the participant, except as necessary for 
monitoring and auditing by the Sponsor or its designee. The CI and study staff involved 
with this study will not disclose or use for any purpose other than performance of the 
study, any data, record, or other unpublished, confidential information disclosed to those 
individuals for the purpose of the study. Prior written agreement from the Sponsor or its 
designee will be obtained for the disclosure of any said confidential information to other 
parties. 
 
Data Protection 
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The CI and study staff involved with this study will comply with the requirements of the 
Data Protection Act 1998 with regard to the collection, storage, processing and disclosure 
of personal information and will uphold the Act’s core principles. The CI and study staff 
will also adhere, if appropriate, to the current version of the NHS Scotland Code of 
Practice on Protecting Patient Confidentiality. Access to collated participant data will be 
restricted to the CI and appropriate study staff. Computers used to collate the data will 
have limited access measures via user names and passwords. Published results will not 
contain any personal data that could allow identification of individual participants. 
Trial Organisation 
Trial management 
Overall management of the trial is being provided by the Tayside Clinical Trials Unit 
(TCTU), a UK Clinical Research Collaboration (UKCRC)-registered clinical trials unit. A 
study Clinical Trial Manager supported by a Study Coordinator will oversee the study and 
will be accountable to the Chief Investigator (CI). They will be responsible for checking 
the Case Report Forms for completeness, plausibility and consistency. However, this  
remains the overall responsibility of the CI. Any queries will be resolved by the CI or 
delegated member of the study team.  
A study-specific Delegation Log will be prepared for the study at each site, detailing the 
responsibilities of each member of staff working on the study.  
A Trial Steering Committee will be established to oversee the conduct and progress of the 
study. The Steering Committee will include the investigators above, as well as the NHS 
Tayside Director of Pharmacy and a representative from the Chief Pharmaceutical 
Officers Team at the Scottish Government. The Steering Committee will take all 
executive decisions. The responsibility of the Steering Committee is to ensure the 
scientific integrity and quality of the project. To achieve this, the specific responsibilities 
of the Steering Committee include: maintaining adherence to the study protocol; 
approving changes to study protocol if required; reviewing quality assurance indicators; 
monitoring study recruitment and the overall study timetable; advising, as required, on 
specific scientific items that may arise; compliance with legislation; adherence to research 
governance; reporting to funders; approving publication and dissemination strategies. The 
Steering Committee will meet every 6 months. 
Trial Status 
Recruitments commenced in December 2016. On 9 October 2017, 234 were consented to 
the trial. 
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Reporting guideline: SPIRIT 2013 statement: defining standard protocol items for clinical 
trials  
http://annals.org/aim/article/1556168/spirit-2013-statement-defining-standard-protocol-
items-clinical-trials  
The references to this paper are located in the manuscript provided in Appendix 9.6 
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5.3 Clinical effectiveness of pharmacy-led versus conventionally 
delivered antiviral treatment for Hepatitis C in patients receiving opioid 
substitution therapy: a pragmatic cluster randomised trial 
The following paper is a verbatim copy of Radley A, de Bruin M, Inglis SK, Donnan PT, 
Hapca A, Barclay ST, Fraser A, Dillon JF (Prepared for submission to The Lancet 
Gastroenterology and Hepatology February 2020) 
SUMMARY 
Background: Highly-effective direct acting antiviral drugs (DAAs) provide the 
opportunity to eliminate Hepatitis C (HCV) infection. This study examined whether a 
community pharmacy pathway increased HCV testing, treatment uptake and completion, 
and cure rates for people receiving opioid substitution therapy (OST), compared to 
conventional care. 
Methods: This cluster randomised trial was performed in 55 community pharmacies with 
patients receiving OST. Pharmacists either referred patients with evidence of HCV 
antibodies to conventional care (27 pharmacies) or treated them in the pharmacy (28 
pharmacies). All pharmacies offered dried blood spot testing (DBST). In the pharmacy 
arm, infection with HCV genotype 1 or 3 was confirmed, assessment bloods were taken, 
and DAAs were prescribed by a pharmacist. In the control arm, the patient received care 
outside the pharmacy. Once prescribed, medication in both arms was delivered as daily 
modified directly observed therapy alongside OST. The primary outcome was number of 
sustained viral responses 12 weeks (SVR12) after treatment completion compared to total 
number of people receiving OST treatment at the participating pharmacies. Trial 
registration: NCT02706223. 
Findings: More OST users in the pharmacy arm versus the conventional care arm agreed 
to DBST (245 vs 145, OR 2∙292, 0∙968-5∙427, p=0∙059); more patients diagnosed with 
HCV, initiated (112 vs 61, OR 1∙889, 1∙276-2∙789, p=0∙0015) and completed treatment 
(108 vs 58, OR 1∙928, 1∙321-2∙813, p=0∙0007); more patients achieved the primary 
endpoint SVR in the pharmacy arm compared to the conventional arm (98 vs 43, OR 
2∙375, 1∙555-3∙628, p< 0∙0001).  
Interpretation: Transferring the primary responsibility for initiating HCV care to 
pharmacists, and increasing convenience of HCV testing and treatment initiation for OST 
users, could be an important strategy in eliminating HCV. 
Funding: Partnership between the Scottish Government, Gilead and Bristol Myers-Squib. 
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INTRODUCTION 
Hepatitis C (HCV) is a blood-borne viral infection causing liver disease. The world-wide 
burden of HCV infection has been estimated as 71∙1 million infections (62∙5—79∙4).1 In 
developed countries, people who inject drugs (PWID) are the group most commonly 
infected with HCV infection and around 10 million or 60% of PWID have been infected 
worldwide.
2
 It has been estimated that 80% of HCV infections are caused by inject ing 
drug use in Western Europe.
3
 In current HCV testing and treatment pathways within the 
United Kingdom, only a small proportion of those who had a positive HCV test had 
evidence of ever receiving treatment (11∙9%) and a smaller number were demonstrated to 
have achieved a sustained virological response (SVR) (5∙9%).4 
The conventional care pathway in the United Kingdom recommends that patients with a 
history of intravenous drug use, or those currently prescribed OST, should be offered 
HCV testing annually. Testing may be available from their GPs, drug workers, drug 
agencies, social workers, community pharmacies and needle exchanges. Once diagnosed, 
patients can be referred to established treatment pathways, usually based around 
hepatology or infectious disease teams in secondary care.
5
 The inefficiency of established 
treatment pathways with many patients lost from care, leads to increased preventable 
deaths from HCV and viral transmission within the injecting population.
6
 
A variety of reasons may explain the low rates of HCV testing, treatment uptake, and 
treatment completion. At the patient level, PWID may encounter a number of barriers that 
prevent them from accessing care, including perceptions or experience of stigma and 
discrimination, issues with the organisation of care and the treatment policies of providers 
or payers.
7
 Low levels of health literacy may also limit understanding of their health, 
illness and treatments; and PWID may find it difficult to consistently attend medical 
clinics.
8, 9, 
Hence, simplifying care pathways to enable treatment initiation and clinical 
monitoring, and close treatment supervision in a familiar and convenient setting may be 
effective in overcoming these barriers.
8
 Offering HCV care in primary care and 
community settings may increase uptake of treatment whilst maintaining high rates of 
cure.
6
 
In the United Kingdom, PWID on OST receive treatment regularly from their local 
community pharmacy.
10
 Patients therefore visit pharmacies much more often than 
secondary care sites and pharmacies may be located nearer to areas of socio-economic 
disadvantage, have longer opening hours and can be accessed without an appointment. 
Pharmacy staff may be trained to offer Dry Blood Spot Testing (DBST) to screen for 
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HCV infection. Whereas in conventional care, following a positive HCV antibody test, 
patients are referred onwards to a secondary care site, the opportunity to provide all 
diagnostic and treatment prescription services from the pharmacy may represent a much 
more convenient and non-threatening route to HCV treatment for PWID on OST. 
Moreover, at the pharmacist level, having primary responsibility for HCV testing and 
treatment; and being able to offer potential HCV patients a more convenient and 
acceptable treatment pathway, could enhance pharmacists’ motivation and effort to recruit 
patients to the pathway.  
The World Health Organisation (WHO) has set targets to eliminate HCV as a public 
health threat by 2030.
11
 Creating the complex public health interventions necessary to 
eliminate HCV needs well-designed cross-disciplinary programmes put in place to 
increase screening, testing and diagnosis.
12
 Strategies advocated to increase linkage to 
care include integration with other services, decentralisation to primary care providers 
and task-shifting to non-specialists.
6
 
The current pragmatic, cluster-randomised trial was designed to evaluate whether a 
pharmacy-led pathway compared with conventional care, increases HCV testing, 
treatment uptake and completion, and ultimately cure rates for the population of OST 
recipients infected with HCV.  
Evidence before this study 
Direct-acting antiviral drugs (DAAs) have a much higher cure rate for HCV than previous 
medication regimes containing interferon and ribavirin and a much lower treatment 
burden and monitoring requirement. Consequently, DAAs have mostly replaced these 
older drugs in current practice and these simple treatments are advocated by the World 
Health Organisation as a key tool in the elimination of HCV by 2030. Guidance on the 
prevention, care and treatment of people with HCV recommends task-shifting to optimise 
available human resources and decentralisation of care to places where people with HCV 
infection already visit, so that the scale and reach of provision can be increased to achieve 
elimination. DAAs may be delivered in the community by affiliated care professionals 
including pharmacists. We undertook a systematic review and meta-analysis of 
community-based treatment pathways and identified 17 studies demonstrating that locally 
delivered care is feasible and can deliver increased uptake of treatment. Such clinics may 
be able to demonstrate similar cure rates to those achieved by specialist clinics in 
secondary care. However stronger study designs comparing community pathways with 
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specialist care are needed to give more certainty about the effect size seen in current 
studies.  
Added value of this study 
This cluster randomised controlled study demonstrates that pharmacists are more likely to 
recruit patients to the HCV care pathway, and that patients are more likely to engage with 
and complete treatment, when the entire process of diagnosis and treatment is offered in 
the pharmacy. There was no evidence of disadvantageous effects, such as lower treatment 
completion rates 
Implications of all the available evidence 
Transferring the primary responsibility for HCV diagnosis and treatment to community 
pharmacies, is likely to increase HCV uptake and cure rates. It may be that this 
intervention could play an important role in the test-and-treat approach in order to 
eradicate HCV. Such services are in line with the WHO guidance for decentralisation of 
service delivery to primary care-based sites and of task-sharing. Close working between 
specialist teams and community and primary-care providers may thus offer an effective 
option for combating HCV in this patient group and moving towards elimination of HCV. 
METHODS 
Study design and participants 
This is a cluster randomised controlled trial comparing HCV care pathways for patients 
receiving OST in community pharmacies, conducted in 55 community pharmacies in 3 
Health Boards. Ethics approval granted by East of Scotland Research Ethics Committee 2 
(15/ES/0086), sponsor, research & development and Caldecott approvals by University of 
Dundee, NHS Tayside, NHS Grampian and NHS Greater Glasgow and Clyde. The 
protocol, has been published elsewhere. 
13
. 
The unit of randomisation in the trial was the eligible pharmacies. These were 
community-based, could offer DBST for HCV by trained pharmacy staff and had around 
30 or more patients attending to receive OST, to ensure adequate recruitment. Within 
those pharmacies, all patients on OST were considered to be included in the trial. Those 
eligible for receiving treatment in the pharmacy care pathway, had to be HCV Polymerase 
Chain Reaction (PCR) positive, infected with HCV genotype 1 or 3, using OST and 
willing to have a pharmacist supervise their antiviral drug administration. Patients were 
ineligible for receiving treatment in the context of this trial if they had a HCV genotype 
other than 1 or 3, evidence of current or previous decompensated liver disease, Human 
Immunodeficiency Virus (HIV) infection, surface antigen of Hepatitis B Virus (HBV) 
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HBsAg positive with detectable HBV DNA, aggressive or violent behaviour towards  
pharmacy staff, being pregnant, and not being able to provide informed consent.  
Randomisation 
Prior to the start of recruitment, pharmacies were randomised into conventional care 
(group 1) or pharmacist-led care (group 2) using http://www.randomization.com (by 
SKI). Neither pharmacists nor patients were blinded to treatment allocation, as knowledge 
of the intervention provided was considered to be elementary to entering the pathway, 
i.e., undergoing HCV testing and initiating HCV treatment. 
Procedures 
Prior to trial initiation, Good Clinical Practice training was provided to all pharmacies 
participating in the study. In addition, training was provided on testing for blood borne 
viruses, the interpretation of laboratory bloods, Fib4 calculation to assess risk of cirrhosis. 
HCV and its treatment. 
14
 
Once the trial commenced, pharmacists in the conventional care pathway 
opportunistically discussed HCV infection with OST patients attending the pharmacy. 
Those with unknown HCV status or previous negative results could be offered test ing 
using a DBST in the pharmacy. Those recently or previously identified as having HCV 
were provided with an information leaflet explaining that their pharmacy was 
participating in a study, asking them to consent to having their data collected. They also 
received a post-test discussion with the pharmacist using a standard infographic 
(supplementary file 1) and were offered referral to a treatment centre. When the patient 
attended an appointment at a treatment centre, a member of the specialist hepatitis team 
undertook an assessment for treatment for HCV as per standard of care. Assessment 
comprised of medical history, concurrent medication and assessment bloods including full 
blood count, urea and electrolytes, liver function testing and viral parameters (genotype 
and load). Prescriptions for DAA treatment were provided by a nurse prescriber and 
dispensed at the participant’s community pharmacy.  
Similar to the conventional pathway, in the pharmacist-led pathway, pharmacists 
opportunistically discussed HCV infection with OST patients attending the pharmacy, 
offering DBST testing, and communicating the possibility of receiving DAA treatment to 
those tested positively (including patients tested positively on a previous occasion, but 
who had not undergone treatment) in the pharmacy. People identified as being HCV 
antibody positive consented to receiving their treatment from the pharmacist rather than 
conventional care, and for their data to be collected. In the pharmacy-led pathway, the 
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pharmacist assessed the participant for treatment, solely within the pharmacy. They 
completed a pre-treatment checklist of medical co-morbidities, took a medicines history 
and identified factors likely to impinge on treatment compliance. A visit from a 
peripatetic phlebotomist or nurse was arranged in the pharmacy for assessment blood tests 
and the pharmacist determined suitability for treatment. Where there were no contra-
indications to therapy, the patient commenced treatment. In patients where there were 
identified contraindications or queries about suitability, the pharmacist contacted the 
specialist hepatitis team for advice. Potential participants with a FIB-4 score of >3.25 
were referred to a hospital consultant. Prescriptions for treatment in the pharmacist -led 
pathway were provided by a pharmacist prescriber or through use of a patient group 
direction. 
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The anti HCV treatment provided in both pathways was sofosbuvir/ledipasvir for 8 weeks 
in genotype 1 infections and sofosbuvir and daclatasvir for 12 weeks in genotype 3 
infections. The DAA dose was administered concurrently with supervised OST treatment 
by the participant’s pharmacy, who observed consumption (modified directly observed 
therapy). In both arms of the study DAA treatment was delivered jointly with OST in 
their normal pharmacy; although at weekends, patients usually self-administered. For 
doses that patients self-administered, the pharmacist and patient made a brief if-then 
action plan (an implementation intention) and coping plan (to overcome anticipated 
barriers). 
16
 
Daily monitoring was undertaken at the pharmacy, recording any occurrence of side-
effects or adverse events. Participants who did not attend the pharmacy for seven 
consecutive days had treatment discontinued. Fidelity of the intervention in both arms  
was promoted through standardised training and concurrent support from the study 
coordinators. Any breaches of protocol were reported to the Sponsor. A comparison of the 
pathways is illustrated in Figure 1 and a comparison of patient and pharmacist behaviours 
illustrated in Figure 2. 
Outcomes  
The Primary Outcome of the study was the rate of sustained viral response at 12 weeks, 
(SVR12) in the pharmacist-led pathway compared with that of the conventional pathway 
12 weeks after completion of HCV therapy, over the total number of patients on OST in 
each treatment arm (denominator). 
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Secondary outcomes assessed key points on treatment pathway, using the care cascade 
convention. 
17
 These were comparison of rates of DBST testing between the pathways, 
DAA treatment initiation, and DAA treatment completion.  
Statistical analysis 
The primary analysis was undertaken at the individual level using the intention-to-treat 
principle. Sample size calculations assumed that approximately 3% of HCV positive OST 
patients enter HCV therapy per year via conventional pathways, with 2.5% of the total 
eligible population achieving SVR per annum. If it is estimated that the new pathway 
increased this to 15%, a sample in each arm of 141 (2N=282) will give 90% power at the 
significance level. The clustered design requires inflation to account for intracluster 
correlation, so if the average infected subjects per pharmacy are 12, the inflation factor 
for sizes of cluster, assuming an intra-cluster correlation of 0.05, is 1.55. This leads to a 
need for 2n=437. The analysis was verified by an independent statistician. 
The primary outcome of SVR was assessed as a binary outcome for subjects and utilised 
logistic regression modelling in STATA. An intention treat analysis was used, so all 
missing SVRs were assumed treatment failures, thus there was no missing data in the 
primary outcome. The numerator was the number of subjects achieving SVR at 12 weeks 
and the denominator was the number attending for OST, since this represents the 
population at risk of infection and not all patients had been tested. In post hoc analysis an 
estimated number of infected patients was also used based on national survey data 
18
. In 
order to account for the clustered nature of the trial, a mixed-effects logistic regression 
model was performed with the parameter indicator of trial arm in the model and a random 
parameter to account for within-cluster correlation as well as stratified by hub. 
For the secondary outcomes on treatment uptake, the numerators were the number of 
patients who (a) undergo HCV testing, (b) initiate HCV treatment, (c) complete the 8 
or12-week HCV course, (d) number of patients with SVR at 12 months (to assess the 
impact of potential re-infection). Secondary binary outcomes have been analysed using 
the same procedure, initially as intention to treat with all eligible patients as the 
denominator and then to explore the steps in the pathway by per protocol. Post hoc 
analysis was performed to investigate attrition rates at individual steps, where they were 
similar between the two pathways, to explore any differences in patients’ behaviours once 
they had reached that stage. 
Role of the funding source 
198 
 
The funders of this study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. All authors had full access to all data in the study 
and the corresponding author had final responsibility for the decision to submit for 
publication. 
 
RESULTS 
Between 9 December 2016 and 31 May 2018, there were 2718 opioid substi tution therapy 
(OST) recipients attending the 55 study pharmacies (intervention n=28 and control n=27). 
This total number is used as the denominator for the primary outcome analysis.  
Detailed information is only available for those who consented to have data collected 
when they elected for therapy: this was a total of 356. The remaining 2,362 OST 
recipients would be those; HCV negative, previously treated or who declined testing. To 
our knowledge no eligible patients were treated outside the trial. All patients previously 
had the opportunity to access HCV treatment via other pathways prior to the trial. 
Evidence of HCV infection was required to enter treatment. This was already available 
for many patients, but the availability of treatment stimulated additional testing. 
Treatment effects along the pathway: from diagnosis to cure 
With regard to the uptake of HCV testing in the treatment arms (secondary outcome), we 
observed that 245 DBST (77 antibody positive) were conducted in the pharmacist -led arm 
and 145 (31 antibody positive) in the conventional pathway (Odds Ratio 2∙292, 0∙968-
5∙427). In total, 356 (137 in the conventional care pathway and 219 in the pharmacy-led 
pathway) newly diagnosed patients, and previously diagnosed patients who did not opt for 
treatment in the pre-DAA era, consented to receiving DAA treatment after being 
approached by their pharmacists (OR 1∙696, 1∙350-2∙131, p<0∙0001). Sixty-one 
participants consecutively initiated treatment in the conventional care arm and 112 
initiated treatment in the pharmacist-led pathway (secondary outcome, OR 1∙889, 1∙276-
2∙789, p=0∙0015). Treatment initiation rates amongst those consenting to treatment was 
very similar in both treatment arms (61/137 (44∙5%) for the conventional and 112/219 
(51∙1%) for the pharmacy arm.  
A total of 58 and 108 participants completed treatment in the conventional and pharmacy 
arm, respectively (OR 1∙928, 1∙321-2∙813, p=0∙0007). Treatment completion rates 
amongst those who initiated treatment, where again very similar between treatment arms 
58/61 (95∙0%) for the conventional and 108/112 (96∙4%) for the pharmacy arm.  
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Forty-three participants demonstrated SVR12 in the conventional care arm compared to 
98 in the pharmacist-led arm (OR 2∙375, 1∙555-3∙628, p<0∙0001) (Table 1, Figure 3). 
There were two treatment failures in each arm. Of the treatment completers, twelve 
participants did not attend for an SVR12 test in the conventional care arm and six 
participants did not attend for an SVR test in the pharmacy-led arm (two patients died 
from unrelated causes). One participant in the conventional arm and two participants in 
the pharmacy-led arm attended for an SVR12 test, but had an insufficient sample taken to 
complete the PCR test.  
One participant in the pharmacy-led arm withdrew after assessment before initiating 
therapy because of pregnancy. One pharmacy-led participant was discontinued from 
treatment due to missing seven consecutive days of therapy. Five participants dropped out 
during treatment (3 conventional care arm, two pharmacy led arm) through personal 
choice. During the study no serious adverse events (SAEs) were identified.  
We would assume that patients completing treatment, but not achieving a confirmatory 
test would also have attained an SVR, given the high cure rates amongst treatment 
completers and the provision of directly observed therapy as part of the intervention. 
There were larger numbers of participants not attending for a confirmatory test in the 
conventional arm. 
Additional participant characteristics  
Detailed patient information was collected for those who consented to have additional 
data collected, which was asked when HCV positive OST users elected to initiate HCV 
therapy (n=356). The remaining 2,362 OST recipients were HCV negative previously 
treated or who declined testing. Assessed characteristics of the consented cohorts were 
similar between groups of pharmacies (Table 2) and participants except for genotype, 
where the pharmacy-led arm had more genotype 3 patients (Table 3). Data on 
recruitment, testing, initiation and completion of treatment and gaining of an SVR 12 by 
site is shown in Table 4. 
DISCUSSION 
This study presents evidence that pharmacies can provide a clinically effective pathway 
for testing and treatment of HCV, as demonstrated by an adequately powered cluster 
randomised controlled trial. In a population that had been exposed to multiple testing and 
treating opportunities over a number of years, with a high proportion of the HCV infected 
population already treated 
19
, the pharmacist-led pathway brought more people on OST 
into HCV treatment. This was achieved through both diagnosing patients who had 
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previously never been tested, as well as initiating therapy in the newly diagnosed and 
those previously diagnosed who had not been initiated into treatment.  
Our intervention development work demonstrated that being treated with respect was of 
prime importance to recipients of care, and that experience of stigma and discrimination 
in healthcare systems was widespread. 
20, 21
 At each point in the care pathway, the 
pharmacist-led pathway provided advantages in terms of the retention in care. Using 
community pharmacies as the focal point of this intervention enabled a number of the 
identified barriers to care to be overcome. Their local nature and the longi tudinal trusting 
relationships formed between the pharmacies and people attending for OST was an 
important factor in encouraging engagement. These established relationships may have 
overcome perceived and real barriers to care, caused by the stigma and discrimination 
experienced by the group. The on-site delivery of the intervention also enabled 
participants experiencing poverty and with low health literacy to engage in care. The 
familiarity of the local community setting may have increased willingness to engage in 
the intervention with fewer barriers preventing attendance: less difficulty in managing to 
attend and finding money to travel 
8, 9
, and fewer problems with navigating the health 
system. 
22
 Evidence from the feasibility trial confirmed that a significant loss to follow-up 
occurred when participants were asked to attend for phlebotomy outside of the local 
pharmacy. 
23
 Since the pharmacist-led intervention was based around the delivery of 
OST, participants had a strong incentive to attend. 
The cure rates achieved in the pharmacy-led arm for both the diagnosed population (45%) 
and notional population of infected individuals (18%) compare favourably with the 
outcomes reported for other pathways (12%, 6%). 
4, 24
 The conventional care arm in this 
study is described as standard of care, which it is in Scotland. However, this pathway 
represents a gold standard pathway of care for HCV infected OST patients compared to 
conventional secondary care based models. 
Testing for HCV was not part of the trial and was already routinely available in some 
pharmacies before the study; all pharmacies had to develop a testing service to 
participate. The study clearly reached people who had not been previously engaged in 
HCV care, despite other testing opportunities being available, as recommended in all 
guidelines and by all health services they interact with. The observed increased uptake of 
treatment may reflect the convenient co-location of testing and OST pickup to the patient, 
but equally may be due to the financial incentivisation of the pharmacist by the item of 
service mechanism established in the United Kingdom National Health Service. In the 
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study treatment pathway there were two very noticeable drop-offs in the cascade of care: 
initial consent to participation and initiation onto treatment; thereafter there was with 
little drop off to cure. At the point of considering treatment, both the patient and the 
pharmacist know whether further care in the pharmacy or referral to another site and other 
health care professionals is available. The pharmacist led pathway was significantly more 
likely to lead to treatment initiation. The reasons behind this could be pharmacist related: 
they are more motivated to recruit as they would be having a new therapeutic experience 
and will also be financially rewarded. The patient related factors may include: ease of 
treatment without having to travel elsewhere; removing the fear of stigma and unknown 
situations. The second drop off in the cascade of care is at initiation of treatment. In the  
pharmacist-led arm, this means that blood tests have been taken, but in the conventional 
arm, this means that the participant must have travelled elsewhere to meet with a nurse. A 
greater drop off at this point is again observed in the conventional care arm despite this 
already being a more selected population. This emphasises the barrier that venepuncture 
still raises in the cascade of care, as this skill set is not widely available in many 
addictions settings; whilst many virology tests can now be done on fresh or dried 
capillary blood, the remainder need to be performed on whole blood or plasma. The 
safety of DAAs should mean that many of the routine analytes measured are no longer 
required. The only outstanding issue is fibrosis estimation which cannot be performed on 
capillary blood but can be managed with imaging modalities such as elastography.  
The study had a number of strengths. The intervention was developed iteratively and 
pragmatically using the Medical Research Council Guidance for developing and 
evaluating complex interventions. 
25
 Pilot work was undertaken using focus groups of 
people prescribed OST and the priorities and experiences further evaluated to aid the 
design of the pharmacist-led pathway 
20, 21
 A process evaluation was employed as part of 
the implementation of the DBST intervention in pharmacies and this was repeated in a 
feasibility trial. 
23
 
For pharmacy staff, the intervention was viewed as straightforward to deliver and 
integrated with an established activity. 
23
 Dried blood spot testing was within the 
competency of staff and provided advantages to participants who were reticent to allow 
venous access. 
26
 A peripatetic phlebotomist was often able to work closely with 
pharmacy staff and meet with patients; the use of DAAs meant that monitoring and 
management were straightforward; assessment of risk of cirrhosis could be achieved 
using blood tests; on-going monitoring of participants was undertaken during routine 
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attendance for OST. The failure to gain assessment bloods was the main reason for loss of 
participants after consenting before initiation, as this was the only step they had to 
perform. The recent introduction of pangenotypic treatments reduces the complexity of 
evaluation, with an assessment for fibrosis being the main requirement and further 
reduces the need for monitoring carried out in this study.
 27
  
Pharmacies lack access to a range of information sources that may be available to hospital 
clinics, meaning that a detailed medical history with evidence of health care interactions 
were not available to pharmacy staff. This proved not to be a barrier to care. Close 
working with the specialist hepatitis team meant that any queries raised by the pharmacies 
could be efficiently dealt with through e-mail or phone. These queries were considered 
during a weekly multi-disciplinary team meeting.  Pharmacies had good knowledge of 
concurrent medication. 
In Tayside, where pharmacies had been involved in testing and treating hepatitis C since 
2013, involvement in this study was unsurprising. In Glasgow and Grampian, where 
pharmacies had been less involved in these processes, the invitation to participate was 
more novel. The participants recruited from the Glasgow site were mainly individuals 
who had previously tested antibody positive but had not engaged with a treatment 
pathway. The proportion of participants recruited to the study from these sites was found 
to be less than for the Tayside sites. 
A recent systematic review has evaluated the performance of care pathways that utilise 
DAAs in a range of community and primary care settings. 
28
 The WHO Guidelines on 
care and treatment of persons diagnosed with chronic HCV infection promote simplified 
service delivery models; integration with other services; decentralised services supported 
by task-sharing and community engagement to address stigma and increase reach. 
6
The 
studies considered in the systematic review and meta-analysis identified a variety of 
locations and providers have been used to deliver care to this group of patients. These 
have included primary care; integrated health care systems; places where people who 
inject drugs (PWID) are treated; in pharmacies; and through telemedicine. These care 
pathways have been developed in acknowledgement of the need to provide local services 
with reach into the communities where people with hepatitis C live. The studies reported 
positive outcomes for uptake of treatment; completion of treatment; attainment of SVR. 
As with this study, other evaluators have noted reduced SVR12 rates because of loss to 
follow-up of patients in community settings. With DAAs SVR rates of greater than 97% 
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are delivered if patients adhere to treatment, therefore completion of therapy can be a 
surrogate for SVR. 
29
 
Other systematic reviews have considered barriers and facilitators to care, as well as the 
views and experiences of people who inject drugs. 
30, 31
 These studies concluded that the 
target groups for HCV often had poor levels of knowledge about the infection and of the 
processes involved with testing and treatment. A fear of stigma and discrimination and a 
reticence to discuss risk behaviours tended to prevent engagement.  These barriers could 
be addressed through educating participants and integrating HCV treatment pathways into 
other services where the target group were likely to go. 
This study demonstrates the advantages of developing novel care pathways targeting 
populations with high prevalence of HCV. Provision of HCV treatment in familiar 
surroundings with the additional benefit of directly observed treatment arrangement, may 
increase attainment of SVR. Achievement of these factors within local health systems 
needs to be commonplace if the WHO target for elimination is to be met.  
Reporting Guideline: Consort extension for cluster randomised trials. 
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Figure 1: Trial Profile 
56 Pharmacies Assessed for Eligibility 
Pool of 2718 OST Patients 
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12 Lost to Follow Up – No SVR 
1 Insufficient Sample DBST 
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Figure 2: Comparison of patient and pharmacist behaviours in the conventional care and pharmacist-led pathways 
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Table 1: Trial Outcomes 
Pool of 2718 OST Patients 
Odds 
Ratio 
Confidence Limit for 
Odds Ratio P value 
Lower Upper 
Conventional Care Pathway 
1353 OST patients 
Pharmacist-Led Pathway 
1365 OST patients 
    
43 SVR 12 98 SVR 12 2.375 1.555 3.628 <0.0001 
145 DBST taken 245 DBST taken 2.292 0.968 5.427 0.059 
137 Consented Participants 219 Consented Participants 1.696 1.350 2.131 <0.0001 
61 Initiated Treatment 112 Initiated Treatment 1.889 1.276 2.798 0.0015 
58 Completed Treatment 108 Completed Treatment 1.928 1.321 2.813 0.0007 
Diagnosed Population Cure Rate*     
31% 45%     
Notional Population Cure Rate+     
8% 18%     
*
Diagnosed Population Cure Rate is number achieving primary outcome (SVR12) compared to number of consented participants 
+
Notional Population Cure Rate is number achieving primary outcome (SVR12) compared to total number of potential participant  
207 
 
 
 
 
Figure 3: SuperDOT-Cascade of Care – Attrition from original cohort to SVR12  
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Table 2: Characteristics of Study Pharmacies  
Characteristics of the Study Pharmacies Conventional 
Care Arm (%) 
Pharmacy-
Led Arm (%) 
Number of OST patients at start of study N=27 N=28 
20-29 4 (15) 3 (11) 
30-39 6 (22) 13 (46) 
40-49 7 (26) 2 (7) 
50-59 6 (22) 2 (7) 
60+ 4 (15) 8 (29) 
SIMD Quintile Pharmacy Address   
 1 (most deprived) 17 (63) 14 (50) 
 2 8 (30) 7 (25) 
 3 1 (3.5) 4 (14) 
 4 1 (3.5) 1 (4) 
 5 (least deprived)  2 (7) 
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Table 3: Characteristics of consented participants 
Treated Study Participants N=61 N=112 
Age Distribution (years) 20-29 3 (5) 3 (3) 
    30-39 28 (46) 63 (56) 
    40-49 24 (39) 43 (38) 
    50-59  4 (6) 3 (3) 
    60+ 2 (3)  
Gender   Male 43 (70) 70 (63) 
    Female 18 (29) 42 (37) 
Fib-4             < 1.45 46 (75) 68 (61) 
        1.46-3.24 14 (23) 42 (37) 
     3.25 0  2 (2) 
Genotype    1 30 (49) 37 (33) 
     3 31 (51) 75 (70) 
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Table 4: Recruitment of participants between sites 
 Total Tayside Grampian Glasgow 
Recruited 356 250 80 26 
Initiated Treatment 173 137 21 15 
Completed Treatment 166 132 20 14 
Drop out during Treatment 7 5 1 1 
Drop out before Treatment 2 0 1 1 
Achieved SVR 141 113 16 12 
No SVR 4 4 0 0 
Lost To Follow Up 18 12 4 2 
Patient completed DBS error 3 3 0 0 
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5.5 Critical Reflection 
The cluster randomised trials comprising the content of this chapter were undertaken as 
the final section of work to model, establish and evaluate an intervention for testing and 
treatment in community pharmacy.  The feasibility pilot was the first opportunity to put 
all of the elements together: operationalising a research protocol; identifying potential 
sites and partners for delivering the study; designing trial documentation; designing and 
delivering training for staff at research sites; putting together site research files; 
facilitating and supporting research sites to engage and participate fully.  
The learning gained from the development and modelling work informed the decisions 
made when creating the research protocol. This work had ensured an appreciation of the 
importance of supportive relationships between the client and pharmacy and that the 
pharmacies should not be applying policies that singled out clients for different treatment. 
The process evaluation work had provided a number of additional themes to recognise, 
including an emphasis on confidentiality and the need to locate as much of the 
intervention pathway as possible in the local community, if not in the pharmacy itself.  
The waterfall plot (Figure 1) in the paper clearly shows the attrition of participants when 
they are asked to attend for an appointment at a different site. 
From a site operational perspective, the learning had been that a pharmacy team delivered 
the intervention more effectively than when a single person undertook the study. For this 
reason, we offered training to teams rather than individuals and offered multiple training 
days, to encourage as many people as possible to attend. The pharmacy site staff required 
training in Good Clinical Practice, to ensure good research governance.  The study days 
incorporated a series of theoretical and practical sessions to apply knowledge and develop 
clinical skills, since many of the training participants had not previously take blood 
samples for blood borne virus testing and had not interpreted laboratory tests.  
The main obstacle to initiating the study was the need to obtain a contract agreement with 
the pharmacy companies, who each had different approval procedures and governance 
requirements to be met. Meetings these requirements meant that delays of several months 
were experienced before the study could be commenced. 
The multicentre study “SuperDOT-C” scaled up work considerably, with the need to 
support and coordinate sites across different areas in Tayside and Grampian and Glasgow 
Health Board.  The different Health Boards in particular, had different administrative 
arrangements and systems for the same activities.  For example, each health board had a 
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different governance requirement to authorise staff to undertake dried blood spot testing. 
Therefore the procedures adopted in Tayside had to be adapted when working in the 
different boards.  These differences meant that training and approaches to implementation 
had to be adapted for the different Boards, to enable that the study could run efficiently. 
Monitoring and facilitating study progress was much more complicated and challenging 
and creating productive relationships and lines of communication required lots of work.  
The involvement of Tayside pharmacies in blood borne virus testing and treatment had 
been on-going since the research programme was initiated in 2013 and therefore the work 
was familiar to pharmacy teams. The involvement in blood borne virus testing and 
treatment was far less familiar to teams from other boards and this presented a further 
issue to address. This was reflected in the activity and recruitment generated. A lower 
recruitment was observed for both Glasgow and Grampian sites. 
5.5.1 Critique of methods 
The methods used in the cluster randomised controlled trials reported in this chapter are 
the same as those discussed in chapter two and will not be repeated here.  For these 
studies, it was identified that a cluster design was advantageous for a series of reasons. A 
cluster design meant that there was no requirement for research-naive pharmacy staff to 
offer more than one intervention in the pharmacy, as they would do if a standard 
randomised controlled trial design was employed.  It was also realised that the client 
group would soon identify the differences between the pharmacy-led and conventional 
treatment pathways and the increased convenience of the pharmacy-led pathway might 
create additional issues. No contamination issues were in fact identified during the course 
of either study. 
In the quasi-experimental study, a difference between the ages of the cohorts was 
observed for intervention and control groups (chapter4). Within the feasibility study, 
statistical testing of the ages of both intervention and control cohorts demonstrated that 
there was no significant difference. This observation therefore provides some evidence of 
the effect of randomisation in minimising systematic bias. 
In cluster randomised trials, statistical power is reduced in comparison to similarly sized 
conventional randomised designs.  Sample size calculations are therefore inflated using a 
cluster inflation factor to accommodate for the clustering.  Within the multi -centre study, 
there were more than sufficient potential participants within each intervention arm to 
provide then required power for the study. Work undertaken as part of the systematic 
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review study (chapter 3) and earlier development work identified the scale of attrition that 
might be expected to occur in the experimental studies.   
The pilot study reports on the simplified structure of the pathways and attributes costs to 
those pathways, as a first step towards an economic analysis.  This baseline work was 
completed in order to lay the foundations for the full economic analysis and modelling 
which will be undertaken at the University of Bristol for SuperDOT-C. 
The process evaluation for both studies in this chapter, utilised the same methodology, 
with semi-structured interviews providing data for integration with previous evaluation 
work, to incrementally increase knowledge of the performance of the intervention. The 
process evaluation for SuperDOT-C reflected the need to consider different levels of 
activity and performance between pharmacy sites and differences between Boards, using 
purposive sampling. This analysis concentrated on an evaluation of staff involvement. 
The range of views and perceptions described were coherent with the previous work, but 
also identified some additional perspectives arising from differences in organisat ional 
cultures and familiarity with extended professional roles. 
5.5.2 Critique of analysis 
In the feasibility pilot, the small numbers of participants completing the pathway meant 
that logistic regression modelling was not attempted and a simple analysis using π2 testing 
and estimation of p-values was considered to be sufficient for a pragmatic analysis. 
Within the pilot study, a significant imbalance between the two arms was identified by 
the analysis, with a greater number of participants in the pharmacy arm experiencing 
spontaneous clearance of their viraemia and a greater number of participants being 
diagnosed with genotype 3 hepatitis C: the direct-acting antiviral drugs to treat genotype 
3 without addition of the rifampicin were not available at the t ime of the study, although 
they were available by the time SuperDOT-C was implemented. This imbalance was not 
prevented by randomisation of pharmacy sites to either intervention or control arms, and 
may be a feature of the small number of study sites. 
In the analysis of cluster randomised trials, failure to control for the correlation between 
individuals in the same cluster can lead to bias, over-estimating the treatment effect and 
increasing the chances of type one error; rejection of the null hypothesis (Hahn, Puffer et 
al 2005).  For this reason, a logistic regression modelling was adopted for the analysis of 
SuperDOT-C, under the supervision of Professor Donnan.  The analysis of SuperDOT-C 
required analysis at three levels (board, pharmacy site, individual), with programming 
undertaken using STATA to operationalise the statistical analysis plan. The analysis 
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demonstrated strong evidence that a statistically significant difference could be identified 
between the conventional and pharmacy pathways that were evaluated by the study.  
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CHAPTER 6: 
MAPPING OF CAUSAL INFERENCES IDENTIFIED DURING THE 
DEVELOPMENT AND EVALUATION OF A COMPLEX PUBLIC 
HEALTH INTERVENTION 
Content 
Using a systems-thinking approach to elucidate programme theory underpinning the 
effectiveness of the SuperDOT-C Intervention: a pharmacy-led test and treat pathway for 
PWID with hepatitis c infection prescribed opioid substitution therapy. Manuscript 
prepared for submission to the International Journal of Drug Policy, July 2019.  
Radley A, Inglis SK, de Bruin M, Dillon JF was conceived by Radley and Inglis. Radley 
and Inglis jointly undertook the thematic analysis and interpretation. Radley, Inglis, de 
Bruin and Dillon provided methodological and clinical advice. The paper and subsequent 
drafts were written by Radley with contributions by all co-authors. 
Evidence Contributions 
This paper reports the analysis undertaken on the experimental and process evaluation 
work under taken during this programme of study, in order to identify the “active 
ingredients” of the intervention.  Review of literature, research findings and qualitative 
themes from the programme have been utilised to identify key elements that are thought 
to influence the SuperDOT-C intervention. These elements are defined as patient 
behaviour, patient environment, health worker performance and healthcare environment. 
The elements therefore span individual, organisational and contextual parameters.  
Knowledge Translation Contributions 
This work has been presented at local and international conferences through both poster 
and oral presentations. Radley has provided guidance to groups in both the USA and 
Canada involved in the implementation of pharmacy-based models to test and treat 
hepatitis C.  
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6.1 Using a systems-thinking approach to elucidate programme theory 
underpinning the effectiveness of the SuperDOT-C Intervention: a 
pharmacy-led test and treat pathway for PWID with hepatitis c infection 
prescribed opioid substitution therapy 
The following paper is a verbatim copy of Radley A, Inglis SK, de Bruin M and Dillon JF 
prepared for submission to the International Journal of Drug Policy in July 2019 
ABSTRACT 
Background: Increasing access and linkage to care for hepatitis C (HCV) are fundamental 
requirements for achieving the WHO target of elimination by 2030. The SuperDOT-C 
research programme designed and evaluated an HCV test and treat pathway delivered 
with direct-acting antivirals, through community pharmacists. As part of the process 
evaluation of the intervention, causal loop diagramming (CLD) was used as a tool to help 
understand complexity and generate hypotheses about causal mechanisms. 
Methods: A systematic literature review and series of community-based participatory 
research activities were undertaken to inform the design and understand the acceptability 
of the SuperDOT-C intervention. Qualitative work included implementation of seven 
focus groups with service users and carers (41 participants), discrete choice experiment 
with service users (103 participants), semi-structured interviews on service acceptability 
with service users (14 participants) and staff providers (36 participants). All transcripts 
were thematically analysed. 
A causal loop diagram was constructed with contributors defined as: health worker 
performance; health care environment; patient behaviors and attitudes; patient 
environment. Components were identified then assigned polarity and arranged into 
feedback loops associated with the contributors, with reinforcing (R) and balancing (B) 
effects. The resultant CLD was used to examine leverage points and the dynamic 
relationships between them. 
Results: 34 components were identified from the literature review and qualitative work 
and plotted onto a CLD. The CLD was reviewed and 5 reinforcing loops and 2 balancing 
loops determined. The reinforcing loops described positive patient relationships, 
proximity to the community and role enhancement as factors promoting uptake of the care 
pathway. The balancing loops described factors such as experience of stigma and fear of 
treatment side-effects, but also the factors such as homelessness, healthcare policy and 
budgetary restraints. 
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Conclusion: A systems-thinking approach using CLD is helpful in the evaluation of 
complex public health interventions and forming hypotheses about causal  mechanisms. 
1.0 INTRODUCTION 
Hepatitis C (HCV) is a blood-borne viral infection causing liver disease. The world-wide 
burden of HCV virus infection has been estimated as 71.1 million infections (62.5—79.4) 
(The Polaris HCV Collaborators 2017). In developed countries, people who inject drugs 
(PWID) are the group most commonly infected with hepatitis C (HCV) infection and it 
has been estimated that around 10 million or 60% of PWID have been infected by HCV 
worldwide (Gountas, Sypsa, Anagnostou, Martin, Vickerman, ... Hatzakis 2017). The 
conventional care pathway in the United Kingdom recommends that patients with a 
history of intravenous drug use, or those currently prescribed OST, should be offered 
HCV testing annually. In current HCV testing and treatment pathways within the United 
Kingdom, only a small proportion of those who had a positive HCV test had evidence of 
treatment (11.9%) and a smaller number were demonstrated to have achieved a sustained 
virological response (SVR) (5.9%) (Simmons, Ireland, Irving, Hickman, Sabin.... Mandal 
2018). 
The World Health Organisation (WHO) has set an ambitious goal to eliminate HCV as a 
public health threat by 2030 (WHO 2016.). Creating the complex public health 
interventions necessary to eradicate HCV requires that well-designed cross-disciplinary 
programmes are put in place using different strategies to increase screening, testing and 
diagnosis (Wade, Veronese, Hellard and Doyle 2016). Strategies advocated to increase 
linkage to care include integration with other services, decentralisation to primary care 
providers and task-shifting to non-specialists. In the United Kingdom, opioid substitution 
therapy is commonly provided by community pharmacies (Matheson, Thiruvothiyur, 
Robertson and Bond 2016). Hence a more central role in the treatment of HCV for 
community pharmacists, who are seeing these clients on a regular basis, may lead to 
increased population coverage through higher HCV testing, treatment uptake, adherence, 
and treatment completion rates
 
(Mathieson et al 2016).  
Evaluations of clinical interventions are often described as linear logical progressions, 
rather than the non-linear iterative attainment of increasing understanding about how an 
intervention performs within a particular context (Craig, Dieppe, Macintyre, Michie, 
Nazareth and Petticrew 2008). A variety of methodological approaches have been 
proposed as ways to conceptualise an understanding of the processes involved that 
determine the effectiveness of an intervention. These processes have included the 
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application of change theory
 
(Rogers 2008), the use of a realist evaluation approach 
(Pawson and Tilley 2015), theory-driven evaluation (Renmans, Holvoet and Criel 2015), 
and systems thinking (Best, Berland, Herbert, Bitz, van Dijk ...and Millar 2016).  A 
systems thinking approach can be a useful way of considering the nature of the complex 
adaptive systems seen in health services.  Such an approach takes a wider perspective, 
considering interaction effects, feedback loops and emergence within the larger system
 
(Carey, Malbon, Carey, Joyce, Crammond, Carey 2015).  Causal loop diagramming is a 
tool used to analyse complex systems. It is a qualitative visual aid used to communicate 
assumptions about a dynamic system (Belue, Carmack, Myers, Weinreb-Welch and 
Lengerich 2012). Visualizing complex adaptive systems can enable a better understanding 
of the behaviour of the system and its agents. A specific function of the tool is to 
elucidate feedback loops (Cavana and Mares 2004). Use of such visualizations can be 
used to generate hypotheses which feed into theory-driven evaluation and exploration of 
potential causal mechanisms and routes to improvement (Renmans et al 2015).  
In undertaking a programme of research to develop, implement and evaluate a 
pharmacist-led testing and treatment pathway, we undertook a series of exploratory and 
feasibility studies (Radley, de Bruin, Inglis, Donnan 2018). This study is part of the DOT-
C research programme evaluating the implementation of a pharmacist-led test and treat 
programme for hepatitis C in people prescribed opioid substitution therapy.  
2.0 MATERIALS AND METHODS 
2.1  Study Setting 
In 2016, an estimated 34,500 individuals were living with chronic HCV infection in 
Scotland, more than half of whom have been diagnosed (Health Protection Scotland and 
Glasgow Caledonian University 2017). Of those aware of their infection, around a quarter 
engaged in specialist treatment and approximately 1750 cases were treated per year. 
Injecting drug use continues to be the most prominent risk factor for HCV infection in 
Scotland, accounting for over 90% of infections. In 2015-16, results from the Needle 
Exchange Surveillance Initiative (NESI) showed that HCV antibody prevalence among 
people who inject drugs (PWID) remained high at 58% (The Needle Exchange 
Surveillance Initiative 2017) there were no major differences in HCV prevalence by 
gender or age-group over time, with rates in the younger (≤30 years) and older (>35 
years) age-groups stable at around 40% and 65%, respectively. 
The policy context set by the Scottish Government is described in the Sexual Health and 
Blood Borne Virus Framework 2015-2020 Update (Scottish Government 2015). This 
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document sets out targets for Scotland, aiming to treat at least 1,500 people per year with 
antiviral therapy and aiming for a 75% reduction in the annual number of people 
developing hepatitis C-related liver failure and/or liver cancer by 2020. 
The Tayside region of Scotland has been a test bed for sequential development of 
integrated services over the last two decades (Tait, Wang, Stephens, Miller , McIntyre... 
and Dillon 2017), moving from standard secondary care‐based hospital outpatients, onto 
nurse‐supported treatment services, then to a HCV managed care network (MCN)(Tait, 
McIntyre, McLeod,  Nathwani and Dillon 2010; Jafferbhoy, Miller, Dunbar, Tait, 
McLeod and Dillon 2012) and finally to a development in the MCN model which 
included a widespread dry blood spot testing programme in drug services and 
development in our outreach services across the region which included providing 
treatment within drug services and prisons
 
(Tait, Stephens, McIntyre, Evans and Dillon 
2013) 
2.2 Data collection and Analysis 
A systematic literature review
 
(Radley, Robinson, Aspinall, Angus, Tan and Dillon 2019) 
and series of community-based participatory research activities were undertaken to 
inform the design, development and implementation of the SuperDOT-C intervention. 
Qualitative work included implementation of a focus group series with service users and 
carers (41 participants (Radley, Melville, Easton, Williams and Dillon 2016), a discrete 
choice experiment (DCE) with service users (103 participants) (Radley, van der Pol and 
Dillon 2019), semi-structured interviews on service acceptability with service users (14 
participants) and staff providers (36 participants) (Radley, Tait and Dillon 2018) 
Focus Group Series 
Seven focus groups with a total of 41 participants were undertaken during 2015 in a range 
of settings, aiming to gain a diversity of views and experiences. Participants were people 
prescribed OST by the specialist substance misuse service in Tayside, who provide the 
majority of care for this group. Participants discussed comparative experiences of 
partners, family and associates who had undertaken testing and treatment for HCV. 
Recruitment to the focus groups utilised the following variables:  
-Place of Residence –large urban / other urban / accessible small town 
-Service Users detained by the Criminal Justice System 
-Perspectives of peer mentors (service users at an advanced stage of recovery)  
Sessions were open-ended and ranged from 70–100 minutes. A discussion guide was 
developed from a literature review and discussion with the research team. The first focus 
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group served as an internal pilot to test the discussion guide.  The seventh focus group 
with peer mentors was undertaken to provide perspective on the findings from this study. 
In the local service configuration, peer mentors are experienced service users who have 
received OST for a number of years and are further along a recovery pathway: we listened 
to their reflections and perspectives on the themes that had emerged. 
Data from each focus group were digitally recorded and transcribed verbatim, before 
being coded and analysed by two researchers.  Analysis drew on the constant comparison 
method, which was operationalised within a general thematic approach (Ritchie and 
Spencer 1994).  
Discrete Choice Experiment 
Focus group participants described a range of attributes that had significant overlap with 
those identified from the literature: stigma, waiting times, confidentiality of results and 
positive relationships with service providers. The final attribute list included the pre-
determined attributes (who does the testing (provider) and incentive payment) as well as 
the most important attributes identified through the literature review and focus groups 
(whether treated with dignity and respect; travel distance; and waiting time to test result). 
The five attributes were utilised in a discrete choice experiment which aimed to elicit 
OST user’s preferences for HCV testing, in order to aid the design of a testing service that 
was acceptable to use from their perspective. Plausible levels were assigned to each 
attribute based on focus group responses and the local context for factors such as 
laboratory turnaround and travel distance.  The attributes and levels in the DCE were 
selected following recommended practice (Reed Johnson, Lancsar, Marshall, Kilambi, 
Mühlbacher...and Bridges 2013).  
A questionnaire in three sections was administered to 103 consented participants. The 
sections ascertained participants’ preferences on the levels within the chosen attributes; 
presented the 16 choice sets and collected details of patient demography including age, 
sex, educational level and employment.  Respondents completed the questionnaire in the 
presence of one of the researchers who provided support where required. The 
administration of the questionnaire in a familiar environment was also chosen, to reduce 
participant stress and enable access. 
Semi-Structured Interviews 
Interviews were held with 14 participants who had either tested HCV antibody positive, 
or had participated in the pharmacy-led pathway. Interviews were conducted using topic 
guides developed in line with the research aims and programme theory. All interviews 
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were recorded as digital audio files and transcribed in full for thematic analysis. 
Transcripts were inductively analysed to identify themes emergent from the interviews.  
These data contributed to the assessment of feasibility and acceptability (including 
barriers and facilitators), that had been gained from this and previous work
 
Semi-structured interviews were conducted with professionals taking part in the research 
programme (Radley et al 2017). These included pharmacy staff and also study 
coordinators and principal investigators for research sites. The interviews were conducted 
using topic guides developed in line with the research aims and programme theory and 
transcribed in full for thematic analysis.  These data contributed to an understanding of 
intervention performance, including barriers, facilitators and unintended consequences, as 
a component of the process evaluation. Transcripts were inductively analysed to identify 
emergent themes and deductively analysed to compare findings with programme theory 
(Radley, Tait, Dillon 2018). 
2.3 The DOT-C Intervention 
In the pharmacist-led pathway, pharmacists opportunistically discussed HCV infection 
with OST patients attending the pharmacy. Those with unknown HCV status or previous 
negative results were offered testing using a dried blood spot test (DBST) in the 
pharmacy. Those identified as having tested positively for HCV antibodies were provided 
with an information leaflet explaining the intervention and received a post-test discussion 
with the pharmacist using a standard infographic.  The pharmacist assessed the participant 
for treatment delivered solely within the pharmacy, completing a pre-treatment checklist 
of medical co-morbidities, a medicines history and identifying any factors likely to 
impinge on treatment compliance. A peripatetic phlebotomist visited the pharmacy for 
safety blood tests, as in the conventional pathway and the pharmacist confirmed 
suitability for treatment. Where there were no contra-indications to therapy, the patient 
commenced treatment. In patients where there were identified contraindications or queries 
about suitability, the pharmacist contacted the central clinical co-ordinator for advice. 
Potential participants with a FIB-4 score of > 3.25 were referred on to the conventional 
care pathway for review (Sterling, Lissen, Clumeck, Sola, Correa... and Nelson 2006). 
These patients were reviewed in hospital by a medical consultant. Prescriptions for 
treatment in the pharmacist-led pathway were provided by a pharmacist prescriber or 
treatment was facilitated using a patient group direction (Medicines and Healthcare 
Regulatory Authority 2018). Daily monitoring was undertaken at the pharmacy, recording 
 203 
 
any occurrence of side-effects or adverse events. Participants who did not attend the 
pharmacy for seven consecutive days were discontinued from care under the pathway.  
2.4 Causal Loop Analysis and Diagramming 
The causal loop diagram was constructed using a number of phases. The boundaries of 
the intended diagram were defined as the patient and organisational contributions to a 
cure for hepatitis C (De Pinho and Larsen 2019).  Elements that might make up the 
diagram were defined and grouped together, drawing on published and unpublished data 
from the DOT-C programme, using relevant research and stakeholder experience (AR and 
SKI). The assumptions underlying the list of elements were discussed between authors. 
The representation of groups of variables was scrutinized and main drivers identified. 
Inter-relationships between variables were explored and flows identified. The major 
drivers and outcomes were built up using an interrelationship digraph and this used to 
consider root causes underlying the purported relationships ( De Pinho yet al 2019). From 
this point, a causal loop diagram was developed iteratively, through discussion. 
2.5 Theoretical frameworks 
The analysis was informed by two theoretical frameworks. Actor network theory was 
used to characterize the context of drug us as the interaction of people and technology 
(Duff 2013). The broader context of drug use has been considered using actor network 
theory, which describes how subjects, activities, agencies, networks and spaces are 
produced in and through the activity of drug consumption. These constructs were helpful 
in the development of our understanding of the causal influences involved in the complex 
system. 
Normalization process theory was used to identify the processes undertaken by pharmacy 
teams in incorporating the activities required by the pathway into their practice (De 
Bruin, O’Reill, de Bruin, O’Donnell and MacFarlane 2016).  The theory utilizes the core 
constructs of coherence, cognitive participation, collective action and reflexive 
monitoring to conceptualise the processes involved with effectiveness of implementation 
(Murray, Treweek, Pope, MacFarlane, Ballini...and May 2010). The concepts were 
helpful in guiding our understanding of pharmacy team behaviours. 
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3.0 RESULTS 
3.1  CLD development 
The main objective and outcome variable for the pharmacy-led pathway is hepatitis c 
cure, therefore it forms the centre of the diagram (Figure1).  From studying the list of 
potential diagram elements and identified drivers, we defined four main contributors, 1 at 
the organizational level (health care environment), 1 at the healthcare worker  level (health 
worker performance) and 2 at the patient level (patient behaviours and patient 
environment). The health care environment  contains items such as health policy, 
organisational drug budgets and contractor politics around remuneration. Health worker 
performance is comprised of elements including leadership and teamwork, attitudes to 
patients and relationships, multi-disciplinary team support, appropriate care provision and 
correct implementation of the care plan. Patient behaviours include experience of shame 
and disapproval, relationships with family and peers, availability of illicit drugs and 
health-seeking behaviour. Patient environment include interactions with the criminal 
justice system, housing and homelessness, income and employment and service 
accessibility. 
3.2  Health Care Environment 
The availability of direct acting antiviral medicines (DAAs) has been greatly influenced 
by their high procurement cost and the response of governance bodies to manage 
healthcare resources (Kamal-Yanni 2015). These responses have included a range of 
measures designed to direct the use these medicines to groups of patients conceptualised 
as being at greatest need and delaying use in groups thought of as having less progressive 
disease or with co-morbidities judged to reduce the potential for an ideal outcome 
(EMCDDA 2017).  Some commissioners chose to cap the annual budget available to 
provide these treatments, in order to manage budgetary risk (Hepatitis C Trust 2018).  For 
community pharmacy contractors who dispense these medicines for their patients, the 
high procurement cost has engendered risks to cash flow. Risk sharing of this factor with 
service commissioners was an important factor in ensuring service uptake (Community 
Pharmacy.Scotland 2018). Community pharmacy contractors reported some difficulties 
with access to medicines that were previously only used in hospital environments.  
3.3  Health Worker Performance 
Our interviews with pharmacy team members identified many sources of motivation. 
Many of the health workers were intrinsically motivated to help patients who used their 
services and they valued the relationships that they developed in the pharmacy
 
(Radley, 
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Melville, Easton…and Dilllon 2016; Radley, Melville Tait… and Dillon 2017)). The 
intervention provided by the pharmacy team was most successful when pharmacists 
worked closely with other local services (such as phlebotomy) and where pharmacists 
were proactive in discussing risks with clients. 
Framing the positive outcomes of testing in terms of responsibility for individual health 
and the health of family and community, building positive relationships and targeting 
stigmatising attitudes were described as factors that supported effective implementation 
in pharmacies.  Variance in the activity seen between individual pharmacies was 
explained by a range of factors including staffing levels, building configuration, profile of 
the client group, as well as staff attitudes and the quality of relationships with patients. 
Staff considered that strong leadership was necessary for pharmacy teams to be successful 
and that teams struggled in areas where this was lacking. Teams also struggled with staff 
turnover. If a motivated trained leader left the pharmacy, then this had a detrimental 
effect on delivery of the pathway. 
“I think it is the right place to do the testing, I think we know the patients; it’s easier to 
approach them as well. They are more likely to do the test than if somebody they don’t 
know asked them” (Pharmacist, Pharmacy National Chain) 
“ I think it’s because I have a special rapport with my clients, it’s very much community 
orientated here, everyone comes in and tells you stories, you take part in their lives” 
(Pharmacy Support Worker, Pharmacy National Chain) 
The presence of leadership and teamwork within the pharmacy created an environment 
where staff members were motivated to complete the task of recruiting patients.  
“The most important thing is the consistency of all staff being aware of what is happening 
at all times and knowing the processes, the people to speak to and how to manage the 
patient” 
(Pharmacist, Independent Pharmacy) 
“When we had everything in place, myself and (staff member) practiced doing dry blood 
samples on each other” (Pharmacy Support Worker, Independent Pharmacy)  
However, the pressure of other tasks, especially dispensing workload could impinge on 
the pharmacy’s delivery of the intervention. The intervention worked less well where it 
was the responsibility of a single staff member. 
“I don’t have double cover and we are quite busy just with prescriptions, so it’s me 
checking everything, but it’s good doing services, but you feel that you need more time” 
(Pharmacist, Pharmacy National Chain). 
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Pharmacy staff were often keen to develop the clinical services that they were able to 
deliver. There was a strong motivation to diversify the range of tasks that they delivered, 
rather than dispensing. 
3.4 Patient Behaviours 
A series of contextual factors were identified through the evaluation work with study 
participants. These include included: expectations and experiences of stigma and 
discrimination; fears about confidentiality; the limited horizons of people receiving OST 
and the poverty they experience. Identified mechanisms that may influence uptake 
included the presence of established relationships with pharmacy staff; a pre-existing 
reason for attending the pharmacy for OST and the proximity of the pharmacy within the 
local community.  Our discrete choice experiment clearly showed the value placed by 
patients of being treated with dignity and respect and of the opportunity to have care 
delivered in a familiar environment
27
. 
Patients in the pharmacy had the expectation of different treatment because of their 
addiction. Pharmacies often make different arrangements for the management of people 
prescribed OST, either to manage the numbers requiring treatment supervision or to 
manage the perceived risk of theft.  Agency between human and non-human actors was an 
important determinant of behaviours of patients and of staff. 
“We are all shoplifters and we have all been stealing to feed wer drug habit.  See when 
you first get out the jail you don’t get paid for about a month, so, after 3 days you are 
skint.  Until about a month later you need to walk all the way into the toon, sometimes its 
4 or 5 miles just to get your Meth, and then you have to walk home another 4 or 5 mile 
back or you can go shoplifting to get money for the buses or something.  Ken what, its 
just how it is and that’s how ye end up in the jail” (patient in receipt of OST, Dundee) 
“You are not allowed any more than two people in the pharmacy at the same time. It 
doesn’t matter if its rain, sleet or snow, you stand outside. She frankly told us that she 
doesn’t want us in there when there’s people in there” (patient in receipt of OST, Dundee) 
People prescribed OST reported that they experienced stigma across the health system, 
not just in pharmacies. The established relationships with the staff in the pharmacies 
could often make the difference when a patient was considering whether to accept the 
offer of a test. 
“I don’t know, sometimes when you got to the hospital I don’t know sometimes you feel 
like you are being treated differently and I just found that in here it was a more warmer 
environment and friendly (in the pharmacy), I wasn’t treated any different, I was just 
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treated as me, for me personally it can understand why people wouldn’t go to a hospital 
appointment and this is probably a better option, no probably knows why you are here, 
not everyone knows your business”. (patient in receipt of OST, Dundee) 
Fear of shame and disapproval also was apparent in relationships with family and with 
peers and so confidentiality in the pharmacy was an important concern. 
“I’ve only told half of my family ken, and its kinda secret aye,  because dinnae want 
anyone tae really ken because its a dirty disease, aye hepatitis is no like a good disease, 
ken whit I mean, aye “(patient in receipt of OST, Dundee) 
The established relationships and trust of the pharmacy, as well as the proximity of the 
pharmacy within the community were recurrent and forceful themes that emerged from 
the interactions with the patient group  
“Yean before I even started the treatment it had been discussed with me and the side 
effects that were known and then when the information pack came in the pharmacist had 
already explained to me that when that comes in first then he would read it first then he 
would give it to me, and that was what he done and talked it all through with me then I 
took the information pack away and re-read it again when I got home, so yeah everything 
was explained properly to me so that was fine yeah”.  (patient in receipt of OST, 
Dundee). 
Participants in the qualitative work carried out during intervention development could 
describe concepts such as viral load from hepatitis infection and many could give 
accounts of poor experiences with interferon. 
No, because I wanted tae get rid of it, I wanted to see if this would work,  I was quite 
excited about it to be honest, I couldn’t believe how quickly it  was all happening, it was 
right I have got this opportunity so I have to grab it with both hands and I had  to come 
everyday for my methadone anyway so I got both at the same time. (patient in receipt of 
OST, Dundee) 
“Em a bit yeah, I do feel a bit more energetic I suppose, I do feel a bitty different, its kind 
of hard to explain, to feel a bit more motivated I suppose and a bit excited now waiting 
for this 12 weeks to pass so I can find  out if its worked, if its not.  The changes are that 
hopefully it has, fingers crossed. I feel a bit more positive, hopefully this will be it done”. 
(patient in receipt of OST, Dundee) 
3.5 Patient Environment 
The literature describes the many psychological, physical and social aspects of living with 
hepatitis (Treolar and Rhodes 2009; Dowsett, Coward, Lorensetti and McKean 2017).  
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Experiences of stigma and discrimination are common in the environment in which 
people who inject drugs live, creating strong barriers to accessing HCV care and 
treatment (Fraser and Treolar 2006).  Physical and mental fatigue arising from HCV 
infection discourages a normal life and frames a person’s social interactions (Groessl, 
Weingart, Kaplan, Clark and Gifford 2008). Changes to employment status and social 
roles have implications for finances and morale, while relationships can be affected 
detrimentally, increasing feelings of isolation (Dunne and Quale 2001). Many individuals 
reported negative experiences with the healthcare system; themes of feeling unsupported, 
not having adequate information, and not feeling involved in decisions are reported 
(Rance and Treolar 2013). Participants may experience a reduced quality of life due to 
physical symptoms and all these of factors contribute to people with HCV undertaking 
part-time work or not working
 
(Hill, Pfeil, Moore and Richardson 2014).  Data collected 
by participants in the discrete choice experiment demonstrated that 43% were 
unemployed and 44% were receiving benefits for illness and disability (Radley et al 
2019).  
3.6 Hypotheses developed about causal inferences and quality improvement 
Depicting the different linkages in a causal loop diagram supports the identification of 
reinforcing loops that continue and accelerate processes of change within a system, and 
balancing loops that establish organizational stability. These linkages enable hypotheses 
to be constructed to explain the effects seen in the intervention (Bardoel 2003).  
Hypothesis 1: Teamwork and Leadership 
Figure 2 depicts the two reinforcing loops (R1 and R2) that identify some of the factors 
concerned with Health Worker Performance.  The hypothesis behind the reinforcing loops 
resembles the “Success to the Successful” archetype (Anderson and Kim 2011). The 
loops describe the interaction between the pharmacy team and the patient and correct 
implementation of the pathway. 
In this hypothesis, the pharmacist leading the community pharmacy team is motivated and 
engaged in the provision of a new clinical service. The leadership they provide creates an 
ethos of positive action amongst the staff group who are given permission to approach 
OST users and facilitate conversations that encourage participation in the pathway; 
pharmacy support staff gain competency in testing and in recruitment. The time 
investment required to manage the pathway is traded off against other activities that may 
take up resources in the pharmacy.  In such pharmacies, there may already be a supportive 
culture towards OST users and staff may already have established longitudinal positive 
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relationships with these clients and routinely provide advice on health matters. The 
pharmacy team connects with the multidisciplinary team and develops positive 
relationships with these actors. These factors are promoted by a pharmacy business model 
that values the income streams created by clinical patient services. 
In the antithesis, to the above situation, the new service is contemplated as an additional 
burden that requires resource input. The provision of the new service may be seen as the 
responsibility of one person, rather than the team. The ethos created in this situation is 
one of the burden of competing workload and lack of staffing. The pharmacy team is 
inward looking and isolates itself from the influence of multi-disciplinary contacts.  The 
pharmacy business model concentrates on prescription numbers and on maximising the 
volumes delivered by dispensing activities. 
Hypothesis 2: Treated with Dignity and Respect 
Figure 3 describes the reinforcing loops (R3 and R4) that identify some of the factors 
encountered when considering the contribution of patient behaviours. In this hypothesis, 
the patient has a longitudinal positive relationship with the local pharmacy team.  The 
pharmacy responds positively to the frequent visits of the individual for OST and a 
dialogue around the experiences of daily living develops between the parties. The patient 
considers that they are treated well and values the frequent interactions with the pharmacy 
staff and the interest in their well-being. 
The offer of a hepatitis test is therefore viewed in the context of this on-going 
relationship. The advantages of testing for HCV in the local pharmacy, by people that are 
already well-known are credible. The knowledge that all of the elements of the care 
pathway will be delivered within this service is reassuring, obviating the need for bus 
fares and journeys outside the local community. 
Such interactions contrast with the experiences of stigma and disapproval that are 
commonly encountered in their interactions with wider society. The difficulties 
encountered in maintaining the requirements for a stable lifestyle such as income and 
accommodation, as well as conflicts and issues caused by drug use, tend to create barriers 
and limitations on progress made towards a cure for HCV (balancing loop B1) (Bruggman 
2012). 
3.7 Hypothesis 3: Organisational Purpose 
Figure 4 depicts the factors identified that influence access to DAAs and the governance 
processes that are created to manage the health resource (balancing loop B2).  The high 
procurement price of DAAs leads government and health care organisations to put in 
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place measures to manage the budgetary risk.  The hypothesis behind the balancing loops 
of this section resemble the “Limits to Success” archetype, where demand is met by a 
limited response and failure to develop sufficient capacity (Anderson at al 2011)  
A clinical leadership response to this would be to mobilise stakeholders and partners in a 
systematic way, to maximise the number of people with hepatitis C that could be treated 
within the financial allocation (Tait et al 2017).  The organized efforts and consensus 
approach would generate confidence that management control was being delivered and 
that investment was being used wisely.  In this context, a narrative of deliberate success is 
created and a reinforcing position is obtained (R5). 
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4.0 DISCUSSION 
This study has brought together the evaluations carried out during the modeling, 
exploratory and feasibility stages of the work undertaken to develop the SuperDOT-C 
intervention
17
. The use of causal modelling has been advocated as a method of 
strengthening the evaluation and design of complex interventions (Hardeman, Sutton, 
Griffin, Johnston, White and Kinmonth 2005).  This approach enabled identification of 
the positive contributions to the performance of the intervention at organisational, 
healthcare provider and patient level (Hoj, Jacka, Minyan, Artenie and Bruneau 2019). 
Our causal loop analysis led us to identify three hypotheses: the “Teamwork and 
Leadership” hypothesis focuses on the way that the pharmacy staff resource can be 
harnessed to engage patients in testing and retain them in treatment. Provision of strong 
leadership enables the challenges of competing workload to be managed and for OST 
recipients to feel welcomed.  The hypothesis also recognizes the trade-off that must occur 
in a busy pharmacy between activities. The “Success to the Successful” archetype 
describes how the investment in delivering the SuperDOT-C pathway is offset against 
other activities that the pharmacy contractor undertakes to provide their pharmacy 
service. 
Within pharmacies, the clinical focus of the pharmacist leading the team was instrumental 
in achieving greater engagement of the OST user group and of creating confidence in 
individual participants on the delivery of the pathway. The “Dignity and Respect” 
hypothesis recognizes the value of longitudinal trusting relationships propagated by 
pharmacy staff with individuals in the OST user group, creating reinforcing effects for the 
uptake of the intervention.  We clearly identified that the opportunity to be treated with 
dignity and respect, in a trusted local service was highly valued 
27
.  The positive 
reinforcing effects of these relationships are carried through into each stage of the care 
cascade (Safreed-Harmon, Blach , Aleman ,Kielland, Bollerup ...and Lazarus 2019). 
The analysis identified the reinforcing effects that occurred when clinical leadership was 
demonstrated, both at an organisational level and at a local level within the pharmacy.  At 
an organisational level, clinical leadership was provided for the SuperDOT-C intervention 
through the regional managed care network, which promoted and supported delivery of a 
range of interventions aimed at elimination of HCV (Tait et al 2017). The leadership 
exhibited through the managed care network could mitigate some of the balancing effects 
of organisational risk management.  Leadership and the description of common purpose 
between stakeholders was able to some extent overcome the “Limits to Success” 
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archetype (where success attracts more resources, despite the needs of lower performing 
groups) and enable the development of capacity and focus. 
The environment in which the patient lives has a pervasive effect on engagement with 
care, with the availability of employment, housing and services determining whether 
accessing heath care is a priority. Experiences of stigma and discrimination are common 
for people who inject drugs, creating strong barriers to accessing HCV care and treatment 
(Treolar, Rance and Backmund 2013). The adverse effects of drug use and the associated 
poverty, created balancing effects that discouraged engagement with testing and treatment 
for HCV.  
A number of studies are currently being undertaken that demonstrate the feasibility of 
decentralising care and providing local services with reach into communities of people 
infected with HCV.  Such pathways may increase uptake of treatment and can provide 
sustained viral responses equivalent to those attained in specialist centres (Wade, Doyle, 
Gane, Stedman, Draper...and Hellard 2018; Swan , Cullen, Macias, Oprea, Story...and 
Lambert 2018; Grebely, Alavi, Micallef, Dunlop, Balcomb...and Dore 2016). SuperDOT-
C utilised pharmacy staff in order to increase reach and access.  Examples of pharmacist -
driven models of hepatitis C virus (HCV) care are now described from multiple single-
center and multicenter retrospective and prospective cohorts in a range of settings (Koren, 
Zuckerman, Teply, Nabulsi, Lee and Martin 2018; David, David, Essex, Deming, Qualls 
and Mera 2017; McNamara, Budlong, Peterson and Tisthammer 2018; Ho, Fong, Tran, 
Gonzalez, Chung... and Morgan 2017), but achievement of the WHO target on 
elimination requires that a range of staff groups with skills and opportunities contribute. 
This study provides some evidence that models of care are likely to be most effective 
when wielding positive and trusting relationships with the groups of people who are 
infected with HCV. Leadership at individual practice and organizational level enables 
available resources to be directed most productively at achieving elimination. 
Causal loop diagrams are a qualitative representation of a complex interactive system. 
Use of this technique has a number of limitations (Schaffernicht 2010). The diagramming 
technique may lack precision with a tendency to over-aggregate variables, so that several 
items may be hidden behind a single term. In a real world complex system, there may be a 
loss of distinction between stock and flow variables and the relationships between events 
and behaviours must be used in a pragmatic way. In developing a causal loop diagram, 
boundaries must be set that mark the limit of the relationships to be considered. Such 
limits necessarily mean that the diagram is an approximation of the real world situation.  
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However, causal loop diagrams describe an explicit model and use is intended to aid the 
understanding of the complex system and the interactions of variables within and between 
levels (Cavana et al 2004).  
CONCLUSION 
This study provides some evidence that models of care are likely to be most effective 
when wielding positive and trusting relationships with the groups of people who are 
infected with HCV. Leadership at individual practice and organizational level enables 
available resources to be directed most productively at achieving elimination. The most 
important dimension of complexity is the context into which the intervention is 
introduced (Hardeman et al 2005). The community in which the individual lives, and the 
support and resources available to them are critical considerations when implementing 
interventions to eliminate HCV. In a complex adaptive system where the system attempts 
to retain equilibrium, each of the reinforcing and balancing relationships should be 
optimised to enable the best chance of achieving success. 
The references to this paper are located in the manuscript provided in Appendix 9.8 
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Figure 3: Reinforcing Loops for Patients Behaviours 
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6.2 Critical Reflection 
The systems-thinking analysis comprising the content of this chapter was undertaken as a 
reflection and summary of the SuperDOT-C research programme. The process of analysis 
required that a high level view of the series of the literature reviews and study evidence 
was taken, so that the components determining the key ingredients of the intervention  
could be identified.  The process of analysis required discussion and reflection with 
colleagues and are-visiting of the data produced by the studies undertake during the 
development of the intervention. The process was satisfying to undertake, as a final  
chapter of this thesis, since it enabled examination and contemplation of the learning that 
had been achieved and review of the development and implementation of the methods 
that had been employed. 
6.1.1 Critique of methods 
A variety of methodological approaches have been suggested as ways to enhance the 
understanding of the processes involved in the effectiveness of an intervention. In this 
thesis, some of the techniques utilised in theory-driven evaluation and realist evaluation 
have been used to underpin exploratory studies.  Implementation processes for pharmacy 
staff have been considered using an application of change theory. The concepts of person, 
place and time seen as part of a realist approach, as well as the complimentary ideas 
described through actor-network theory were key foundations of the analysis. 
A systems-thinking approach was selected for this study as a useful way of considering 
the nature of a complex adaptive system in an integrated health system in Scotland. The 
application of this approach requires that a wider perspective is taken and that 
interactions between components, feedback effects and positive reinforcement within a 
larger system are considered. The use of causal loop diagramming proved to be a useful 
technique in visualising the assumptions that had been made about the dynamic system. 
The linking and interaction of components and the assignment of polarity enabled a better 
understanding to be gained of the behaviour of the system and its agents. 
6.1.2 Critique of analysis 
The analysis requires that decisions are made through discussions with co-researchers and 
that agreement on the components of the causal loop diagram, as well as the direction of 
travel and polarity of the interaction are obtained. The findings of the analysis are 
therefore a result of these discussions and are based on a thorough examination of the 
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supporting evidence.  Other researchers considering similar data might have different 
conversations and agree a different profile of components and interactions. 
Causal loop diagramming requires that a series of assumptions and approximations are 
made. The extent of the causal loop is achieved through a decision about how far out to 
proceed. The interaction of this system with wider systems and wider effects means that 
all diagrams are limited by their agreed extent. Similarly, the components of the diagram 
are also approximations, since a single term may very well be a compound term made up 
of several different functions. 
However this approach, to visualise the assumptions made about causal inferences 
underlying the intervention was valuable and enabled hypotheses about the key 
ingredients of the intervention to be described.  The analysis enabled the effects seen 
around good quality relationships to be recognised and the limiting factors around patient 
environment and organisational budgets to be highlighted. 
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CHAPTER 7 
DISCUSSION AND CONCLUSION 
This chapter reviews the findings that have been produced and reflects on their meaning 
in terms of the development of the complex intervention, as well as the limitations that 
the methods selected for the studies used have brought. In addition, a narrative linking 
together the different studies that discusses the methodological and conceptual issues is 
included. 
The research programme described in this thesis follows the process of development of a 
complex intervention to provide testing and treatment of HCV infection in people 
receiving OST from community pharmacies. The programme, consisted of a series of 
eight studies, which were undertaken to understand the context for delivery; evaluate 
service users and provider preferences for the shape of the service; pilot the delivery of 
the intervention and then evaluate its effectiveness; analyse the findings of the 
programme to form ideas about what the essential ingredients underlying the success of 
the intervention. 
At many stages of the research programme I interacted with the service user group and 
the people providing the services that they relied upon. I also spent time in community 
pharmacies and observed the daily work routines and systems that are used to provide the 
care to the patients using these practices. 
During this work I became very aware of the vulnerabilities of the group of people who 
inject drugs: the fragility of their home circumstances and accommodation; their reliance 
on supporting services for food and income and shelter because of poverty they live with; 
the everyday traumas and casual violence they experience and the additional burden of 
stigma and discrimination that society places upon them. However I also was engaged by 
the candour that they used in discussing their experiences and by their openness and 
friendliness when asked about their situation. 
As part of this work I spent time talking to pharmacy staff. Community pharmacies are 
contracted to provide pharmacy services and are remunerated mainly for dispensing 
services, with other clinical services being largely subsidised by this main activity. Most 
staff in community pharmacies tried very hard to provide caring and high quality services 
to their patients within the constraints of their training and the pharmacy contract. I 
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observed many examples of excellent care and of strong relationships between staff and 
the people receiving their services 
 
7.1 Critical Reflection  
This thesis made use of the Medical Research Councils guidance on developing and 
evaluating complex interventions (Craig, Dieppe et al 2006) as a structure to steer the 
research programme. The guidance provided advice on the process of understanding how 
an intervention worked within a specific context and gave case histories to illustrate the 
processes that were features of competent research. There was a development from the 
initial version of the guidance (MRC 2000) to the newer guidance in 2006, which 
suggested that development processes were an iterative rather than a progressive increase 
in understanding. In this programme, I found that each study I undertook increased my 
understanding and deepened my appreciation of the effect of context. Triangulation is a 
concept that requires that more than one method of data collection or evaluation is 
employed to answer a research question. The data achieved from these triangulating 
activities are compared with the objective of providing a more comprehensive 
understanding of the mechanisms at work (Rosaline 2008).  In this programme, 
understanding was increased through following this way of working and used to generate 
ideas about the “essential ingredients” of the intervention and how these ideas might be 
refined in the light of new data (Rutter, Savona et al, 2017). 
A further important component of the approach taken was the activities undertaken to 
understand the views of service users. The ideas around patient and public involvement in 
the design and implementation of research were very much appreciated in this 
programme. The first stage of designing the intervention was based around listening to 
the voices of service users and working to understand their priorities for service 
provision. 
The recognition of Actor Network Theory was a key step forward in helping 
understanding of the way that people interacted with the environment and the human 
systems that had been put in place (Latour, 2005). Through the concepts contained in this 
approach, a better understanding of the meaning of the “methadone queue” in pharmacies 
was gained and the narrative provided by both service users and service providers could 
be contextualised within an explanatory framework. 
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The researcher’s position and background and the effect it has on the research, in terms of 
construction of the research and interpretation of the data it generates (Rosaline 2008) is 
an important point of reflection. Reflexivity is an evaluative process by which the 
research reflects on their own beliefs and opinions with regard to the research and 
considers the biases that this may confirm on the study. In this programme, my 
professional background and training in professional behaviours were quickly identified 
as guiding my approaches and attitudes to research participants. Other influences may 
include age, sex, race, religion, sexuality, politics and life experiences (Berger, 2015).  In 
this programme, observation of the experiences and study of participant narratives made 
my empathy for and understanding of the lives of participants in the research much 
greater. 
The studies contained in this thesis were undertaken with a group of people understood to 
be vulnerable in a number of ways.  There was the potential to have to tell them upsetting 
news that might disturb their fragile relationships or bring them into contact with people 
and circumstances that they might find distressing. This was managed from the beginning 
of the programme by working with more experienced staff who were familiar with the 
procedures that could be used to manage these risks. By working to a great extent from 
community pharmacies, we also were able to meet with these people in a familiar 
environment where they were able to see familiar faces. Reflecting back on the 
interaction with the patients whose experiences and lives provided the data for these 
studies, these participants were not distressed by recounting their experiences, even 
though some of the accounts they described would have been traumatic. They were 
generally willing to give up their time and share their stories and I am most grateful to 
them. 
 
7.1.1 Developing and evaluating a complex intervention in community pharmacy 
Complex interventions are widely used across many sectors of public services, including 
public health practice, education, transport and housing. Within the health service, such 
interventions may have important consequences for the health of target populations and 
for communities and families. Current guidance from the Medical Research Council, 
recommends the use of a variety of approaches to addressing the methodological and 
practical challenges faced when establishing a complex intervention (Craig, Dieppe et al 
2006). This advice suggests that greater attention is given to piloting and development 
work, that a less linear model of evaluating processes is used, that process and outcomes 
 221 
 
evaluations are integrated and that insights provided by the theory of complex adaptive 
systems are utilised (Rutter, Savona et al, 2017). 
This thesis has sought to utilise the Medical Research Council’s recommendations for 
developing and evaluating a complex intervention.  It has employed a range of different 
methodological approaches to support the accumulation of knowledge and insights into 
how a care pathway to deliver testing and treatment of HCV infection might operate in a 
community pharmacy. 
The contemporary history of pharmacy is one in which the traditional work practices and 
mechanics of medicines dispensing have been infiltrated by technology. Barcode readers  
and robotic dispensing have largely replaced the need for medicines stock manipulation 
and accuracy checking of prescriptions and this existential threat to the profession has 
been debated widely (Anderson 2007). There has been a lack of evidence of the beneficial 
outcomes to patients of the care provided by pharmacies and the emerging area of 
improving public health has been used for evidence of the continued relevance of 
pharmacy (Anderson, Blenkinsopp, Armstrong, 2009). There are also a range of 
recognised advantages that pharmacies bring to health care: the location of pharmacies in 
the high street; the proximity of pharmacies within disadvantaged neighbourhoods; the 
access to a registered health profession without appointment and the longitudinal 
relationships that develop between pharmacies and the public; the access to medication to 
treat a widening range of conditions; the anonymity of usage of a pharmacy where no 
appointment is needed to access advice (Lowrie, Morrison et al, 2015). The contractual 
basis of community pharmacy also brings a range of different factors into the practice 
environment.  As with general medical practitioners, general dental practitioners, 
opticians and podiatrists, community pharmacists are contractor bodies practising 
according to a nationally negotiated contract within standard terms and conditions. 
Additionally in pharmacy, a commercial offer is also in place, whereby customers can 
purchase a range of products outside of the nationally funded provision. This dual identity 
has led to tensions between the clinical aspirations of the profession and the commercial 
necessity of delivering profit.  The development of an intervention in community 
pharmacy therefore is undertaken with an awareness of all of these factors.  
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7.1.2 Delivering Hepatitis C testing and Treatment in Community and Primary Care 
Settings 
Publication 1 – Systematic review and meta-analysis of care pathways evaluated 
using direct-acting antiviral medicines 
 
The systematic review and meta-analysis of community and primary care based HCV 
testing and treatment services, using DAAs, found that across a broad base of locations, 
more people access care when it was provided with other care that they engaged with.  
The study also identified that similar outcomes were achievable in primary care and 
community-based settings to those identified in specialist centres (Wade, Veronese et al 
2016). 
However, identified studies showed large amounts of heterogeneity. There was wide 
variation in the numbers of participants recruited and a lack of direct comparisons with 
care pathways in specialist centres.  GRADE assessments showed evidence for the uptake 
of HCV treatment (medium), evidence for completion of HCV treatment (low) and 
evidence for achievement of a virological cure (SVR) at 12 weeks (medium). There was a 
lack of high quality definitive experimental studies that could provide evidence of a 
definitive effect for decentralised services that used a task-shifting approach. This finding 
demonstrated a gap in the evidence base and provided the rationale for undertaking this 
course of study.  The systematic review suggested that services sited in community 
setting are feasible and can encourage a vulnerable group of people prescribed OST to 
access care. 
The introduction of direct-acting antiviral medicines represented a huge change in the 
ability of health services to cure HCV and led to the inclusion of the elimination of HCV 
as a public health concern being included in the Sustainable development Goals (Goal 
3.3) (WHO, 2016 a).  The uptake of these new medicines was initially by specialist 
services, used to managing the more problematic and difficult to manage regimes 
containing interferon and ribavirin (Tait, Wang et al, 2017). The shift of care provision to 
primary care sites was initially reported through poster presentation and with observation 
study and even case report formats (Bajis, Dore et al, 2017). The novelty of the 
therapeutic area provided confidence that there was a question worth answering and that 
undertaking a programme of research to develop an intervention would likely to be 
fruitful. In parallel to these findings, the lack of good quality pharmacy-based research in 
this area also provided reassurance. 
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Despite the assessment that this was a new area with very few high quality reliable 
studies on the subject, our literature review revealed over 10,000 hits before de-
duplication. There was a significant amount of work required to assess the identified 
studies and I gained a much better appreciation of what makes a good and a bad 
manuscript through this exercise. I also gained a much better awareness of how reporting 
guidelines and standardisation of reporting makes research more accessible and easy to 
interpret. The evidence indicated that there would be a place for a definitive study in 
which DAAs were deployed by non-specialist personnel within community environments. 
7.1.3 Development and Modelling of an Intervention in Community Pharmacy 
Publication 2- Focus group series evaluating the experiences of service users of 
pharmacy services 
Publication 3 – Discrete choice experiment to evaluate features of a preferred service 
Publication 4- Quasi-experimental study to evaluate whether testing in pharmacies 
was feasible 
This phase of the research programme was fundamental in developing a theoretical 
understanding of the likely process of change that would be utilised by the planned 
intervention. The research resulting in these three publications was enabled by a 
Fellowship gained from Gilead, a pharmaceutical company who manufacture DAAs to 
treat HCV infection.  
The focus group series enabled a description of the social context surrounding attendance 
at a community pharmacy to be gained.  The participants in this study described how they 
were often treated differently from other people who accessed care in the pharmacy. The 
way delivery of OST was arranged in the pharmacy, often denied patients the right to 
confidentiality and high numbers of OST recipients attending a pharmacy could cause 
issues when patients requiring other services were attending the pharmacy at the same 
time. Participants readily identified poor experiences of care, yet valued some of the good 
relationships built up over time with pharmacy staff.  Constructive attitudes and humanity 
from pharmacy staff could contribute to progression towards recovery and help address 
the inequalities experienced by this group (Read, Lothian, 2017). 
The focus group series drew on the insights of service users experiencing care within 
community pharmacies. Participants in this study could readily describe their experiences, 
both good and bad.  The group dynamic helped facilitate description of the experiences 
and also helped in gaining peer recognition of the discourse (Bloor, Frankland et al, 
2002).  The approach also led to a group narrative in some respects, where dominant 
 224 
 
voices talking about resonating themes tended to take up the discussion. Several strategies 
were used to overcome this limitation, including awareness of the facilitator, gaining 
perspectives on findings from feedback of other groups, use of specific groups – women’s 
groups and peer supporters – to gain further insights into the experiences of care. The 
context provided by the study and the insights it provided into the interaction between 
person, place and time were a key stage of intervention development. The exercise meant 
that the research could be grounded within the experiences of people’s lives.   
In order to access the people who would be able to give the most useful discourse, we 
arranged groups in church halls and recovery cafes where support services were accessed. 
Links were made with service staff who circulated leaflets and asked people if they were 
interested in attending. Once participants understood what we wished to talk about, there 
was no difficulty in generating a relevant conversation. A greater challenge was 
facilitating a balanced narrative in which each participant had the opportunity to 
contribute their perspective. In achieving this balance, a purposive strategy to undertake a 
women’s group and a peer mentor group was undertaken, to increase the prospect of a 
valid and generalisable outcome (Bloor, Frankland et al, 2002).  The findings from this 
study amply demonstrate the range of experiences of service users visiting pharmacies. 
The views expressed by participants regarding those things that went wrong with 
pharmacy services and how pharmacy services could be valued provided the material to 
start the next study – A discrete choice experiment.  We used these data to identify the 
variables we could use as attributes to describe an ideal service from the perspective of 
service users.  The experiences of stigma and discrimination within pharmacies, that were 
highlighted in the focus groups, led us to formulate the attribute of “dignity and respect” 
in the subsequent econometric study. 
The discrete choice experiment utilised the attributes of a service, identified through this 
development work, to further assess the relative preferences and to try and quantify the 
value placed on different parameters (De BekkerGrob, Ryan and Gerard, 2012). The 
study provided clear evidence that being treated with dignity and respect was a critical 
factor in service acceptability. The study also provided supporting evidence that care 
provided in a person’s “own pharmacy” were strongly favoured. 
The study utilised a standard format for choice presentation.  The language used to 
describe the choices was piloted using a “speak aloud” process to test understanding and 
assess cognitive burden. The issue of stigma and discrimination was very real to 
participants. Many of them had experienced poor treatment in the care they had received 
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during their treatment careers and responded very strongly to the suggestion of “dignity 
and respect”.  The strength of this response may have meant that other less important 
attributes were given less consideration.  Nonetheless, the appreciation of dignity and 
respect, plus the way care provision in the participants’ “own pharmacy” was valued gave 
clear indications on how an intervention might be structured. 
The way the respondents reacted to the suggestion of being treated with dignity and 
respect was striking and dominated the narrative of the interviews.  The response was so 
strong, that it usually made the other attributes contained in the questionnaire of much 
lesser importance. The response to “own pharmacy” was also strong and may have 
reflected that the participant had found a safe place to visit to gain their methadone. This 
finding gave reassurance that service users would accept the offer of a test from their own 
pharmacy. A consequence of the finding was that when pharmacy staff were trained to 
offer testing, we set out a standard script in an infographic that could be used to set the 
tone of the conversation. Our training emphasised the need to use the day-to-day 
interactions with service users to mention the possibility of testing and we also presented 
a lot of material that was designed to heighten awareness of the potential for stigmatising 
behaviours. 
The quasi-experimental evaluation of dried blood spot testing in pharmacies showed that 
this technique could be delivered by pharmacy staff and that service users were prepared 
to be tested in the pharmacy environment.  Interviews with service users of the 
intervention provided further insights into the context for delivery, about fears and 
anxieties about a diagnosis and treatment and about feeling of shame around having been 
infected with HCV.  Service providers also provided insights into the ingredients for 
success, including strong leadership and teamwork. They were often enthusiastic about 
undertaking a new role, but some were unfamiliar with a more hands-on care approach. 
The observational study had a number of limitations, as well as benefits (Craig, Cooper 
2012). The primary limitation of the study was the small number of participating 
pharmacies in a single location and the lack of experimental procedures to limit 
systematic selection bias. Some variance in uptake of the intervention was observed 
between pharmacies. This observation is commonplace across regular day-to-day services 
such as provision of smoking cessation, as well as with this intervention. The variance is 
usually conceptualised and  explained by the different business models in pharmacies and 
by the different staffing levels that pharmacies employ to deliver their contract. Further 
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variables include the leadership provided by the pharmacist in undertaken clinical work 
and by the motivation of staff team members: the ethos within the pharmacy. 
This study design provided a rapid and straightforward way to test the feasibility of 
testing and provided the research programme with reassurance that the intervention was 
acceptable and could be delivered by pharmacies. The finding that service users were 
twice as likely to accept the offer of a test from pharmacy staff as from specialist nurses 
working in community setting and from third sector support organisations was interesting 
and provided insights into the potential of a pharmacy-based intervention for improving 
health. 
The process of contracting with community pharmacy companies to undertake research 
was new to me. The agreement process required that I work simultaneously with the 
contractor representative body, individual contractor companies and staff within 
pharmacies in order to gain agreement in participation. This process was not only about 
staff governance and professional standards, but also about guaranteeing the return on 
investment of staff time by the company and ensuring that insurance covered the activity.  
Training the pharmacies to undertake the blood test also meant that I had to be competent 
myself. The study also required that I become competent in performing standard 
statistical tests in order to analyse data generated and to use reporting guidance to write 
manuscript of an acceptable standard. The planning of research outcome using a logic 
model as a planning tool was also a new skill to be applied. 
The evidence provided from the quantitative data of testing uptake and the process 
evaluation conducted with service users and staff provided sufficient justification to 
comme.ce the planning for a feasibility study of the entire testing and treatment pathway.  
7.1.4 Feasibility Assessment and Evaluation of a Care Pathway for Testing and 
Treatment in Community Pharmacies 
Publication 5 – Feasibility cluster trial of the pharmacy pathway compared to the 
standard of care 
Publication 6 – Published protocol for the multi-centre randomised controlled trial 
Publication 7 – Outcomes from the definitive multi-centre trial of the pharmacy 
pathway compared to the standard of care 
This phase of the research programme assessed the feasibility of the intervention and 
measured the outcomes associated with deployment of the intervention in different 
locations (Craig, Dieppe 2006). The research in this section was undertaken using a 
further grant from Gilead for the feasibility RCT and by a funding partnership with the 
 227 
 
Scottish Government, and with Gilead and Bristol Myers Squibb, donating free DDAs for 
the treatment of study participants.  
The feasibility study looked to deploy all the elements of the intervention and test how 
pharmacies could support the delivery of testing and treatment as part of the efforts of the 
multi-disciplinary team.  The experimental design for the study was utilised to address 
potential selection bias and give some indication of the effect size that might be achieved 
in a definitive trial (Eldridge, Lancaster, 2012).  The study confirmed that participants in 
a pharmacist-led pathway were more likely to take a DBST and that attrition from the 
pathway was lower at all points than for the conventional pathway of care. The study also 
demonstrated the loss of participants from the pharmacy pathway when they were asked 
to attend a different site for phlebotomy. Service users had mainly positive perceptions of 
the care provided. They thought that pharmacies were a good place to receive care where 
they enjoyed positive relationships with staff; they already had a reason for attending and 
did not need bus fare to attend the hospital.  Staff members had strong views about the 
value of leadership and teamwork in creating an environment for performance. Good 
quality relationships with patients were a key ingredient in engaging them in testing and 
treatment. A comparison of the costs of providing care in pharmacies and in conventional 
care pathways demonstrated that the pharmacy pathway was associated with lower costs. 
The feasibility study was not able to determine a significant difference for the primary 
endpoint of virological cure (SVR12).  This was because of the attrition caused by offsite 
phlebotomy, because of the number of participants with a genotype 3 infection (who 
could not be treated with study drugs) and because of a larger number of participants than 
expected who attained spontaneous clearance of virus. However, the cascade of care 
developed through the programme demonstrated that a worthwhile effect was likely to be 
achieved in a larger study.  This evidence helped us to further refine our pathway, in 
particular creating the facility for peripatetic phlebotomists to take assessment blood tests 
within pharmacies instead of asking participants to visit another site. We also were 
required to develop a patient group direction for DDA prescribing, since there was not the 
same availability of pharmacist prescribers in Grampian and Glasgow, as in Tayside 
(“MHRA”, 2019) 
The multi-centre cluster randomised trial was able to utilise developments in medicines 
technology, so that genotype 3 infections could be treated with a simple oral regimen of 
direct-acting antiviral drugs: these medicines were not available when the feasibility 
study was planned and only genotype one infections could be treated in this way. 
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The multi-centre study was also able to demonstrate a significant difference for the 
primary outcome. A greater number of participants in the trial achieved virological cure 
(SVR 12) in the pharmacist-led arm, than for the conventional care arm. This difference 
was apparent at the recruitment for testing stage and this was maintained through the care 
cascade.  
The deployment of the intervention in different locations meant a large increase in 
complexity for implementation and evaluation. The different contexts and cultures of 
each health board site meant that training and some procedures had to be adapted for the 
local situation. An example would be the administrative bureaucracy required to enable 
pharmacy staff to perform DBSTs.  In Tayside, a simple training course across 90 
minutes was sufficient, whereas in Grampian, a course over several days, with assessment 
and certification was required. 
The pharmacist-led pathway provided advantages across the care pathway in terms of 
recruitment and retention. The key ingredients identified during intervention 
development: trusting relationships, local care in the community; no requirement to move 
to access treatment at different sites; treatment with dignity were deployed in the design 
of the complex intervention and contributed to demonstration of positive outcomes across 
the care pathway (Gartlehner, Hansen, 2006).  
A range of new learning was required for this phase of the research programme. Preparing 
submissions for research ethics and using the  IRAS system effectively was a new 
experience, as was working with Sponsors and Research and Development departments.  
The governance requirements were more than this though and included writing contracts 
with university solicitors to engage pharmacy companies and constructing service 
specifications to describe how we expected the pharmacies to act. The approval of the 
contracts and documentation by the pharmacy companies Superintendent Offices 
(professional governance) caused a long delay in finalisation of arrangements and study 
implementation. The delay amounted to around eight months, meaning that some of our 
donated drug had expired and that we had to ask for further supplies.  The politics of the 
project meant that we also had to gain support from the policy leads at government and 
liaise with professional Board leads A further complication that we had not appreciated 
was around staff turnover in pharmacies. Pharmacist and their staff often move jobs to 
another pharmacy and this created difficulties for study management, requiring us to re-
train on several occasions: two pharmacists moved from one pharmacy in the study to 
another pharmacy also in the study, which was less problematic. 
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The evidence provided through this programme demonstrated that the pharmacy-led 
intervention enabled approximately twice as many people prescribed OST to achieve a 
virological cure as the standard of care. This finding was coherent with the understanding 
and data collected from development work and fitted well with our theory about the value 
of being treated with dignity and respect and in offering treatment in a well-known and 
familiar environment. The piloting and feasibility work provided a rich source of data 
from which to undertake the final part of the research programme that formulated 
hypotheses about why the intervention had succeeded. 
7.1.5 Mapping of Causal Inferences Identified during the Development and 
Evaluation of a Complex Public Health Intervention 
Publication 8 – Systems-thinking analysis of the hypothesised causal mechanisms 
underpinning intervention effectiveness. 
As part of the evaluation of the SuperDOT-C intervention, a systems-thinking approach 
drawn from the theory of complex adaptive systems was utilised (Peters, 2014). This 
study utilised causal loop diagramming to describe the components surrounding the 
intervention and to describe the possible interactions and linkages between these.  From 
analysis of these diagrams, hypotheses were formed on the potential causal mechanisms 
that formed the key ingredients in the success of the intervention.  This analysis utilised 
evidence from the surrounding literature as well as data produced through the programme 
of research to define important components and suggest their inter-relationships.  Several 
reinforcing relationships were suggested.  These included the relationships between the 
pharmacy and the participants. The support from the multi-disciplinary team to the 
pharmacy was important in creating an integrated perspective to care.  Trust in the 
pharmacy and the environment surrounding care provision, encouraged health-seeking 
behaviours and engagement.  Several inhibiting factors were also identified.  The high 
cost of the anti-viral drugs placed budgetary constraints on the availability of the 
medicines.  The cost also had the potential to disrupt the business models of the pharmacy 
and the cash flow that they required. These factors could be mitigated through 
organisational leadership provided through the managed care network. Environmental 
factors that included the availability of illicit drugs, of employment and housing, also had 
profound effects on the ability of participants to engage in the intervention. 
This type of analytical approach has well recognised limitations (Carey, Malbon et al, 
2015).  These include the definition of the boundaries of the analysis and the effects of 
describing a number of variables under one component. Assessment of the polarity of 
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effect may be problematic, where stock and flow variables are mapped to health 
behaviours. Nonetheless, the analysis provided a useful summation of the research 
programme and helped to make clear insights and inferences that had been identified.  
The construction of the pathway required a group interaction from the research team with 
active discussion of the way that the effects were mapped and which direction the effect 
travelled. The diagram was constructed in staged with a consensus forming around a final 
draft.  The end point provided a suitable summary of the work that had been undertaken 
and formed a graphical representation of all we had learned. 
 
7.1.6 Future Development of the Programme 
A number of tasks remain to be completed in order to bring this programme of research to 
a natural conclusion. At the time of submission, six manuscripts from eight drafted have 
been published in relevant peer reviewed journals, but two remain to be brought into the 
public domain. These are the papers describing the findings of SuperDOT-C and also the 
Systems-thinking analysis. 
A further series of papers require to be drafted in order to complete the publication of 
work that has been undertaken. These are: 
- A reflection on the learning achieved from carrying out research in community 
pharmacy with a presentation of the particular challenges that this environment provides.  
- A health economic analysis of the pharmacy-led pathway 
- A presentation of the qualitative themes identified through the three process evaluations 
that were undertaken at points within the programme. 
It is hoped that this further work will provide a satisfactory summation of the 
development and evaluation of a complex intervention. 
7.2 Conclusions 
The programme of research has deployed a variety of qualitative and quantitative 
approaches to gain an understanding of the way that the SuperDOT-C intervention is 
likely to perform, when used to test and treat people infected with HCV who are 
prescribed OST.  The insights gained have enabled design, implementation and evaluation 
of a complex intervention. Evaluation of the SuperDOT-C intervention in a definitive 
multi-centre trial provides evidence that a greater number of participants in the trial 
achieved virological cure (SVR 12) in the pharmacist-led arm, than for the conventional 
care arm. 
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Information gained during a series of development and feasibility studies has provided 
insights into the key ingredients that are likely to be necessary for successful 
implementation. These ingredients are thought to concern the quality of relationship 
between participant and provided, the supportive nature of the community in which the 
service user lives and the way that organisations identify the need for vulnerable groups 
to access care and treatment in an equitable way. 
This thesis therefore contributes to the body of knowledge supporting the delivery of the 
WHO’s guidance on the screening, care and treatment of persons with chronic hepatitis c 
infection (WHO 2016c) and the aspiration set out in the Sustainable Development Goals 
(3.3) for elimination of Hepatitis C as a public health concern by 2030 (WHO 2016a).   
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7.3 Summary of knowledge and evidence contributions of the thesis to 
policy development and scholarship 
Overview of the case presented 
Primary Research Objective: 
Can a pharmacist-led care pathway designed to test and treat HCV infection in people 
prescribed OST, increase the numbers of this population who access treatment and cure 
for Hepatitis C? 
This programme of research has modelled, established and evaluated a testing and 
treatment pathway for people with HCV infection in community pharmacy. A review of 
evidence and policy has described the case for task-shifting of care to the wider multi-
disciplinary team and of decentralising care to community locations. A systematic 
literature review identified and evaluated published examples of where task-shifting and 
decentralisation had been evaluated and found evidence that these strategies may increase 
access to care whilst maintaining cure rates when direct-acting antiviral drugs are 
prescribed. 
A series of studies examined important factors that might contribute to the uptake of a 
pharmacist-led intervention, including service user and service provider views. 
Experimental work evaluated the intervention, both from a feasibility perspective and also 
looking of the generalisability of the intervention in different contexts. Evidence is 
provided that a pharmacist-led care pathway can increase the numbers of this population 
who access treatment and cure for Hepatitis C. 
Secondary Questions: 
What are the views and experiences of people who access pharmacy services to receive 
OST? 
A series of studies examined the experience of healthcare from the service-user 
perspective. These studies recorded both good and unsatisfactory aspects of the 
experience of care. The pervasive experiences of stigma and discrimination encountered 
when using pharmacy services were documented using a focus group series. The way that 
the pharmacy service was organised and the attitudes and actions of staff were important 
factors that impinged upon the satisfaction of people using these services. People who 
access pharmacy services often valued the care provided by a pharmacy and its place in 
the local community. 
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What are the important factors to be considered in the design of a pharmacist -led care 
pathway, from the perspective of the service-user population? 
Attributes identified from the focus group series were utilised to undertake a discrete 
choice experiment. The questionnaire administered as part of the discrete choice 
experiment demonstrated that the most important feature of a service was being treated 
with dignity and respect. The relationship established with a trusted pharmacy was also 
valued. Waiting time for results and travelling distance were also important factors in 
creating a treatment pathway that would be appreciated by service users.  
Can a pharmacy-based testing service for HCV infection encourage the target population 
of service-users to take a test for blood borne viruses (BBVs)? 
A pilot project to establish dried blood spot testing in a group of pharmacies was 
evaluated as a quasi-experimental model and views of service users and service providers 
were obtained.  The pilot provided some evidence that testing could be provided by 
pharmacy staff within a pharmacy and that more people might take up the offer of a test. 
Factors such as good relationships with pharmacy staff and the need to attend the 
pharmacy regularly may have increased the uptake of testing. 
Is the delivery of a pharmacist-led pathway to deliver testing and treatment for HCV 
feasible? How do service providers describe the provision of this service?  
A feasibility trial was undertaken to evaluate whether the pharmacist-led care pathway 
could be delivered. Alongside this cluster randomised controlled trial, a process 
evaluation was undertaken.  The trial provided some evidence that service users would 
accept the offer of care provision from and pharmacy and that the method of HCV 
diagnosis, assessment for treatment and delivery of medication, could be successfully 
delivered in the pharmacy.  Previous work had established that the place of the pharmacy 
within the community and the development of trusting relationships were important.  The 
feasibility trial demonstrated that more service users were retained on the care pathway 
when care was provided from that one location. Attempts to move patients into other 
locations to receive care resulted in increased attrition from the pathway.  Pharmacy staff 
in general appreciated the opportunity to develop their practice and valued the ability to 
provide more care to the service user group.  Factors such as staffing complement and 
dispensing workload could impinge on their ability to deliver the pathway.  
What are the barriers and facilitators identified that impinge on the access to and delivery 
of effective care? 
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A review of published evidence and policy and data obtained during this programme were 
utilised in a systems-thinking approach to reflect upon possible causal mechanisms for the 
intervention.  The relationships between identified components were described in a causal 
loop diagram and this was used to formulate hypothesise about how different factors 
might inhibit or promote the effectiveness of the intervention. Facilitators to the success 
of the intervention included positive patient relationships, proximity to the community 
and role enhancement as factors promoting uptake of the care pathway. Barriers to the 
uptake of the intervention included factors such as experience of stigma and fear of 
treatment side-effects, but also the factors such as homelessness, healthcare policy and 
budgetary restraints.  
7.3.1 Summary of research contributions 
The research included in this thesis has provided evidence that a pharmacist-led care 
pathway designed to test and treat HCV infection in people prescribed OST, can increase 
the numbers of this population who access treatment and cure for Hepatitis C.  It has 
identified the role that stigma and discrimination can play in provision of care.  It has 
shown that positive relationships between providers and service users can increase health -
seeking behaviours in a vulnerable patient group who experience profound health 
inequalities. It has shown that the introduction of new medicines technology can decrease 
the need to deliver care from hospitals and that such technology can enable non-specialist 
staff to become an integrated component of care provision. 
Its global evidence contributions include: 
-The identification of a fragmented but developing pool of evidence indicating that 
hepatitis care can be delivered in primary care and community settings, by non-specialist 
staff 
-The identification that service design that utilises service users perspectives may lead to 
the development of a more effective intervention. 
-That inertia in established hospital-based care pathways may be reducing the number of 
people with HCV infection that are able to access care and therefore cure of their 
condition. 
-That developing a complex intervention requires a systematic approach to gain an 
understanding of context, assess feasibility, assess effectiveness, measure outcomes and 
understand processes. 
-That generation of evidence demonstrating the delivery of effective is a strategy that 
supports policy development 
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-That generation of evidence from real-world, multi-stakeholder engagement processes 
requires a range of additional skills to those recognised as central to delivery of high-
quality research. 
Its knowledge translation impacts include: 
-Support for the WHO recommendations for the care and treatment of persons diagnosed 
with chronic hepatitis C virus infection 
-Support for the Scottish Government’s policy ambition to eliminate hepatitis c infection 
as a public health concern from Scotland by 2025 (through participation in the Short Life 
Working Group Report, “Recommendations on hepatitis c virus case-finding and access 
to care”) 
-Support for the implementation of the Welsh Government’s policy initiative for 
community pharmacy-based hepatitis-c testing service, commissioned though 
WHC/2017/048. 
-Knowledge exchange with policy makers, academics, practitioners and stakeholders 
engaged in the world-wide efforts to eliminate hepatitis C. 
Concluding Comments 
This thesis has aimed to present the case that decentralised care provided by non-
specialists can enable more people infected with hepatitis C to access a cure, using the 
example of a pharmacist-led pathway. The research programme has utilised an iterative 
approach to developing and evaluating a complex intervention.  The activities involved in 
the generation of research have aimed to develop the practice of pharmacy: a clinical 
profession. 
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